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ABSTRACT OF THESIS: The Control of the Release of Some
Hypophysial Portal Vessel Peptides
by Anoop K. Brar MRC Brain Metabolism Unit
University Department of Pharmacology
1 George Square, Edinburgh EH8 9JZ
The aim of this thesis was to investigate hypothalamic-pituitary
control by measuring the release of neuropeptides into pituitary stalk
blood. The neuropeptides measured were luteinizing hormone-releasing
hormone (LHRH) and the 'gut peptides' cholecystokinin (CCK), gastrin
and vasoactive intestinal polypeptide (VIP).
Studies in castrated rats showed that, (1) despite marked increases
in pituitary gonadotro_phin secretion and the number of LHRH receptors
in the anterior pituitary gland, the amount of LHRH in stalk blood was
similar to that in control rats; (2) the release of LHRH into stalk blood
induced by electrical stimulation of the median eminence (ME) was
significantly lower than in control rats; (3) administration of oestradiol,
5a-dihydrotestosterone or testosterone (T), suppressed the post-castra¬
tion rise in plasma luteinizing hormone (LH) but had no effect on LHRH
released into stalk blood or the increased number of LHRH receptors
in the anterior pituitary gland.
Experiments using intact and castrated rats made hyperprolactin-
aemic by implanting two anterior pituitary glands under the kidney
capsule showed that, (1) the suppression of gonadotrophin release in
intact and castrated hyperprolactinaemic rats was not accompanied by
a decrease in LHRH release into stalk blood; (2) electrical stimulation
of the ME was as effective in hyperprolactinaemic rats as in control rats
in increasing LHRH release into stalk blood; (3) implantation of T
capsules into castrated hyperprolactinaemic rats suppressed gonado¬
trophin but not LHRH secretion.
Catechol oestrogens stimulated the release of LH in pre-pubertal
male and female rats but suppressed LH release induced by pregnant
mare serum gonadotrophin.
CCK and VIP, but not gastrin, were released in significantly
higher concentrations into stalk blood than into peripheral blood of
adult male rats. Electrical stimulation of several areas of the brain
known to contain CCK, gastrin or VIP did not alter the release of these
peptides. Removal of the major peripheral source of CCK and gastrin
(the gastric antrum) or VIP (the entire gut), significantly lowered
CCK and gastrin concentrations but did not reduce VIP release into
stalk blood. VIP release into stalk blood at various times of the oestrous
cycle under Althesin, Ketalar, Sagatal or urethane anaesthesia showed
no clear-cut changes. Therefore, it is unlikely that CCK and gastrin
are physiological hypothalamic-pituitary regulatory factors. The
physiological significance of the higher amounts of VIP in stalk blood
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1.
The involvement of the hypothalamus in the control of LH and
FSH release by the anterior pituitary was first postulated over 30 years
ago (Sawyer, Markee and Everett, 1950; Harris, 1955). Extensive
research led to the isolation and synthesis of the hypothalamic peptide,
luteinising hormone-releasing hormone (LHRH), which is released into
hypophysial portal vessel blood on stimulation of higher brain centres.
Since one of the main aims of this thesis was to investigate the control
of the release of LHRH, the evidence supporting the hypothesis that
LHRH is the major determinant of gonadotrophin release and that the
hypothalamic dopaminergic system and gonadal steroids exert important
modulatory influences is outlined below. The recent evidence suggesting
that other peptides (e.g. cholecystokinin) may also modulate gonado¬
trophin secretion is also presented. In addition, the mechanisms
controlling prolactin secretion and the effects of prolactin on gonado¬
trophin release are discussed with relevance to this thesis.
1.1 Neurohumoural Regulation of the Adenohypophysis
7. 7. 7 The Neurohumoural Hypothesis
The current concept of the main mechanism controlling the
release of hormones from the adenohypophysis is that substances
liberated into the hypothalamo-hypophysial portal circulation from
nerve terminals in the median eminence modulate adenohypophysial
secretions. This 'neurohumoural hypothesis' has been reviewed in
detail by Harris ( 1955, 1972), Guillemin ( 1967), Everett ( 1969) and
McCann and Porter ( 1969). The early observations that ovulation in
some female mammals (e.g. rabbits) occurred only after mating (Heape,
1905; Barry, 1939) and that environmental factors played a role in
reproductive functions (Marshall, 1936, 1942), first lead to
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the hypothesis that the activity of the adenohypophysis was stimulated
by sensory stimuli acting through reflex pathways in the central
nervous system. This hypothesis was supported by demonstrations
that ovulation and pseudopregnancy could be induced in the rabbit
by applying a large electrical stimulus to the whole head (Marshall and
Verney, 1936) or to localised areas of the hypothalamus (Harris, 1937;
Haterius and Derbyshire, 1937). However, the demonstration by
Popa and Fielding (1930, 1933) of the existence, in the human, of a
portal vessel system between the hypothalamus and the adenohypophysis
started serious investigations into the suggestion that stimuli from the
hypothalamus or neurohypophysis modulated adenohypophysial secre¬
tions by 'humoural transmission', by way of the portal vasculature
(Hinsey and Markee, 1933; Friedgood, 1936; Harris, 1937; Haterius,
1937). The initial controversy regarding the direction of the blood flow
in the hypophysial portal vessels was resolved by studies in the living
toad (Houssay, Biasotti and Sammartino, 1935), rat (Green and Harris,
1949) and mouse (Worthington, 1955) which clearly indicated that blood
flowed from the hypothalamus towards the adenohypophysis, thus
supporting the neurohumoural hypothesis. In addition, the unique
arrangement of the hypophysial portal vessels which permitted the
transport of substance between the hypothalamus and adenohypophysis,
in the absence of direct innervation of the adenohypophysis, was
confirmed to occur in up to 76 species studies of animals (Wislocki and
King, 1936; Barrnett and Greep, 1951; Green, 1951; Torok, 1954;
Daniel and Pritchard, 1975).
Harris ( 1950) was the first to conclusively demonstrate that if the
pituitary stalk of female rats was sectioned and vascular regeneration
prevented by the placement of a plate between the cut ends of the stalk,
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the uteri and ovaries became atrophic and a state of anoestrus was
induced. If regeneration of the portal vessels was permitted, normal
oestrous cycles and pseudopregnancy could be established. The
functional importance of the portal vessels in the control of reproductive
function was also confirmed in other mammals (Benoit and Assenmacher,
1953; Donovan and Harris, 1954; Fortier, Harris and McDonald, 1957;
Daniel and Pritchard, 1958). Further support for the neurohumoural
hypothesis came from experiments by Harris and Jacobsohn (1952) who
transplanted pituitary tissue under the median eminence or temporal
lobe of hypophysectomised rats. Transplants at both sites became well-
vascularised but reproductive fertility only remained in those rats with
transplants under the median eminence, which were vascularised by the
hypophysial portal vessels as opposed to the systemic blood vessels,
which vascularised the transplants under the temporal lobe. These
experiments were extended and confirmed by Nikitovich-Winer and
Everett (1958). The demonstration that crude extracts of the median
eminence stimulated luteinising hormone (LH) release, determined by the
ovarian ascorbic acid depletion test (McCann, Taleisnik and Friedman,
1960; Smith, 1961), and induced ovulation in the rabbit (Campbell,
Feuer and Harris, 1960) provided the most direct evidence in support
of the neurohumoural hypothesis for the control of adenohypophysial
secretions.
7. 7. 2 The Hypophysial-Portal Vasculature
Detailed descriptions of the hypophysial-portal vasculature have
been published by Daniel ( 1966), Porter, Ondo and Cramer ( 1974),
Bergland and Page ( 1978, 1979) and Flerko ( 1980). Apart from the
rabbit (Harris, 1947), the adenohypophysis receives no direct arterial
supply; its entire afferent vascular supply is provided by the
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hypophysial portal vessels. The arterial blood supply of the median
eminence, the pituitary and the pituitary stalk is derived from hypo¬
physial arteries which arise from the circle of Willis or directly from
the internal carotid arteries and form a network in the external zone
of the median eminence called the primary capillary plexus. From this
plexus, the so-called long portal vessels arise, which lie on the surface
of the pituitary stalk. Another primary capillary bed lies in the
neurohypophysis in rats, and derives its blood supply mainly from the
inferior hypophysial arteries and comprise the so-called short portal
vessels. When the pituitary stalk is cut, the so-called long portal
vessels are severed (Daniel, 1966). The resulting infarct has been
reported to destroy up to 78% of the adenohypophysis in the rat (Adams,
Daniel and Pritchard, 1963).
There is little mixing of the blood carried to the different parts
of the adenohypophysis by the long and short portal vessels. The
outflow from the sinusoids of the adenohypophysis is through small
collecting veins at the periphery of the lobe, which open into one of
the adjacent veins. Bergland and Page (1978, 1979) have suggested
that some venous blood from the adenohypophysis returns by way of
the short portal vessels to the neurohypophysis, and from there to the
systemic circulation, as postulated by Torok (1954). In addition, there
have been suggestions that there is retrograde blood flow in the portal
vessels in the pituitary stalk (Ambach, Palkovits and Szentagothai,
1976; Setalo', Vigh, Schally, Arimura and Flerko, 1976; Oliver, Mical
and Porter, 1977; Porter, Barnea, Cramer and Parker, 1978).
Portal vessel blood samples were first collected in the dog using
a temporal approach to the vessels, followed by hypophysectomy (Porter
and Jones, 1956), Subsequently, a parapharengeal approach to the
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vessels was developed by Porter and Smith (1967) in the rat, and
portal vessel blood samples collected from hypophysectomised rats
after placement of a cannula over the cut stalk which was connected
to a pump to withdraw blood. Worthington (1966) described a method
involving a transpharyngeal approach to the portal vessels in the rat,
in which portal vessel blood samples were collected from the cut end
of the pituitary stalk. Worthington's technique avoided the contamina¬
tion of portal vessel blood samples with blood from the infundibular
artery which would be damaged in the process of hypophysectomy.
However, the blood collected using Worthington's method is a mixture
of portal vessel blood, small amounts of cerebrospinal fluid and pituitary
sinosoidal blood. The portal vessel blood samples collected in the
experiments described in this thesis were collected using a modification
of Worthington's method (Fink and Jamieson, 1976), therefore the portal
blood collected will be referred to as 'pituitary stalk blood' and all data
assessed in terms of concentration (amount/volume) and content
(amount/unit time).
7. 7. 3 Hypothalamo-Hypophysial Stimulating and Inhibiting Substances
Substances that modulate the release of adenohypophysial hormones
reach the gland by way of the hypophysial portal vessels (Section
1.1.1). For a substance to be considered as a physiological stimulator
or inhibitor of adenohypophysial hormones, it should therefore
i) be located within diffusion distances of the primary capillary
plexus of the portal vessels (these substances would therefore
be extractable from the hypothalamus, stalk-median eminence
tissue) ;
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ii) be identified, characterised and present in higher concentra¬
tions in portal vessel blood than in systemic blood;
iii) be capable of altering the rate of release of at least one hormone
from adenohypophysial cells, under several experimental and
environmental situations that alter the concentration of the
substance(s) in portal vessel blood.
Thyrotrophin releasing hormone (TRH), characterised in 1969
(Burgus, Dunn, Ward, Vale, Amos and Guillemin, 1969; Bdler,
Enzmann, Folkers, Bowers and Schally, 1969), was the first hypothalamic-
pituitary peptide to be sequenced. The structures of the other hypo-
thalamo-hypophysiotropic hormones to be characterised to date are LH-
releasing hormone (LHRH: Matsuo, Baba, Nair, Arimura and Schally,
1971; Burgus, Butcher, Amoss, Ling, Monahan, Rivier, Fellows,
Blackwell, Vale and Guillemin, 1972), somatostatin (Brazeau, Vale,
Burgus, Ling, Butcher, Rivier and Guillemin, 1973), corticotrophin-
releasing hormone (CRH: Vale, Speiss, Rivier and Rivier, 1961) and
growth hormone-releasing hormone (GRH): Guillemin, Brazeau, Bohlen,
Esch, Ling and Wehrenberg, 1982; Rivier, Spiess, Thorner and Vale,
1982). The evidence supporting a physiological role for the monoamine,
dopamine (DA), as the major prolactin inhibiting factor is discussed
in Section 1.4.2.
7. /. 4 Luteinising Hormone-Releasing Hormone (LHRH) as a
Neurohumoural Substance
The isolation and characterisation of LHRH in the porcine and
ovine hypothalamus was reported (Burgus et at., 1971; Matsuo et al. ,
1971) almost a decade after the first demonstration of LH-releasing
activity in hypothalamic extracts of rats and domestic animals
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(Schally, Kastin and Arimura, 1972). The decapeptide LHRH, (pyro)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, stimulates the
secretion of both LH and follicle-stimulating hormone (FSH: Schally,
Arimura, Kastin, Baba, Matsuo, Redding, Nair, Debeljuk and White,
1971; Koch, Chobsieng, Zor, Friedman and Lindner, 1973; McCann,
1974). Administration of anti-LHRH serum to intact or castrated rats
lowered plasma concentrations of both LH and FSH (Koch et al., 1973;
Arimura, Debeljuk and Schally, 1974; Kerdelhue, Catin and Jutisz,
1975), indicating the key role of LHRH in maintaining secretion of both
LH and FSH. However, there is evidence that FSH release is inhibited
by a substance distinct from LHRH (Bowers, Currie, Johansson and
Folkers, 1973; Shin and Kraicer, 1974; Chappel and Barraclough,
1976). Although an FSH-inhibiting hormone has not yet been isolated,
a gonadal peptide named 'Inhibin' has been found to selectively inhibit
FSH secretion at the level of the pituitary (Morris and Jackson, 1978;
Franchimont, Verstraelen-Proyard, Hazee-Huelstein, Renard,
Demoulin-Bourguignon and Hustin, 1979; Lumpkin, Negro-Vilar,
Franchimont and McCann, 1981).
The highest concentration of radioimmunoassayable LHRH in the
rat central nervous system is in the median eminence, with lower
concentrations in the arcuate and ventromedial nuclei (Palkovits,
Arimura, Brownstein, Schally and Saavedra, 1974; Brownstein,
Palkovits, Saavedra and Kizer, 1976). Nerve terminals containing
immunoreactive LHRH have been identified in the external layer of the
median eminence surrounding the portal vessels (Pelletier, Labrie,
Puviani, Arimura and Schally, 1974; Goldsmith and Ganong, 1975).
The concentration of LHRH in portal vessel blood has been found
to be higher than in systemic blood, measured by bioassay (Fink,
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Nallar and Worthington, 1967; Fink and Harris, 1970; Porter, Goldman
and Wilber, 1970) and radioimmunoassay methods (Fink and Jamieson,
1976). LHRH release into portal vessel blood was shown to increase
during the spontaneous LH surge on pro-oestrus in adult rats (Sarkar,
Chiappa, Fink and Sherwood, 1976; Ching, 1982) and during the LH
surge induced by pregnant mare serum gonadotrophin injections into
immature female rats (Sarkar and Fink, 1979). The LHRH surges
could only be demonstrated if anaesthesia was induced using the
steroid anaesthetic, Althesin, which did not block the LH surge on
pro-oestrus or ovulation when administered during the critical period
(Section 1.2.3) on pro-oestrus (Sarkar et at., 1976). Earlier attempts
by Fink and Jamieson (1976), using urethane, and by Eskay, Mical and
Porter ( 1977), using pentobarbitone, probably failed to demonstrate
the LHRH surge because both urethane and pentobarbitone modulate
LH release and ovulation (Section 1.2.3). The release of LHRH into
portal vessel blood has also been modulated by experimental procedures
that alter the steroid environment and by electrical stimulation of
specific brain regions. Electrical stimulation of the medial preoptic
area (mPOA) increased LHRH release into portal vessel blood (Fink and
Jamieson, 1976). The amount of LHRH releaseJby stimulation of the mPOA
could be varied with different current strengths. In addition, the LHRH
response was highest during the early afternoon on pro-oestrus and
lowest on dioestrus. Stimulation of the median eminence and supra-
chiasmatic nucleus resulted in greater and less release of LHRH,
respectively, while stimulation of the amygdala, dorsal hippocampus or
ventral hippocampus had no effect on the release of LHRH into portal
vessel blood (Chiappa, Fink and Sherwood, 1977). Ovariectomy chestrus
on pvt>-oesWu-S
produced a decrease in LHRH concentration in portal vessel blood^that
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could be restored or increased by oestrogen or testosterone administra¬
tion (Sherwood, Chiappa and Fink, 1976; Chiappa et al., 1977). The
pulsatile release of LH in long-term ovariectomised rats (Gay and
Sheth, 1972; Gallo, 1980) has been suggested to be induced by
fluctuating LHRH concentrations in portal vessel blood (Sarkar and
Fink, 1980). This concept is supported by the demonstration that
intravenous injections of antiserum to LHRH to ovariectomised rats
inhibited LH pulsatile release (Snabes and Kelch, 1979). The diurnal
LH surge induced by oestrogen administered to long-term ovariectomised
rats (Caligaris, Astrada and Taleisnik, 1971; Henderson, Baker and
Fink, 1977) has also been correlated to the LHRH concentration in
portal vessel blood (Sarkar and Fink, 1980). Oestrogen also potentiated
LHRH release induced by mPOA stimulation (Sherwood et al., 1976).
Progesterone, on the other hand, decreased the LHRH response to
ovariectomy (Sherwood et at., 1976; Sarkar and Fink, 1979).
From the studies described it is evident that LHRH satisfies all
the criteria required to classify a substance as a hypothalamo-hypo-
physial releasing factor as defined by the neurohumoural hypothesis
(Section 1.1.1).
7. 7. 5 Neurohumoural Role for Peptides Found in the Brain and Cut
During the last decade several peptides, such as cholecystokinin
(CCK: Dockray, 1976; Rehfeld, 1978b; Larsson and Rehfeld, 1979),
neurotensin (Carraway and Leeman, 1973; Uhl and Snyder, 1976;
Kobayashi, Brown and Vale, 1977), somatostatin (Schally, Dupont,
Arimura, Redding, Nishi, Linthicum and Schlesinger, 1976; Kobayashi
et al., 1977; Krisch, 1979), Substance P (Pearse and Polak, 1975;
Kanazawa and Jessel, 1976; Lungdahl, Hokfelt and Nilsson, 1978) and
vasoactive intestinal polypeptide (VIP: Said and Mutt, 1970; Larsson,
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Fahrenkrug, Schaffalitsky de Muckadell, Sundler, HSkanson and
Rehfeld, 1976), have been demonstrated in gastrointestinal endocrine
cells and in neurones in the peripheral and central nervous systems.
The biological significance of this dual distribution of these peptides
is not yet clear. One explanation put forward has been that endocrine
and nerve-cells share a common embryological (neuroectodermal)
origin and have similar histochemical properties (Pearse, 1976). Some
of these properties have been summarised in the acronym APUD
(Amine Precursor Uptake and Decarboxylation: Pearse, 1976). However,
studies by Fontain and Le Douarin ( 1977) involving transplantation of
quail tissues into chick embryos suggested that gut and pancreatic
endocrine cells are derived from the endoderm rather than the ectoderm,
as postulated by Pearse (1976). The possibility that changes in the
pattern of gene expression in different tissues may account for the
distribution of peptides in neural and endocrine cells has been reviewed
by Dockray ( 1979). There is accumulating evidence which suggests
that the same peptide functions both as a neurotransmitter (defined
as a substance released by nerve endings that acts at synaptic junctions
in the vicinity of its site of release) as well as a neurohormone (defined
as a substance released by nerve endings and transported in the blood
stream to its site of action). The evidence supporting a role for CCK
and VIP as a neurotransmitter and a neurohormone, has been reviewed
by Emson, Hunt, Rehfeld and Fahrenkrug ( 1979); Dockray ( 1982);
Fahrenkrug and Emson ( 1982); Rosselin, Maletti, Besson and Rotsztejn
(1982).
Both CCK and VIP have been reported to influence pituitary
hormone release (Ruberg, Rotsztejn, Arancibia, Besson and Enjalbert,
1978; Vijayan, Samson and McCann, 1979a; Vijayan, Samson, Said and
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McCann, 1979b; Morley, 1981). The presence of CCK and VIP in the
O
hypothalamus and median eminence (Loren, Alumets, Hakanson and
Sundler, 1979b; Roberts, Woodhams, Bryant, Crow, Bloom and Polak,
1980; Sims, Hoffman, Said and Zimmerman, 1980; Vanderhaeghen,
Lotstra, de Mey and Gilles, 1980) and the cerebrospinal fluid
(Fahrenkrug, Schaffalitsky de Muckdell and Fahrenkrug, 1977;
Rehfeld and Kruse-Larsen, 1978), and the presence of VIP in the
hypophysial-portal circulation (Said and Porter, 1979; Shimatsu, Kato,
Matsushita, Katakami, Yanaihara and Imura, 1981) and in prolactin -
secreting cells in the pituitary, which appear to have specific receptors
for VIP (Nicosia, Spada, Borghi, Cartelazzi and Giannattasio, 1980;
Morel, Besson, Rosselin and Dubois, 1982), is compatible with a role
for CCK and VIP in the control of pituitary hormone release. However,
the criteria for designating CCK and VIP as physiological hypothalamo-
hypophysial regulating factors, as stated by the neurohumoural hypo¬
thesis (Section 1.1.1), has only partially been established in the case
of VIP and still largely uninvestigated in the case of CCK. The
evidence suggesting a role for VIP and CCK in modulating the secretion
of adenohypophysial hormones is discussed in detail in Chapters VI
and VII.
1. 2 The Rat Reproductive Cycle
Adult female rats maintained on a schedule of 14 h light : 10 h
darkness have cyclical gonadotrophin secretion patterns with ovulation
occurring every 4 days. The absence of a similar phenomenon in the
male rat has been attributed to sexual differentiation of the brain
(Brown-Grant, 1973; McEwen, 1981).
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7. 2. 7 Hormonal Changes During the Oestrous Cycle
The main hormonal changes over the four-day oestrous cycle of
the rat can be summarised as follows:
i) The concentration of LH in peripheral plasma remains low until
the afternoon (between 17.00- 19.00 h) of pro-oestrus when a
surge of LH secretion occurs and plasma LH concentrations may
be up to fifty times those at dioestrus (Monroe, Rebar, Gay and
Midgley, 1969; Brown-Grant, Exley and Naftolin, 1970; Piacsek,
Schneider and Gay, 1971; Aiyer, Fink and Greig, 1974a; Blake,
1976).
ii) Plasma concentrations of FSH also increase with the rise in LH,
but peak secretion does not occur until about 05.00 h of oestrus
(Daane and Parlow, 1971; Butcher, Collins and Fugo, 1974;
Fink and Aiyer, 1974).
iii) There is also a surge of PRL during the afternoon of pro-oestrus
(Gay, Midgley and Niswender, 1970; Wuttke and Meites, 1970;
Neill, Freeman and Tilson, 1971), which has been correlated with
a decrease in the DA concentration in portal vessel blood (Ben-
Jonathan, Oliver, Weiner, Mical and Porter, 1977; Plotsky,
Gibbs and Neill, 1978).
iv) The concentration of LHRH in the hypophysial portal vessel blood
increases rapidly during the afternoon of proestrus, reaching a
peak at the same time as the peripheral plasma concentrations of
LH (Sarkar et al., 1976; Ching, 1982). A second smaller surge
of LHRH which has been postulated to be related to peak FSH
secretion, occurs between midnight of pro-oestrus and 02.00 h
of oestrus (Sarkar et a!., 1976).
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v) The gonadotrophin surges are preceded by an increase in plasma
oestradiol-178 concentration which begins during the evening of
dioestrus and reaches a peak during the morning and early
afternoon of pro-oestrus (Ferin, Tempone, Zimmering and Van de
Weil. 1969; Paicsek et al. , 1971; Brown-Grant et al. , 1972;
Shaikh and Shaikh, 1975; Henderson et al. , 1977).
vi) An elevation in progesterone secretion begins before the LH
surge but is markedly increased during and after the LH surge
(Barraclough, Collu, Massa and Martini, 1971; Feder, Brown-
Grant and Corker, 1971; Brown-Grant et al., 1972).
An increase in pituitary responsiveness to LHRH on pro-oestrus
(Section 1.3.2a; Aiyer, Chiappa and Fink, 1974b; Cooper, Fawcett
and McCann, 1974; Gordon and Reichlin, 1974), together with a priming
effect exerted by LHRH on the anterior pituitary (Section 1.2.2; Aiyer
et al., 1974a) ensures the culmination of all these hormonal changes in
ovulation early on the morning of oestrus.
7. 2. 2 The Priming Effect of LHRH
The priming effect is the ability of LHRH to increase the respons¬
iveness of gonadotrophs to subsequent exposures to itself (Aiyer
et al., 1974a, 1974b). The priming effect was demonstrated by the
fact that the LH response to the second of two successive injections
of LHRH (50 ng/rat, i.v.) and was maximal if the two injections were
separated by 60 min (Aiyer et al., 1974b). The effect was also
elicited if endogenous LHRH release was increased by electrical
stimulation of the mPOA, applied over two successive 15 min
periods separated by 60 min (Fink, Chiappa and Aiyer, 1976).
Since the content of LHRH in stalk blood during the two stimulations
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periods was similar (Fink et a!., 1976), the priming effect could not
be attributed to an increased secretion of LHRH induced by the second
period of stimulation. Moreover, the priming effect was demonstrated
in rats anaesthetised with pentobarbitone and infused with LHRH at
a constant rate for 90 min or by the application of a constant stimula¬
tion to the mPOA (Fink et al., 1976; Chiappa et al., 1977). The
priming effect was not mediated by adrenal or ovarian steroids since
it can be demonstrated in adrenalectomised and acutely ovariectomised
rats (Aiyer et al., 1974b), although ovarian steroids (oestradiol and
progesterone) determined the magnitude of the effect (Aiyer et a!.,
1974b; Speight, Popkin, Watts and Fink, 1981; Padmanabhan, Leung
and Convey, 1982). The priming effect was also elicited in vitro
(Pickering and Fink, 1966, 1977) although the maximal effect occurred
on pro-oestrus (Aiyer et al., 1974b; Waring and Turgeon, 1980),
while ovariectomy on the morning of dioestrus reduced the priming
effect on the afternoon of pro-oestrus (Speight et al., 1981) and the
release of LHRH into stalk blood. Oestradiol (2.5 pg/rat, s.c.)
administration immediately after ovariectomy only partially reversed
the suppression of the priming effect produced after removal of the
ovarian steroids (Aiyer et at., 1974b). Studies done to determine the
mechanism of the priming effect have been reviewed by Fink and
Pickering (1980).
7. 2. 3 The Critical Period on Pro-oestrus
The administration of neural blocking agents, such as atropine,
chlorpromazine, morphine or pentobarbital, in the early afternoon
(14.00- 16.00 h) on pro-oestrus blocked the pre-ovulatory LH surge
and ovulation (Everett, Sawyer and Markee, 1949; Everett and
Sawyer, 1950; Barraclough and Sawyer, 1955^ 1957; Greig and
Weisz, 1973), while stimulation
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of the mPOA induced secretion of comparable amounts of LH, which¬
ever of the drugs was used (Everett and Tyrey, 1982). The primary
suppressive action of these drugs does not appear to be on the pre-
optico-infundibular tract (Section 1.3.3a), the availability or release
of LHRH or the ability of the pituitary to release LH (Everett and
Tyrey, 1982). However, the exact timing of the 'critical period' on
pro-oestrus before which administration of the neural blocking drugs
effectively inhibited ovulation was dependent on the lighting schedule
of the animals (Everett, 1964, 1977). In rats maintained on a 14 h
light : 10 h dark schedule, the critical period occurred 14 h after the
midpoint of the dark period (Everett and Tejasen, 1967; Hoffman, 1970).
1.3 Control of Gonadotrophin Release
7. 3. 7 Role of the Hypothalamus
The neural signal that results in the release of LHRH into the
hypophysial portal vessels and the pre-ovulatory LH surge is thought
to be generated in the mPOA and suprachiasmatic nucleus regions of
the rostral diencephalon, which contain LHRH cell bodies (Barraclough,
1966; Koves and Halasz, 1970). The importance of the neural connec¬
tions between the mPOA and median eminence for ovulation has been
demonstrated by lesioning studies and experiments involving deafferen-
tiation of the medial basal hypothalamus (MBH) which included the
paraventricular and arcuate nuclei (Barraclough and Gorski, 1961;
Halasz and Pupp, 1965; Blake, Weiner, Gorski and Sawyer, 1972).
The mPOA has also been postulated to initiate cyclic release of LH
preceding ovulation in the rat, while the MBH appears responsible for
tonic release of gonadotrophins during meto-oestrus and dioestrus,
for follicular growth and maturation of the ovary (Barraclough and
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Sawyer, 1961; Dorianski, Przekop and Polkowsta, 1980). Inter¬
ruption of the amygdaloid complex and/or hippocampal afferents to
the basal hypothalamus have no inhibitory effect on the oestrous cycle
and ovulation (Velasco and Taleisnik, 1971; Brown-Grant and Raisman,
1972; Chiappa et at., 1977). However, the LH surge induced by
oestrogen in ovariectomised rats appears to involve the limbic system,
particularly the amygdala, since lesions of neural pathways to the
hypothalamus from the limbic system or bilateral lesions of the amygdala
prevent the release of LH by oestrogen (Rabii, 1981).
1. 3. 2 The Role of Gonadal Steroids
The influence of gonadal steroids on the hypothalamo-hypophysial
system has been extensively studied (Davidson, 1969; Goodman, 1978;
Lipsett, 1979; McEwen and Parsons, 1982; Martini, 1982). Investiga¬
tions into the mechanisms by which gonadotrophin secretion is regulated
show that steroids exert both a stimulatory and inhibitory influence,
depending on the duration, timing and level of exposure to the steroids.
Oestrogen exerts an inhibitory influence on gonadotrophin secretion
except on the morning and early afternoon of pro-oestrus during the
cycle when oestrogen switches over to exerting a facilitatory effect.
(a) Positive feedback effects of steroids:
In rats, the spontaneous pre-ovulatory surge of LH on the
afternoon of pro-oestrus depends on a significant increase in plasma
oestradiol-176 during the evening of dioestrus and morning of pro-
oestrus (Shirley, Wolinsky and Schwartz, 1968; Ferinef cr/., 1969;
Aiyer and Fink, 1974). Administration of antiserum to oestradiol-17 6
on dioestrus blocked the pre-ovulatory gonadotrophin surge and
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ovulation (Ferin et at., 1969; Neill et al., 1971). The facilitatory
effect of oestradiol-17 6 is enhanced by ovarian progesterone, secreted
in response to LH on the afternoon of pro-oestrus (Everett, 1964;
Rothchild, 1965; Brown-Grant and Naftolin, 1972; Mann and
Barraclough, 1973; Aiyer and Fink, 1974). This enhancing effect
of progesterone only occurred in oestrogen-primed rats (Everett,
1964; Aiyer and Fink, 1974; Brown-Grant, 1974); the reason for
this has been suggested to be due to the fact that the concentration of
progesterone receptors in the hypothalamus and pituitary is modulated
by exposure to oestrogen (Maclusky and McEwen, 1978). Progesterone
by itself has little or no effect on LHRH secretion (Sarkar and Fink,
1979) or gonadotrophin secretion (Everett, 1964; Brown-Grant and
Naftolin, 1972; Aiyer and Fink, 1974).
There is substantial evidence to suggest that oestradiol and
progesterone increase pituitary responsiveness by a direct action on
gonadotrophs (Drouin, Lagace and Labrie, 1976; Fink and Henderson,
1977; Hseuh, Erickson and Yen, 1978; Goodman and Knobil, 1981;
Turgeon and Waring, 1981), in the absence of a significant increase in
LH and LHRH release (Martin, Tyrey, Everett and Fellows, 1974;
Sarkar et al., 1976; Fink and Henderson, 1977; Lagace, Massicotte
and Labrie, 1980). The pituitary responsiveness to LHRH shows a
gradual increase between 13.30 h of dioestrus to 15.00 h of pro-oestrus
followed by a further abrupt increase between 15.00 h and 18.00 h on
pro-oestrus (Aiyer et al., 1974; Cooper et al., 1974; Gordon and
Reichlin, 1974). The initial increase in responsiveness depends on the
rise in plasma oestradiol (Aiyer and Fink, 1974; Henderson et al.,
1977). Oestradiol exerts a biphasic effect on pituitary responsiveness
to LHRH; it is inhibitory during the first few hours after administration
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then 8-12 h later it exerts a facilitatory effect on the pituitary
(Libertun, Orias and McCann, 1974; Henderson ef a/ ., 1977).
The increase in progesterone which accompanies the LH surge,
contributes to the later abrupt increase in pituitary responsiveness
(Aiyer et at., 1974a; Fink and Henderson, 1977). Since administra¬
tion of antiserum to progesterone does not block the LH surge (Ferin
et al., 1969), it is postulated that progesterone does not initiate the
increase in LH secretion.
A hypothalamic site of action for the positive feedback action of
oestradiol, at the level of the preoptic area (POA) rather than the
MBH (which appears to be the site for the negative feedback of
progesterone), has been suggested by experiments in which oestradiol
implants were placed in different regions of the brain (Goodman, 1978;
Goodman and Knobil, 1981). In contrast, progesterone implants
in the POA blocked oestradiol-induced LH (McLean, Change and
Nikitivitch-Winer, 1975) and LHRH release (Sarkar et al., 1976).
Moreover, progesterone decreased LHRH output in response to stimula¬
tion of the POA (Campbell, Schwartz and Firlit, 1977).
(b) Negative feedback effects of steroids:
The existence of a negative feedback relationship between gonadal
steroids and pituitary gonadotroph secretion was first postulated by
Moore and Price (1932). The negative feedback action of the gonadal
steroids maintains plasma gonadotrophin at fairly constant low concentra¬
tions in the intact male rat and in the female rat, at all stages of the
oestrous cycle except pro-oestrus (Gay et al., 1970). The
importance of the negative feedback control of the pituitary by the
gonadal steroids is demonstrated by the fact that removal of the gonadal
steroids evokes a pronounced and sustained increase in circulating
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concentrations of gonadotrophins (Gay and Midgley, 1969; Yamamoto,
Diebel and Bogdanove, 1970; Tapper, Grieg and Brown-Grant, 1974).
Administration of oestradiol, oestradiol and progesterone or testosterone
to gonadecomised rats rapidly reverses the post-castration rise in plasma
gonadotrophins (Gay and Bogdanove, 1969; Caligaris et at., 1971;
Kalra, Fawcett, Krulich and McCann, 1973; Negro-Vilar, Orias and
McCann, 1973). Progesterone administration without oestradiol is
ineffective in lowering the post-castration increase in gonadotrophin
secretion (McCann, 1963; Schally, Bowers, Carter, Arimura, Redding
and Saito, 1969), while administration of progesterone together with
oestradiol results in an enhancement of the negative feedback action of
oestradiol on LH secretion and a suppression of the positive feedback
effect of oestradiol on LH secretion (Goodman, 1978).
The mechanism by which steroids exert the negative feedback in
influence on gonadotrophin secretion appears to be by a modulation of
pituitary responsiveness and hypothalamic LHRH secretion. Numerous
studies have shown that androgens are capable of directly inhibiting
the pituitary response to exogenous LHRH (Kingsley and Bogdanove,
1973; Cheung and Davidson, 1977; Labrie, Drouin, Ferland, Lagace,
Beaulieu, DeLean, Kelly, Caron Raymond, 1978), although intra-
hypothalamic implants of testosterone suppressed plasma LH concentra¬
tions before any change in pituitary responsiveness was detected
(Cheung and Davidson. 1977). While it has been demonstrated that
LHRH neurones in the MBH respond to changes in plasma testosterone
titres (Kalra, Kalra and Mitchell, 1977; Kalra and Kalra, 1980), there
is no published study demonstrating a modulation of LHRH release by
the androgens. In contrast, measurements of immunoreactive LHRH
in portal vessel blood after oestradiol administration to ovariectomised
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rats showed that the rise in LHRH secretion induced by ovariectomy
could be reversed by oestradiol replacement (Sarkar and Fink, 1930).
However, since ovariectomy increased (Cooper et aI. , 1974; Henderson
et at., 1977) and oestradiol decreased (Libertun et a/., 1974; Debeljuk,
Vilchez-Martinez, Arimura and Schally, 1974; Henderson ef o/., 1977),
the magnitude of the LH release in response to LHRH administration,
a pituitary site of action for the negative feedback effect of oestradiol,
has also been postulated. In addition, oestradiol, progesterone,
oestradiol plus progesterone or testosterone inhibited the post-gonadec-
tomy rise in LHRH receptors in the pituitary (Clayton and Catt, 1981;
Fraser, Popkin, McNeilly and Sharpe, 1982b).
7. 3. 3 Role of Catecholamines in the Control of Gonadotrophin Secretion
Evidence of the involvement of brain catecholamines in the regula¬
tion of anterior pituitary secretion of gonadotrophins has been discussed
in several reviews (Fink and Geffen, 1978; Weiner and Ganong, 1978;
Barraclough and Wise, 1982). There is a vast amount of controversial
literature on the numerous experiments carried out in this field. Most of
the controversy is probably due to the complex experimental models used,
the lack of knowledge of the specificity of the pharmacological drugs used
and of the neuroanatomical pathways involved and the inadequacy of
quantitative techniques. An overview of the control of gonadotrophin
secretion by monoamines relevant to this thesis is given here.
(a) Neuroanatomy of the LHRH, dopamine (DA) and noradrenaline
(NA ) systems :
The LHRH system: The failure of early studies to demonstrate
LHRH in perikarya (Baker, Dermody and Reel, 1974; King, Parsons,
Erlansen and Williams, 1974; Gross, 1976) has been attributed to the
concentration of LHRH in the perikarya being below the threshold of
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the immunochemical techniques used, since subsequent studies in
which drugs such as colchicine were used to raise the LHRH concentra¬
tions clearly demonstrated the existence of LHRH immunoreactivity in
the rat central nervous system (Setalo, Vigh, Schally, Arimura and
Flerko, 1976; Vigh, Setalo, Schally, Arimura and Flerko, 1978;
Kawano and Daikoku, 1981). Conflicting conclusions have been reached
concerning the location of LHRH in the perikarya, presumably due to
differences in the LHRH antisera used. Some investigators favour the
mPOA or the suprachiasmatic nucleus as the region where the majority
of the LHRH cell bodies are localised (Barry, Dubois and Poulain, 1973;
Setalo etaI., 1976; Ibata, Watanabe, Kinoshita, Kubo, Sano, Sin,
Hashimura and Imagawa, 1979), while others favour the arcuate nucleus
(Zimmerman, Hsu, Ferin and Kozlowski, 1974; Naik, 1975). With the
use of highly specific antisera to LHRH and refined methodology, such
as the use of vibrotome sections of brains from normal untreated animals
which enable immunohistochemical procedures to be carried out on
unembedded tissue, the main regions which contain LHRH cell bodies
have been demonstrated to be the septal and mPOA (Merchenthaler,
Kovacs, Lovacs and Sdtgfld, 1980; Kawano and Daikoku, 1981; Witkin,
Padan and Silverman, 1982). The presence of LHRH cell bodies in the
MBH is still controversial (Kawano and Daikoku, 1981; Kelly and
Ronnekliev, 1981; Shivers, Harlan, Morrell and Pfaff, 1981). Lesions
which isolate the MBH reduced, but did not completely eliminate the
LHRH in this region (Weiner, Pattou, Kerdelhue and Kordon,
1975; Brownstein, Arimura, Schally, Palkovits and Kizer, 1976;
Taketani, Nozaki, Taga, Minaguchi, Kigawa, Sakamoto and Kobayashi,
1980). It has been suggested that these lesions failed to eliminate the
ventral-most LHRH input to the MBH, although the presence of
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neurones capable of synthesizing LHRH could explain why the MBH
retains 20-30% of its LHRH content after total deafferentation (Taketani
et al., 1975; Weiner etal., 1975; Brownstein et al. , 1976; Kordon,
Patton, Herman and Palkovits, 1982).
A dense localisation of LHRH axons in the lateral perivascular
region of the median eminence, surrounding the primary capillary
plexus of the portal vessels, has been repeatedly reported (Baker
etal., 1974; Kinget a/., 1974; Naik, 1975; Setalo, 1976). The major
innervation of the median eminence originates from cell bodies in the
septal and mPOA, passes through the MBH (retrochiasmatic area and
anterior hypothalamus) and is joined by fibres from the bed nucleus of
the stria terminalis. All these fibres merge at the level of the arcuate
nucleus to terminate in the lateral layer of the median eminence (Setalo
etal., 1978; Ibataeto/., 1979; Merchenthalar et al. , 1980; Kawano
and Daikoku, 1981). The fibres from this preoptico-infundibular tract
are suggested to release LHRH into portal vessel blood. Electro¬
physiological evidence has been presented for a role of the preoptico-
infundibular pathway in the control of pituitary gonadotrophin release
(Kawakama and Sakuma, 1976).
The organum vasculosum of the lamina terminalis (OVLT) is the
other main region, apart from the median eminence, that receives a
large number of LHRH axons (Brownstein, Palkovits, Tappaz, Saavedra
and Kizer, 1976; Selmanoff, Wise and Barraclough, 1980). The LHRH
cell bodies which project fibres to the OVLT are located mainly in the
preoptic-septal region (Weiner et al. , 1975; Palkovits, Mezey, Ambach
and Kivovics, 1978; Kawano and Daikoku, 1981; Witkin et al. , 1982).
Since the venous drainage of the OVLT is directly into the systemic
circulation, it seems unlikely that the LHRH terminals in the OVLT
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contribute directly to the LHRH in the portal vessel blood (Palkovits
et at., 1978). However, it has been proposed that LHRH terminals in
the OVLT release LHRH into the cerebrospinal fluid of the third
ventricle, which is then taken up by tanycyctes of the median eminence
and transported to pituitary portal capillaries (Ben-Jonathan, Mical
and Porter, 1974; Scott, Dudley and Knigge, 1974; Goldgefter, 1976).
This suggestion is supported by the demonstration that placement of
radioactive materials of different molecular weights (Ondo, Eskay,
Mical and Porter, 1973) or LHRH (Ben-Jonathan et at., 1974), in the
ventricular system rapidly results in the appearance of these substances
in the hypophysial portal vessel blood.
The Dopamine (DA) system: The distribution of DA neurones in
the rat brain has been studied primarily using histofluorescent tech¬
niques (Falck, Hillarp, Thieme and Torp, 1962; Dahlstrom and Fuxe,
1964; Ungerstedt, 1971; Lindvall and Bjorklund, 1974). Dopaminergic
neurones in the hypothalamus are derived from two independent
dopaminergic systems, the incertohypothalamic (ICH) and the tubero-
infundibular (TIF) systems. The ICH fibre system originates from the
dorsal and caudal hypothalamic cell groups (All, A13, A14) and project
for short distances into the medial preoptic, suprachiasmatic, dorso-
medial and anterior hypothalamic nuclei (Bjorklund, Lindvall and Nobin,
1975). The cell bodies of the TIF system are located in the arcuate
nuclei and a portion of the periventicular nucleus just dorsal to the
arcuate nucleus which terminate in the median eminence, pituitary stalk,
pars nervosa and pars intermedia of the adenohypophysis (Bjorklund,
Falck, Hromek, Owman and West, 1970; Smith and Fink, 1972;
Bjorklund, Moore, Nobin and Stenevi, 1973). The axons of the TIF
project ventrally to the median eminence and terminate in the peri-
24.
capillary spaces around the primary capillary plexus that coalesces to
form the hypophysial portal vessels (Fuxe and Hokfelt, 1966). That
these TIF DA terminals secrete DA is suggested by the demonstration
of significantly higher DA concentrations in the portal vessel blood than
in the systemic circulation (Ben-Jonathan et at., 1977).
The dorsolateral projection of the TIF DA axons to the median
eminence terminates close to LHRH-containing axon terminals (Bjorklund
et al. , 1973). By applying simultaneous histofluorescence and immuno-
histochemical techniques to rat median eminence tissue, it has been
shown that LHRH and catecholamines do not co-exist in the same terminals
(McNeill and Sladek, 1978; McNeill, Scott and Sladek, 1980). In
addition, administration of 6-hydroxydopamine caused severe depletion
of the DA content in the median eminence, without affecting the LHRH
content (Kizer, Arimura, Schally and Brownstein, 1975). However,
the close anatomical localisation of the DA- and LHRH-containing
terminals does support the suggestion that DA modulates the secretion
of LHRH into portal vessel blood, although axo-axonal contact between
DA and LHRH contacts between DA- and LHRH-containing terminals
have not yet been reported to be histologically visualised.
The Noradrenaline (NA) system: The major NA innervation
of the hypothalamus is from the ventral NA bundle (Ungerstedt,
1971; Lindvall and Bjorklund, 1974; Kizer, Muth and Jacobowitz,
1976; Loftstrom, Johnsson and Fuxe, 1976), which forms one
of the two major ascending NA pathways to the brain which is
derived from the lower brainstem cell groups of the lateral
tegmentum (Olsen and Fuxe, 1972). The ventral NA pathway
innervates the whole of the hypothalamus including
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the supraoptic, preoptic and arcuate nuclei, the internal layer of the
median eminence and the retrochiasmatic area (Moore and
Bloom, 1979; Palkovits, 1981). The other NA fibre system in the brain
which originates in the locus coeruleus has been shown by autoradio¬
graphic tracing methods (Segal, Pickel and Bloom, 1974; Jones and
Moore, 1977) to project only to the periventricular, paraventricular and
supraoptic nuclei and the dorsal medial nucleus of the hypothalamus.
(b) Experimental evidence supporting a role of catecholamines
in gonadotrophin secretion:
The experimental approaches used to elucidate the role of the
catecholamines in gonadotrophin secretion have been reviewed by
McCann and Moss (1975), Fink and Geffen (1978), Weiner and Ganong
(1978), Sawyer (1979), Barraclough and Wise (1982). The contribution
of central DA pathways in modulating the secretion of gonadotrophins
in the cycling rat is still controversial. The existence of an inhibitory
dopaminergic influence on LH secretion has been repeatedly claimed by
Fuxe and his colleageus. For example, studies assessing changes in
DA turnover showed that in the TIF DA terminals the turnover is
decreased during the critical period of pro-oestrus (Fuxe, Hokfelt,
Lofstrom et al., 1976; Lofstrom, 1977), while the inhibitory feedback
action of oestradiol on LH secretion induced a marked increase in DA
turnover in the lateral perivascular region of the median eminence
(Lofstrom, Eneroth, Gustaffson and Skett, 1977). In addition, ovula¬
tion was blocked by DA receptor agonists while blockade of the DA
receptors by pimozide, antagonised this action of the DA agonists (Fuxe,
Lbfstrom, Agnati, Everitt, Hokfelt, Jonsson and Wiesel, 1975). On the
other hand, a stimulatory role for DA in the control of LH secretion has
been proposed by McCann and his colleagues, largely due to demonstrations
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that intraventricular injections of DA agonists or infusions of DA
stimulated LH secretion in oestrogen-primed female rats (Vijayan and
McCann, 1978b). Support for both a stimulatory and an inhibitory
influence of DA on LH secretion has accumulated, often resulting in
further controversy. For example, in vitro studies showed that DA
stimulated the release of LHRH from hypothalamic fragments (Rotsztejn,
Charli, Pattou, Epelbaum and Kordon, 1976; Negro-Vilar and Ojeda,
1978), while lesions of DA fibres localised predominantly in the median
eminence also results in a stimulation of the LHRH surge in prepubertal
rats treated with pregnant mare serum gonadotrophin (PMSG: Sarkar,
Smith and Fink, 1981). Studies with DA receptor agonists and antag¬
onists have suggested that DA could either facilitate or inhibit LHRH
and thus LH secretion (Sarkar and Fink, 1980). The existence of two
or more pharmacologically distinct receptors with opposing effects may
explain these findings.
The evidence favouring a stimulatory role of NA in LH secretion
and ovulation in the rat (Rubinstein and Sawyer, 1970; Tima and
Flerko, 1974; Kriegand Sawyer, 1976) has been confirmed by a number
of studies. These include the demonstration that the turnover of NA
in the median eminence and mPOA is increased before the LH surge on
pro-oestrus and in prepubertal rats treated with PMSG (Agnati, Fuxe,
Lofstrom and Hokfelt, 1977; Lofstrbm, 1977; Negro-Vilar, Chiocchio
and Tremezzani, 1977; Ranee, Wise, Selmanoff and Barraclough, 1981).
In addition, castration increased the NA content of the median eminence
(Chiocchio, Negro-Vilar and Tremezzani, 1976), while interference with
the NA system reduced the post-castration increase in plasma LH
concentrations (Drouva and Gallo, 1976; Gnodde and Schuiling, 1976).
Furthermore, the steroid-induced suppression of the post-castration
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rise in LH secretion was accompanied by a reduction in the turnover
of NA in the median eminence (Lofstrom et al., 1977). Acute injections
of 6-hydroxydopamine^ to lesion the ventral NA tract, blocked the
spontaneous and steroid-induced surges of LH (Martinovic and McCann,
1977) although a permanent loss of oestrous cycles after lesions of
the ascending NA systems did not occur (Nicholson, Greeley, Humm,
Youngblood and Kizer, 1978; Clifton and Sawyer, 1979, 1980).
However, a-adrenoceptor blockers (e.g. phenoxybenzamine) inhibited
the PMSG-induced surges of LH and LHRH in the prepubertal rat
(Sarkar and Fink, 1981; Sarkar, Smith and Fink, 1981). The facilita¬
tion of LHRH release into pituitary stalk blood by NA neurones is in
agreement with studies that demonstrated that NA released LHRH from
hypothalamic fragments in vitro (Negro-Vilar and Ojeda, 1978) and
that catecholamines do not act directly on the pituitary gland to alter
LH secretion (Schneider and McCann, 1970; Kamberi, Mical and Porter,
1970, 1971).
The coincidental localisation of DA cell bodies and oestrogen target
areas in the periventricular and arcuate nucleus and the ability of
catecholamine-containing neurones to concentrate tritiated oestrogen in
the arcuate nucleus and median eminence (Grant and Stumpf, 1973),
as well as immunofluorescence studies following pharmacological manipula¬
tions , have suggested that DA neurones are under feedback control by
gonadal steroids. It was also suggested that an inhibition of LHRH
release, by increased DA output, accounted for the inhibitory feedback
action of gonadal steroids on gonadotrophin release. The release of
LHRH from incubated medial basal hypothalamic fragments (Bennett,
Edwardson, Holland, Jeffcoate and White, 1975) and the palisade layer
of the median eminence (Rotsztejn et a!., 1976) was increased by DA,
28.
provided the animals were pretreated with oestradiol (Rotsztejn,
Charli, Pattou and Kordon, 1977). On the other hand, some studies
suggest that the treatment of ovariectomised rats with gonadal steroids
converts the action of DA to a stimulatory one with respect to LH
release (Kawakami, Kimura, Manaka and Kawagoe, 1975; Vijayan and
McCann, 1978b). In the male, the majority of the evidence favours a
stimulatory role for oestrogens on DA turnover in the median eminence
(Fuxe, Hokfelt and Nilsson, 1972; McEwen and Parsons, 1982)
and release into portal vessel blood (Gudelsky, Nansel and Porter, 1981).
A sex difference in the response of hypothalamic TIF DA systems during
the cycle and in response to gonadectomy has also been found (Demarest,
McKay, Riegle and Moore, 1981b; DePaolo, McCann and Negro-Vilar,
1982). The contribution of sex steroids to this sexual differentiation
is, however, still under investigation.
1. 4 Control of Prolactin Secretion
7. 4. 7 Hypothalamic Influence
In contrast to other pituitary hormones, the secretion of prolactin
(PRL) in mammals is regulated by a predominantly inhibitory influence
from the hypothalamus (MacLeod, 1976). This was suggested
by studies showing that a dramatic increase in PRL release followed
transplantation of the pituitary to sites such as the kidney capsule which
are removed from the hypothalamic influence (Everett, 1954; Chen,
Amenomori, Lu, Voogt and Meites, 1970) destruction of the hypothalamus
or deafferentation of the medio-basal hypothalamus (Haun and Sawyer,
I960; Chen et al. , 1970; Bishop, Krulich, Fawcett and McCann, 1971;
Blake, Scaramuzzi, Norman, Hilliard and Sawyer, 1973)or pituitary stalk
section (Dienfenbach, Carmel, Frantz and Ferin, 1970; Kanematsu and
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Sawyer, 1973). Moreover, pituitary cells maintained in culture released
large amounts of PRL (MacLeod, 1976). Acid extracts of rat
hypothalamus decreased the concentration of PRL in the medium, when
the extracts were incubated with rat anterior pituitary gland, but not
rat cerebral cortex; this suggested the existence of hypothalamic PRL
inhibiting factors (PIF; Talwalker, Ratner and Meites, 1963). This
view was supported by the fact that injection of hypothalamic extracts
either systemically (Amenomorri and Meites, 1970) or into the hypophysial
portal vessels (Kambieri, Mical and Porter, 1971) reduced plasma PRL
concentrations but increased plasma LH and FSH concentrations.
7. 4. 2 Role of Biogenic Amines
A function of the hypothalamic catecholamines in regulating the
secretion of PRL was first suggested by Kanematsu, Hillard and
Sawyer (1963). They demonstrated that injections of reserpine, like
electrolytic lesions of the hypothalamus, induced lactation and decreased
pituitary PRL concentrations. Subsequent studies showed that
administration of either monoamine oxidase (MAO) inhibitors that prevent
catabolism of the catecholamines and so increased catecholamine con¬
centrations, or L-dopa, the precursor of the catecholamines, inhibited
the release of PRL and post-partum lactation in rats (Mizuno, Talwalker
and Meites, 1964: Lu and Meites, 1972; Donoso, Banzan and Barcaglioni,
1974). Agents that reduced synthesis of catecholamines or blocked
catecholamine receptors were found to increase PRL release
(Meites and Clemens, 1972; Weiner and Ganong, 1978). The suppression
of PRL release by infusion of a purified preparation of either procine
PIF or catecholamines into hypophysial portal vessels of rats also
supported a role of the catecholamines in regulating PRL release
(Takahar, Arimura and Schally, 1974). Moreover, enzymatic digestion
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of hypothalamic extracts with MAO or adsorption of catecholamines with
alumina were found to abolish PIF activity (Shaar and Clemens, 1974).
Intravenous administration of DA was later found to inhibit PRL
secretion in a number of physiological situations including the oestrous
cycle, sleep and stress as well as from PRL-secreting tumours
(Weiner and Ganong, 1978). Since DA administered peripherally did
not cross the blood-brain barrier, it was postulated that DA was
acting at the level of the anterior pituitary or brain regions outside
the blood-brain barrier such as the median eminence and other circum-
ventricular organs. Evidence supporting the view that DA is a PIF
includes,
i) the demonstration that TIF dopaminergic neurones terminate
in the external layer of the median eminence, adjacent to the
primary plexus of capillaries of the hypophysial portal circula¬
tion (Hokfelt, 1967; Fuxe, Hokfelt and Nilsson, 1969);
ii) the presence of DA in portal vessels supplying blood to the
anterior pituitary of rats and monkeys at concentrations suf¬
ficient to inhibit pituitary PRL release (Ben-Jonathan, Oliver,
Weiner, Mical and Porter, 1977; Gibbs and Neill, 1978; Neill,
Frawley, Plotsky and Tindall, 1981);
iii) the suppression of PRL secretion from pituitary PRL cells
and the pituitary gland by physiological concentrations of DA
(MacLeod and Lehmeyer, 1974), or by DA agonists (Lamberts
and MacLeod, 1978);
iv) the demonstration of specific DA receptors on the plasma mem¬
brane of pituitary cells (Caron, Beaulieu, Raymond, Gagne, Drouin,
31.
Lefkowitz and Labrie, 1978; Calabro and MacLeod, 1978; Cronin,
Roberts and Weiner, 1978);
v) the demonstration of an increase in DA turnover in the
TIF DA neurones, but not in the nigrostriatal neurones, when
circulating PRL concentrations are increased by injections of PRL
(Gudelsky, Simpkins, Mueller, Meites and Moore, 1976; Hokfelt
and Fuxe, 1972), pituitary transplants (Olsen, Fuxe and Hokfelt,
1972) or in lactating and pregnant rats (Fuxe et a!., 1969);
vi) that removal of pups from lactating mothers for 24 h, which reduced
circulating PRL, resulted in a significant increase in DA concentra¬
tions in pituitary stalk blood (Ben-Jonathan, Neill, Arbogast,
Peters and Hoefer, 1980), while a decrease in the DA content of
the hypothalamus occurred within 5 min after the onset of suckling
(Mena, Enjalbert, Carbonnel, Priam and Kordon, 1976; Chiocchio,
Cannata, Cordero-Funes and Tramezzani, 1979);
vii) damage to TIF DA neurones was associated with development of
PRL-secreting pituitary tumours in rats (Sarkar, Gottschall and
Meites, 1982).
Several lines of evidence suggest that PIF activity in purified
hypothalamic extracts devoid of catecholamines (Greibrokk, Currie,
Johansson, Hansen, Folkers and Bowers, 1974; Enjalbert, Priam and
Kordon, 1977; Schally, Redding, Arimura, Dupont and Linthicum, 1977),
is due to y-amino butyric acid (GABA), which may supplement the
inhibitory influence of DA on PRL release (Schally et at., 1977;
Grandison and Guidotti, 1979; Dow, Fink, Grieve and Mitchell, 1982;
Nicolleti, Canoninco, Rampello, Patti et at., 1983). NA also
inhibited PRL release from the anterior pituitary in vitro (MacLeod, 1969;
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Birge, Jacobs, Hammer and Daughaday, 1970; Koch, Lu and Meites,
1970; Shaar and Clemens, 1974) and when injected into portal vessels
(Takaharaef al., 1974). However, NA terminals in the median eminence
are located predominantly in the internal zone, some distance from the
primary portal capillaries (Swanson and Hartmen, 1975) and the con¬
centration of NA in portal vessel blood was significantly lower than
peripheral blood (Ben-Jonathan et al., 1977). Although pharmacological
studies suggest the NA may be involved in pulsatile release of PRL in
oestrogen-induced and stress-induced release of PRL (Subramanian
and Gala, 1976; Carr, Conway and Voogt, 1977; Langelier and Gala,
1977), it appears unlikely that NA-containing neurones are involved to
any great extent in regulating unstimulated or suckling-induced release
of PRL (Blake, Weiner, Gorski and Sawyer, 1972; Carr et al., 1977;
Weiner and Ganong, 1978).
A stimulatory role of serotonin (5HT) is generally accepted
(Kambieri et at., 1971; Lu and Meites, 1973; Caligaris and Taleisnik,
1974; Garthwaite and Hagen, 1979; Clemens and Shaar, 1980), involving
activation of hypothalamic 5HT neurones originating from the midbrain
raphe nucleus (Advis, Simpkins, Bennett and Meites, 1979; Van de Kar
and Lorens, 1979). 5HT did not stimulate PRL release directly from the
anterior pituitary (Birge et al.. 1970; Kambieri et al., 1971). The
mechanism of action of 5HT may involve stimulation of the release
of vasoactive intestinal polypeptide (VIP), a putatitive PRF (Kato,
Iwasaki, Iwasaki, Abe, Yanaihara and Imura, 1978; Vijayan, Samson,
Said and McCann, 1979b; Shimatsu, Kato, Matushita, Katakami, Yanaihara
and Imura, 1982), rather than inhibition of dopaminergic suppression
of PRL release (Clemens, Rousch and Fuller, 1978; Lamberts and
MacLeod, 1978) or suppression of DA release into portal vessel blood
(Pilotte and Porter, 1981).
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7. 4. 3 Prolactin Releasing Factors (PRF)
Evidence that PRL may be under stimulatory as well as inhibitory
control was first presented by Nicoll, Yaron, Nutt and Daniels (1970),
who found that hypothalamic extracts which initially inhibited PRL
secretion from incubated pituitary glands, stimulated PRL release
during prolonged periods of incubation.
(a) Thyrotrophin releasing hormone (TRH):
The tripeptide, pGlu-His-Pro-NH2 (TRH) has been found to
stimulate the release and synthesis of PRL in humans (Bowers, Friesen,
Hwang, Guyda and Folkers, 1971; Jacobs, Snyder, Wilber, Utiger,
Utiger and Daughadey, 1971; Tashijan, Barowsky and Jensen, 1971)
and in rats (Mueller, Chen and Meites, 1973; Rivier and Vale, 1974).
The minimum concentration of TRH that was required to increase plasma
TSH concentration was also effective in stimulating PRL release (Noel
Dimond, Wartofsky, Earll and Frantz, 1974). The demonstration that
TRH stimulated PRL secretion by ectopic pituitary transplants in rats
with bilateral median eminence lesions (Porteus and Malven, 1974)
and by pituitary tumour cells in vitro (Tashijan et al., 1971), as well
as rat pituitary cell cultures (Yale, Blackwell, Grant and Guillemin,
1973), suggested that TRH acted directly on the pituitary gland and
not through a hypothalamic releasing factor. In addition, TRH induced
a rapid increase in the firing rates of PRL-secreting cells (Dufy,
Vincent, Fleury, Du Pasquier, Gourdji and Tixier-Vidal, 1979). An
increase in TRH concentration in portal vessel blood (Fink, Koch and
Ben Aroya, 1983) and TSH concentrations in systemic blood at pro-
oestrus (Brown-Grant, Dutton and ter Haar, 1977) has been associated
with the pro-oestrous PRL surge. While TRH has been found to
stimulate PRL release in the presence of DA and DA agonists (Hill-Samli
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and MacLeod, 1974, 1975; Labrie, Beaulieu, Ferland, Raymond, Di
Pauli, Caron, Veilleux, Denizeau, Euvrard, Raynaud and Boissier, 1979),
the PRF activity of TRF was enhanced by a brief removal of DA from
the perifusion system (Fagin and Neill, 1981). In lactating females,
TRH injections do not release PRL when given before a brief suckling
period but are highly effective if given after it (Grosvenor and Mena,
1980). It has been suggested, therefore, that although the small (~20%)
decrease in the release of DA into stalk blood following mammary nerve
stimulation (de Greef, Plotsky and Neill, 1981) cannot account for the
5- to 7-fold increase induced in PRL secretion, a brief decrease in
hypothalamic DA secretion resulted in an increased responsiveness of
the pituitary to the PRF(s) released by the hypothalamus, in response
to suckling (Plotsky and Neill, 1982).
PRL and TSH secretions are, however, dissociated in a number of
physiological conditions such as lactation (Gautvik, Tashijan, Kourides,
Weintraub, Graeber, Maloof, Suzuki and Zukerman, 1974), when plasma
PRL is elevated and plasma TSH concentrations are normal, and stress
(Reichlin, 1966; Meites and Clemens, 1972; Harris, Christianson,
Smith, Fang, Braverman and Vagenakis, 1978), when plasma PRL is
elevated and plasma TSH concentrations may be lower than normal.
The fact that extracts of the hypothalamus possess PRF activity distinct
from TRH (Boyd, Spencer, Jackson and Reichlin, 1976; Szabo and
Frohman, 1976; Grosvenor and Mena, 1980) supports the existence of
additional PRF(s) distinct from TRH. This view is substantiated by
pharmacological studies which show that administration of L-dopa or
pilocarpine induced a marked fall in plasma PRL concentrations without
affecting plasma TSH concentrations and oestrogen injections stimulated
PRL release and decreased TSH secretion (Meites and Clemens, 1972;
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Meites, 1977). The recent demonstration that in the ewe,
TRH-immunisation suppresses TSH secretion without exerting any
major influence on PRL secretion in a number of physiological situations
(Fraser and McNeilly, 1982) also supports the view that TRH plays a
minor role in the physiological control of PRL secretion.
(b) Oestrogens:
Oestrogens have also been found to stimulate PRL synthesis and
release (Ratner, Talwalker and Meites, 1963; Chen and Meites, 1970;
Ajika, Krulich, Fawcett and McCann, 1972; Frantz, Kleinberg
and Noel, 1972; Neill, 1980). Oestrogens have been demon¬
strated to be essential for the surge of PRL on pro-oestrus, when a
decrease of DA turnover in the hypothalamus has been reported to occur
(Ahren, Fuxe, Hamberger and Hokfelt, 1971). Antiserum to oestrogens
administered on dioestrus abolished the expected increase in plasma
PRL on pro-oestrus (Neill et al., 1971). This effect of the oestrogen
antiserum could be prevented by concomitant injections of diethylstil-
bestrol (a synthetic oestrogen) with the antiserum. The presence of
oestrogen receptors on lactotrophs (Keefer, Stumpf and Petrusz, 1976)
and the demonstration that oestradiol-17g induced action potentials in
pituitary cells (Dufy et al., 1979) suggest that oestradiol could act on
prolactotrophs to stimulate PRL release. Although the oestrogen-
induced increase in plasma PRL concentrations does not appear to be
due to the suppression of DA release into hypophysial portal vessel
blood (Gudelsky et al., 1981), oestrogen did reverse the inhibitory
effect of DA on PRL secretion from cultured pituitary cells (Raymond,
Beaulieu, Labrie and Bossier, 1978). Oestrogen treatment of ovariec-
tomised rats either had no effect or decreased dopaminergic binding sites
in the anterior pituitary (Di Paolo, Carmicheal, Labrie and Raymond,
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1979; Heiman and Ben-Jonathan, 1982), while a significant increase
occurred in the number of pituitary TRH binding sites in adult female
rats treated with oestrogen (De Lean, Ferland, Drouin, Kelly and
Labrie, 1977). These data suggest that the mechanism by which
oestrogen stimulates PRL release may involve a facilitation of TRH-
induced release of PRL and possibly a suppression of DA binding to
lactotrophs, in addition to a direct effect of oestrogen on the anterior
pituitary. An oestrogen-induced reduction in the capacity of the PRL
cell to incorporate DA into PRL secretory granules (Gudelsky et aI.,
1981) provides evidence for another site of action by which oestrogens
may modulate PRL release. In primates, oestrogen reinforces the
inhibitory effect of DA on PRL release and has little stimulatory effects
on PRL release, in contrast to its potent PRL-releasing effects and
antagonism of DA inhibition in rodents (Judd, Rigg and Yen, 1979).
(c) Other prolactin releasing factors:
The suggestion that some metabolites of oestrogens, the catechol-
oestrogens, are more active than the oestrogens themselves in stimulating
PRL secretions is discussed in Chapter y.. A number of peptides found
in the hypothalamus or pituitary also influence PRL release in vivo but
not in vitro (Vale, Rivier and Brown, 1977; Neill, 1980).
Of these peptides that increase PRL secretion, neurotensin (NT) and
vasoactive intestinal polypeptide (VIP) are the best candidates for
physiological PRFs distinct from TRH (Carraway and Leeman, 1973;
Enjalbert, Arancibia, Ruberg, Priam, Bluet-Pajot, Rotsztejn and Kordon,
1980; Vijayan and McCann, 1980; Enjalbert, Arancibia, Ruberg, Bluet-
Pajot and Kordon, 1982). Both NT and VIP are found in cell bodies in
the hypothalamus, in terminals of the median eminence and have been
reported to be released from hypothalamic nerve terminals upon
37.
depolarisation, by a calcium-dependent mechanism (Uhl and Snyder,
1976; Kobayashi, Brown and Vale, 1977). The PRL-releasing action
of NT is additive to that of VIP and TRF (Ruberg, Rotsztejn, Arancibia,
Besson and Enjalbert, 1978; Enjalbert, Arancibia, Priam, Bluet-Pajot
and Kordon, 1982). The effects of NT or VIP on PRL cells do not
involve either DA, opiate or GAB A receptors since antagonists to these
substances were ineffective in modulating PRL secretion by NT and VIP
(Ruberg ef al., 1978;' Enjalbert et al., 1980). However, VIP-stimulated
release of PRL is inhibited by L-dopa, the precursor of DA (Kato et al.,
1978) and VIP significantly diminished the effect of DA on PRL secretion
from cultured pituitary cells (Kato et al., 1978). NT-induced stimula¬
tion of PRL secretion was partially reversed by diphenhydramine (a
histamine antagonist), suggesting an involvement of histamine pathways
in the modulation of PRL release by NT (Carraway and Leeman, 1973;
Vale et aI., 1977). VIP and NT immunoreactivity has been found in
the anterior pituitary, although only VIP has been reported to be
present in portal vessel blood at greater concentrations than in systemic
blood (Said and Porter, 1979; Shimatsu et al., 1981). In addition,
serotonin, a potent stimulator of PRL release, has recently been reported
to increase VIP release into portal vessel blood (Shimatsu et al., 1982).
Other details of the postulated mechanism of action of VIP are discussed
in Chapter VII.
7. 4. 4 Hyperprolactinaemia and Hypogonadism
The existence of an inverse relationship between PRL and LH
secretion together with an inhibition of ovarian cyclicity during
lactation (Lu, Chen, Huang, Grandison, Marshall and Meites, 1976b;
Smith, 1978c) and clinical abnormalities of the hypothalamo-hypophysial
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axis (Besser and Edwards, 1972; Frantz, Kleinberg and Noel, 1972)
has prompted investigations in to the physiological role of PRL in
regulating the release of gonadotrophins. Hyperprolactinaemia in
pathophysiological conditions in humans is frequently associated with
hypogonadism (Bohnet, Dahlen, Wuttke and Schneider, 1976; Carter,
Tyson, Tolis, Van Vliet, Faiman and Friesen, 1978), while ovulation
and ovulatory surges of hormones are suppressed in nursing women
(Delboye, Demaegd and Robyn, 1978; McNeilly, Howie and Houston,
1980 ). The galactorrhoea-amenorrhoea syndrome in non-nursing women
represents another situation in which hyperprolactinaemia and decreased
LH secretion occur, although this situation occurs in the absence of a
suckling stimulus (Franks, Murray, Jequier, Steele, Nabarrow and
Jacobs, 1975; Seki, Seki and Okumura, 1975; Kleinberg, Noel and
Frantz, 1977). Treatments of pituitary tumours by surgery, irradiation
or by DA agonists (e.g. Bromocriptine) that lower PRL concentrations,
are found to effectively restore fertility and increase LH secretion
(Von Werder, Eversmann, Rjosk and Fahlbusch, 1982).
A reduction in plasma gonadotrophin concentrations can be produced in
experimental animals by inducing persistent hyperprolactinaemia, by
placement of pituitary glands or pituitary tumours under the kidney
capsule (Everett, 1954; Mena, Haiweg and Grosvenor, 1968; Grandison
et at., 1977). These animal models together with the lactating rat
model have been studied to determine the mechanism(s) by which
hyperprolactinaemia modulates gonadotrophin secretion (Smith,
1980), although in contrast to the animal models plasma PRL concentra¬
tions are not continuously elevated over the entire post-partum period
(Lu et a/., 1976; Smith, 1978a). In the lactating rat, the suckling
stimulus may be the primary factor responsible for reduced LH release
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(Smith, 1978a), although high PRL concentrations in plasma contributed
to the suppression of LH secretion during late lactation and after
ovariectomy (Muralidhar, Maneckjee and Mougdal, 1977; Smith, 1978a).
Certainly, the suckling stimulus facilitated the action of PRL in sup¬
pressing LH release (Muralidhar et al., 1977; Smith, 1978a).
Several mechanisms have been proposed to explain how hyper-
prolactinaemia inhibits LH synthesis and release and delays the post-
gonadectomy rise in plasma gonadotrophins. In general, they suggest
that hypogonadism associated with pathological and experimental hyper-
prolactinaemia encompasses deficits over the entire hypothalamic-
pituitary-gonadal axis. At the hypothalamic level, excess PRL increases
the inhibitory influence of DA on LH release (Fuxe, Hokfelt and Nilsson,
1972; Hohn and Wuttke, 1978; Gudelsky and Porter, 1980; Moore,
Demarest and Johnson, 1980) and suppresses the positive feedback
effect of gonadal steroids on LH release (Glass, Shaw, Butt, Edwards
and London, 1975; Smith, 1978b; Steger and Pelusa, 1978). The
sensitivity of the hypothalamic-pituitary axis to negative feedback by
gonadal steroids appears to be increased by hyperprolactinaemia
(McNeilly, Sharpe, Davidson and Fraser, 1980b). On the other hand,
the pituitary appears to be less sensitive to stimulation and priming by
LHRH during hyperprolactinaemic conditions (Lu et al., 1976a; Muralidhar
et al., 1977; Smith, 1978c, 1980; Winters and Loriaux, 1978; Greeley
and Kizer, 1979; Wuchen and Cheung, 1981). The role of the adrenals
and gonads in contributing to hypogonadism by hyperprolactinaemia is
still not clearly established (Bartke, Smith, Micheal, Peron and Dalterio,
1977; McNeilly et at., 1978; Greeley and Kizer, 1979; Bartke, 1980;
Evans, Cronin and Thorner, 1982).
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1.5 Aims of this Thesis
From the above account of the mechanisms known to be involved
in the regulation of gonadotrophin and PRL secretion, it is clear that
several questions remain unanswered. The unique anatomical arrange¬
ment of the hypophysial portal vasculature enables the study of the
control of the release of adenohypophysial hormones since substances
released into the portal vessels regulate the adenohypophysial secretions
(Section 1.1). The development of techniques (Section 1.1.2) that
have enabled the collection of hypophysial portal vessel blood samples
in the living, although anaesthetised, rat have been decisive in estab¬
lishing the role of LHRH as a hypothalamo-hypophysial releasing factor
(Section 1.1.4). The aim of the experiments described in this thesis
was to answer some of the questions regarding the control of gonado¬
trophin secretion by determining changes in the secretion hypothalamic
peptides into the hypophysial portal vessel circulation. The key
questions asked were whether
i) the negative feedback influence of the testicular steroids on
gonadotrophin secretion (Section 1.3.2) is exerted, in part
at least, by suppressing the release of LHRH into pituitary
stalk blood - Chapters III and IV;
ii) the enzymatic conversion of the oestrogens to hydroxylated
metabolites produces biologically active metabolites, as is
found to occur when testosterone is reduced to 5a-dihyro-
testosterone - Chapter V.
iii) prolonged hyperprolactinaemia affects the secretion of LHRH
and DA into pituitary stalk blood, in view of the marked suppres¬
sion of gonadotrophin release that is produced by hyperprolactin-
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aemia (Section 1.4.4) and the known role of DA as a PIF
(Section 1.4.2) - Chapter IV;
iv) during periods of prolonged hyperprolactinaemia, the ability
of testosterone to suppress the release of LHRH into stalk blood
is more pronounced than during periods when the concentration
of PRL in the systemic circulation is not increased above normal -
Chapter TV;
v) there is any basis for considering that CCK, gastrin and VIP,
three peptides originally isolated in the gut and subsequently
in the brain (Section 1.1.5), should be considered as physiological
releasing factors as defined by the neurohumoural hypothesis
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2.1 Animals
Wistar COBS ('caesarian originated barrier sustained') rats
used in the majority of the experiments were supplied by Charles
River Ltd (Margate, Kent) or obtained from breeding colonies in the
Department of Pharmacology, University of Edinburgh. For studies
on rats with pituitary transplants (Chapter IV), rats of the inbred
PVG strain were supplied by Bantin and Kingman Ltd (Hull).
The rats were housed in groups of 4 per cage in a room equipped
with a programmed 14 h light - 10 h dark illumination cycle (lights on
06.00- 20.00 h) at a constant temperature of 23 ± 1°C and a constant
humidity. Tap water and food (rat diet Oxoid, modified 4IB) were
freely available. All animals used were adapted for a minimum period
of one week before experiments.
2.2 Experimental and Surgical Procedures
2. 2. 7 Anaesthetics, Drugs and Steroids
The following anaesthetics were used:
(i) ALTHESIN (Glaxo, Middlesex)
9 mg alphaxolene (3ot-hydroxy-5a-pregnane-ll,20-dione) plus
3 mg alphadone acetate (21-acetoxy-3a-hydroxy-5a-pregnane-ll, 20-
dione) per ml aqueous vehicle consisting of 20% polyoxyethylated castor
oil made isotonic with sodium chloride. The dosage was 0.4-0.6 ml/
100 g body weight (b.w.) for females and 1.0- 1.5 ml/100 g b.w. for
males, injected intraperitonially (i.p.).
(ii) ANAESTHETIC ETHER (Macfarlane Smith Ltd, Edinburgh)
Diethyl ether, dosage as required.
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(iii) AVERTIN (Winthrop, Surrey)
1 g tribromoethanol per ml amylene hydrate diluted 2.0 : 8.0 ml
in absolute alcohol, then 1.0 : 9.0 ml 0.9% sodium chloride solution.
The dose used was 0.25 g/kg b.w., i.p.
(iv) KETALAR (Parke-Davis & Co. Ltd, Pontypool, Gwent)
Ketamine hydrochloride, diluted with 0.9% sodium chloride, to
give a 15 mg/ml solution. The dosage was 100-150 mg/kg b.w. in a
2.5- 3.8 ml i.p.
(v) SAGATAL (May & Baker Ltd, Dagenham)
60 mg/ml sodium pentobarbitone in alcohol. This was admin¬
istered at a dose of 36 mg/kg b.w., i.p.
(vi) URETHANE (BDH Chemicals Ltd, Poole)
Ethyl carbamate made into a 10% solution with 0.9% sodium chloride
solution. The dose was 1 mg/kg b.w., i.p.
(vii) XYLOCAINE (Astra Sweden)
Lignocaine hydrochloride 2.0%. A dose of 0.2-0.4 ml/rat was
injected subcutaneously (s.c.).
The following drugs and steroids were used:
(!) HEPARIN (Tularin', Weddel Pharmaceuticals Ltd, London)
2500 i.u./rat in a volume of 0.5 ml was injected into the external
jugular vein in all experiments in which pituitary stalk blood was
collected. Heparinised saline was made up by diluting stock heparin
with 0.9% saline to give 1000 i.u./ml.
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(ii) PREGNANT MARE SERUM GONADOTROPHIN ('Folligon',
Intervent Laboratories Ltd, Cambridge)
Stock solutions of 200 i.u./ml solvent were diluted with saline
(0.9%) and stored frozen in 0.5 ml aliquots of 100 i.u. A dose of
20 i.u./rat in 0.1 ml volume was injected i.p.
(iii) STEROIDS
5-dihydroxytestosterone propionate (Steraloids Inc., New Hampshire,
U.S.A.)
The powder was dissolved in ethyl oleate and the dose required
administered by s.c. injection.
2-hydroxyoestradiol and 2-hydroxyoestrone (Sigma, St. Louis,
Missouri)
The required dose was made up just before use in propylene
glycol containing 0.01% absorbic acid and injected s.c. in a volume
of 0.25 ml. The crystalline powder was stored in the dark under
nitrogen.
oestradiol benzoate ('Benztrone', Paines and Byrne, Middlesex) ;
testosterone propionate ('Viromone', Paines and Byrne, Middlesex)
These were both supplied dissolved in ethyl oleate. The required
concentration was obtained by diluting the stock with arachis oil
(Hopkins and Williams).
oestrone (Sigma, Poole, Dorset)
The powder was dissolved in propylene glycol containing 0.01%
ascorbic acid and the required dose administered by s.c. injection.
testosterone (Sigma, Poole, Dorset)
Crystalline testosterone was used to fill silastic tubing to make
implants.
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2. 2. 2 Determination of the Oestrous Cycle, Ovulation and Uterine
Weights
The oestrous cycles were monitored by daily vaginal lavages.
The following cytological characteristics were observed in the vaginal
smears of 4-day cyclic rats.
Oestrus: Cornified epithelial cells.
Metoestrus: Predominantly leucocytes with nucleated
and cornified epithelial cells.
Dioestrus: Leucocytes only with occasional epithelial
cells.
Pro-oestrus: Nucleated epithelial cells, often in clumps.
Approximately 95% of the rats showed 4-day oestrous cycles and
these animals were used for experiments only after at least two con¬
secutive, regular cycles had been confirmed.
The uterotrophic effect of the catechol oestrogens (Chapter V)
was assessed by weighing the uterus after removal from the animal.
The uterus was removed and stripped of adhering fat and connective
tissue, and any fluid present was expressed. The uterus was blotted
before being weighed.
2. 2. 3 Castration and Testosterone Implants
Male rats were castrated underA(24 mg/rat) anaesthesia. A single
midline incision in the ventral surface of the scrotal sac was used to
expose the tunica vaginalis of each testis. A further incision here
enabled complete exteriorisation of the testis which was ligated around
the spermatic cord. Both testes and vas deferens were removed.
Before suturing the incisions, the area was sprayed with antibiotic
(Rikospray Antibiotic; Bacitracin, Polymyxin and Neomycin aerosol,
Riker Laboratories, Loughborough). Sham-castration consisted of
exteriorising and then replacing the gonad.
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Implants of testosterone were prepared by the following method.
Silastic tubing (Dow Corning Corp., Michigan) with an inner diameter
of 1.57 mm, an outer diameter of 3.18 mm and 10 mm or 30 mm in
length were filled with crystalline testosterone (Sigma, Poole). The
ends were closed with Silastic glue (Dow Corning Corp., Michigan).
The implants were then kept in 1 litre of 0.9% saline for 24 h at room
temperature with 3 changes of saline 2, 6 and 12 h later. Any leakage
from the implants can be detected at this stage by checking that the
saline is not clouded. The implants were stored in dry, sealed plastic
vials.
Before use, the implants were put in 0.9% saline for 4 h at room
temperature. This prevented a massive leakage of testosterone which
occurred if the implants were put straight into the animal. The
implants were placed under the skin through a small incision in the
back. Metal clips were used to close the incision.
2. 2. 4 Antrectomy and Vagotomy
Both these procedures were performed on anaesthetised animals.
A midline incision was made to provide wide exposure of the abdominal
organs. The stomach and duodenum were ligated and the gastric
antr urn dissected out.
Bilateral abdominal vagotomy was carried out by transecting
between two ligatures tied one above the other around the oesophagus
and the right and left vagal trunks. This procedure was carried out
under a Zeiss operating microscope to ensure both vagal trunks to the
gastric antrum were cut.
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2. 2. 5 Pituitary Stalk Blood Collection
The hypophysial portal vessels were exposed and blood samples
collected from the cut pituitary stalk, using the method developed by
Worthington (1964), and modified by Fink and Jamieson (1976), based
on the transpharyngeal approach of Green and Harris (1949).
The anaesthetised animals were placed supinely on an operating
board and a midline incision made in the skin and subcutaneous tissues.
These tissues, together with the salivary glands were separated in the
midline along their entire length. After passing a silk suture under
the trachea, a small transverse incision was made into which a poly¬
thene tube 2 cm long was inserted and secured in position. This
airway was kept clear of mucous at all times using a suction pump.
Silk sutures were then placed into the flaps of the divided lower lip
and through the tip of the tongue. After tight ligatures had been
secured around each mandibular ramus, the lower jaw was divided in
the midline. The muscles of the floor of the mouth and oral mucosa
were divided by incisions on the left and right sides of the mandible.
To mobilise the tongue sufficiently to expose the soft palate and
epiglottis, a further incision along the medial border of the mandible
was extended posteriorly, taking care to avoid damaging the lingual
arteries. The tongue was ligated at its base while the suture placed
earlier in its tip was used to maintain the tongue retracted from the
soft palate. Using an iris electro-cautery, a midline incision was made
in the soft palate, extending from the posterior edge of the hard palate
to about 1 mm anterior towards the epiglottis, and laterally to the
pterygoid process of the sphenoid bone. The underlying mucosa of
the posterior pharyngeal wall was scraped away with cotton wool.
The rest of the procedure was carried out with the aid of a binocular
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microscope. A hole was drilled in the outer table of the basispheroid
bone, approximately 1 mm caudal to the transverse venous sinus.
This was filled with bone wax (Ethicon Ltd, Edinburgh) and gradually
extended anteriorly through the venous sinus to the basispheroid-
prespheroid suture. Haemorrhage during this process was minimised
by packing with bone wax at frequent intervals. Drilling was per¬
formed using a minimum amount of downward pressure. The inner
palate was gradually exposed and drilled to uniform thinness which
would yield to touch and enable its removal with watchmaker's forceps.
Any bleeding beyond this stage was controlled using gentle pressure
for a few minutes with cotton wool.
The dura mater overlying the median eminence and the pituitary
stalk was incised in a V-shape with a triangular fragment of stainless
steel razor blade held in a pinchuck. The apex of the incision was
made to lie just anterior to the median eminence with base at the junction
of the pituitary stalk and the anterior pituitary gland. The flap of the
dura mater and similar flap of arachnoid mater were carefully retracted
caudally with jeweller's forceps revealing the portal vessels (see Figure
2.2a). After ensuring no bleeding was taking place, 2500 i.u. of
Heparin (Weddel Pharmaceuticals Ltd, London) were injected into the
external jugular vein.
The pituitary stalk was cut with iridectomy scissors (Weiss Ltd,
London, B1053R) at the junction with the pituitary gland in order to
include as many portal vessels as possible. The blood pooled in the
trough of the basi-spheroid bone was aspirated slowly, every 20-40
seconds, with a glass pasteur pipette (1.0- 1.2 mm internal diameter)
and stored in small plastic tubes (PT 15734, Luckhams Ltd, Sussex)
on ice. In the majority of the animals, the pituitary stalk was cut and
FIGURE 2.2a: The anterior pituitary gland (AP), hypophysial portal
vessels (HPV) and median eminence (ME) after removal
of the dural membranes, as seen under a Zeiss
dissecting microscope. The transpharyngeal approach
described by Worthington (1966) was used to expose the
stalk.
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collection of portal blood begun within 20-25 minutes of injection of
the anaesthetic. In order to minimise protease inactivation of the
peptides cholecytokinin and vasoactive intestinal peptide, blood
samples were collected on ice in tubes in which the protease inhibitor
Trasylol (5,000 Kallikrein Inactivator Units (KI U)/ml blood) (Bayer
Pharmaceuticals Ltd) and ethylenediaminetetraacetic acid (EDTA)
(5.4 mM/1 blood) were added. At the end of the collection period,
the volume of blood was recorded before centrifugation at 4°C at
approximately 2500 g (MSE Mistral 2L Centrifuge) for 15 minutes.
The plasma was stored at -40°C until assayed for peptides and mono¬
amines .
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2. 2. 6 Peripheral Blood Sampling and Storage
Peripheral blood samples were obtained from the external jugular
vein of anaesthetised animals. To expose the vein, a longitudinal
incision (length 2 cm) was placed 1.0-1.5 cm anterior to the right
clavicle. The required amount of blood was withdrawn from the vein
using syringes previously heparinised with 1000 i.u./ml heparinised
saline, attached to 25 gauge hypodermic needles. The needle was
introduced into the vein through the pectoralis major muscle. This
method of blood sampling enables frequent collections without further
surgery. In between collection periods the vein was covered with
cotton wool moistened with saline. In experiments where plasma PRL
levels were to be measured (Chapters IV &V), the volume of blood
removed from the jugular vein was replaced immediately with warm
isotonic saline. The blood samples obtained were immediately trans¬
ferred from the syringes into plastic tubes (LP3, Luckham Ltd, Sussex)
which had been cooled on ice and were thus maintained until centri-
fuged at 4°C. The plasma obtained was removed using pasteur pipettes
into plastic tubes (Eppendorfs No. 72.690, Sarstedt, West Germany)
and stored at -40°C until assayed.
2. 2. 7 Electrode Implantation and Electrical Stimulation Parameters
Manufacture: In all experiments involving electrical stimulation of
various parts of the brain, platinum electrodes were used to avoid
electrochemical stimulation of the brain by deposition of iron which
occurs when steel electrodes are used. These were constructed from
10-13 mm lengths of platinum wire (Precious Metals Ltd, London),
0.125 mm in diameter. Glass tubing was drawn to an inside diameter
sufficient to tightly encase the wire and fixed in place with cement
(Araldite, Ciba-Geigy, Cambridge), leaving 0.3 mm bare at one end.
51.
Insulated copper wire was soldered to the other free end of the platinum
wire, and the whole assembly was mounted on a teflon jig, and fixed
in place with acrylic cement (Dental Fillings Ltd, London). The
overall length of the electrodes was 11-13 mm with a bared tip 0.3 mm
in length. Both single and twin unipolar electrodes (parallel and
separated by 1-2 mm) were used, depending on the area of the brain
to be stimulated.
Implantation: Adult male rats (180-200 g) were anaesthetised with
10% Urethane (10 mg/kg i.p.). The head was fixed in a stereotaxic
apparatus calibrated for use with the stereotaxic atlas of the rat fore-
brain by de Groot (1959); that is, the incisor bar was 5.0 mm higher
than the intra-aural line. The scalp was incised in the midline to
expose the dorsal surfaces of the frontal and parietal bone beneath the
cranial periosteum which was removed before a hole (approximately
4x4 mm) was drilled in the required area of the skull. Bone fragments
were carefully removed to avoid compression of the cerebral hemisphere.
The cranial endosteum and dura mater were incised to facilitate electrode
insertion, taking care to avoid laceration of the superior sagittal sinus.
Any bleeding was controlled by light pressure with cotton wool. The
electrode was then lowered into place using a triplanar micromanipulator
(Prior, Bishop Stortford, Herts) and fixed in place with dental cement
using stainless steel screws in the skull as anchors. The leads of the
electrode were tucked subcutaneously as the wound was sutured and the
animals were housed individually.
During the post-operative period, 300 mg of Aureomycin (Cyanamid
(GB) Ltd, Gosport, chlorotetracyclin hydrochloride) and 25 mg of
Glucose (BDH Chemicals Ltd) was added to each litre of the rats'
drinking water. ■■ _ ....
^.ED//ta,
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Stimulation parameters: The electrical stimulus used was based on
experiments by Fink and Aiyer (1974), and Jamieson and Fink (1976).
The stimulus was applied for a period of 30 minutes using a simple relay
circuit delivering accurately balanced, biphasic square wave pulses
with a frequency of 60Hz, pulse duration of 1 ms and pulse amplitude
of 500 pA (1 mA peak to peak). The stimulus was produced by a constant
current stimulator (Neurolog, Digitimer Ltd, Herts) in a 30 sec on 30
sec off sequence, and monitored on a calibrated oscilloscope (Model
S51B, Telequipment, London).
Electrode site verification: On completion of the experiment, the
animals were decapitated and the skull placed in 10% buffered formalin.
After fixation, the dental cement securing the electrodes was dissolved
with chloroform (BDH Ltd, Poole) and the electrodes were carefully
withdrawn. The brain was dissected out and placed in 30% sucrose
overnight. Coronal sections 75-100 pm thick were cut on a freezing
microtome ('Frigomobil' model 1206, Reichert-Jung, Germany) and
stained in 1% cresyl fast violet (details in Appendix). Electrode tracks
and their final placement were verified by examining the stained serial
sections with the aid of an optical microscope.
2. 2. 8 Pituitary Transplantation
Adult male rats (130-150 days old, 200-240 g b.w.) of the inbred
PVG strain supplied by Banting & Kingman Ltd (Hull) were used as
donors and recipients of anterior pituitary glands. Anterior pituitary
glands were dissected away from the posterior pituitary and intermediate
lobe and placed in saline. Two anterior pituitary glands per rat were
grafted under the kidney capsule of a recipient using light ether
anaesthesia. After spraying with antibiotic (Rikospray, Riker
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Laboratories, Loughborough) the flank incisions were closed by placing
one stitch in the muscle and metal clips to hold the skin together.
Forty-two days later, when pituitary stalk blood was collected
from the implanted rats, the adequacy of vascularisation of the grafted
pituitary glands was determined by examination of the graft under a
dissecting microscope. In addition, the rats were perfused with
Indian ink at the end of the collection of pituitary stalk blood and the
kidney with the pituitary transplant dissected out and fixed in buffered
formalin. The kidneys were wax-embedded and 8-10 pm thick sections
were stained with either haematoxylin-eosin or orange fuchsin green
(OFG; Slidders, 1961). Elevated plasma PRL concentrations in the
rats with anterior pituitary transplants (ChapterIV) confirmed that the
grafts had been functional. Details of the methods and solutions used
to prepare the histological sections are given in the Appendix.
2.3 Radioimmunoassays
2. 3. 7 Introduction
The basis of radioimmunoassays (RIA), in broad terms is competi¬
tion between labelled and unlabelled molecules for a limited number of
binding sites on a specific reactor (e.g. the specific antibody). A
progressive inhibition of the binding of labelled molecules occurs as the
concentration of the unlabelled molecules is increased. The concentra¬
tion of a substance in an unknown sample can be determined by comparing
the degree of inhibition observed in the sample with that produced by
known standards. Several reviews have been published on the basic
principles, theory and techniques of RIA (Midgley, Niswender and Rebar,
1969; Kirham and Hunter, 1971; Rodbard, 1971; Abraham, 1974;
Ekins, 1974; Yalow, 1980). Therefore, only the methods which were
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used to measure rat plasma concentrations of peptide hormones in
the studies described in this thesis are discussed.
Ovine LH, rat FSH, rat PRL, synthetic LHRH, porcine VIP and
synthetic unsulphated CCK-8 were labelled with I125 (Nal125, Amersham
International, Bucks.), using modifications of the chloramine-T
method of Greenwood, Hunter and Glover (1963). The double antibody
technique (Utiger, Parker and Daughaday, 1962) was used to separate
the 'free' hormone from the antibody-hormone complex or 'bound'
hormone in the assays of LH, FSH, PRL and LHRH. 'Free' VIP and
CCK was separated from 'bound' hormones by selective adsorption to
silicate and ion exchange resin respectively. These assays were done
in the laboratories of Dr. W. Rotsztejn (Inserm U55, Service de
Diabdtiologie et d'Etudes Radioimmunologiques des Hormones Proteiques,
Hopital Saint-Antoine, Paris) and Professor G.J. Dockray (Department
of Physiology, Liverpool University, England). Details of the methods
for radioisotope labelling and preparation of stock solutions for LH ,
FSH, LHRH and PRL assays are given in the Appendix.
The 'bound' hormone was counted using an automatic Gamma
Counter (Berthold Mag 310, Scotlab, Lanarkshire) and the concentration
of the peptides was obtained by linear regression of the standard
curves of logit B/B0 on the ordinate against log concentration on the
abcissa; B/B0 = cpm of standard of sample minus background/cpm of
total bound minus background; ie, logit B/B0 = In (B/Bq/1-B/B0).
The lower limit of sensitivity of the assay was determined by calculating
mean counts per minute (cpm) minus 2 x standard deviation of the total
bound tubes (Rodbard, 1971).
The coefficient of variation between assays for any one peptide
was monitored by adding two pools (high and low) to each assay. The
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pools were plasma from ovariectomised rats for both the high and low
pools in the LH and FSH assays. Plasma from male rats with either
an acid extract of rat hypothalamic tissue to give the high pool or
synthetic LHRH to give the low pool, were used for the LHRH assay.
In addition, the variation of the 'total counts' (labelled hormone),
'blanks' (zero antiserum added) and the 'total bound' (zero unlabelled
hormone) as a percentage of the total counts to give % bound and the
equivalent concentratfons of the 20%, 50% and 80% B/B0 was also recorded
for each assay.
2. 3. 2 Radioimmunoassays of LH and FSH
The concentration of LH and FSH was measured in rat plasma
and homogenates of anterior pituitary glands.
The ovine-ovine RIA developed by Niswender, Midgley, Monroe
and Reichert (1968) was used to measure the LH concentration. Details
of the method used have been described by Aiyer (1974), Aiyer and
Fink (1974) and Henderson (1976) and are outlined in Appendix Al.
The ovine pituitary LH (LER- 1056 -C2) used for iodination was provided
by Dr. L.E. Reichert Jr. (National Institute of Arthritis, Diabetes,
Digestive and Kidney Diseases [NIADDK], Baltimore, U.S.A.) and
ovine LH (NIH-LH-S18) used to prepare the standards (range 0.25 -
16 ng/ml) was provided by the NIADDK. The hormone-specific antibody,
antiovine LH (GDN 15) was raised in rabbits and provided by Dr. G.D.
Niswender (NIADDK). The antibody was used at a final dilution of
1 : 240,000. The second antibody, used to separate 'bound' hormone
from 'free' hormone was anti-rabbit gamma globulin (ARGG), raised in
donkeys against rabbit gamma globulins (Wellcome Reagents Ltd,
Beckenham, Kent). The antibody was used at a final dilution of 1 : 150.
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The concentration of FSH in rat plasma was determined by an
RIA method based on the method used by Daane and Parlow (1971)
and described in detail by Aiyer (1974), Jamieson (1974), Chiappa
(1976) and Henderson (1976). An outline of the method used is given
in Appendix A.l. The hormones used for the iodination and prepara¬
tion of standards (range 62.5- 4000 ng/ml) were NIADDK rat FSH-I-3
and NIADDK rat FSH-RP-1, respectively. The hormone-specific
antibody was NIADDK anti-rat-FSH-56, raised in rabbits and used
at a final dilution of 1 : 10,000. The ARGG was used at a final dilution
of 1 : 100.
The standard curves of representative assays of LH and FSH
are shown in Figure 2.3a and 2.3b, respectively. The quality control
data for LH and FSH assays are shown in Figures 2.3c and 2.3d,
respectively. The interassay coefficient of variation for the LH high
pool was 10% (mean 39.7 ng/ml, n=4) and 10% for the LH low pool
(mean 16.4 ng/ml, n=4). For the FSH high pool the coefficient of
variation was 9% (mean 758.8 ng/ml, n=3) and 14% for the FSH low pool
(mean 4Z4-.3 ng/ml, n=3). The lower limits of sensitivity for 20 pi
plasma samples were between 4.0 and 6.0 ng/ml for the LH assay and
between 2.0 and 3.0 pg/ml for the FSH assay.
2. 3. 3 Radioimmunoassay of LHRH
The double antibody RIA developed by Nett, Akbar, Niswender,
Hedlund and White (1973) was used for measuring the concentration
of LHRH in rat pituitary stalk plasma samples. The method has been
described by Jamieson (1974), Fink and Jamieson (1976) and Chiappa
(1976) and is outlined in Appendix A.2. Synthetic LHRH (ICI
Pharmaceuticals, Macclesfield) was used for iodination and to prepare
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FIGURE 2.3b: Standard curve of a representative assay for follicle-
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antibody (R-42-anti-GnRH), raised in rabbits was provided by Dr.
G.D. Niswender (NIADDK) and used at a final dilution of 1 : 32,000.
This antibody recognised the whole LHRH molecule and did not cross-
react with LHRH analogues and LHRH fragments (Nett et at., 1973) or
various peptides and pituitary hormones (Nett et a!., 1973; Chiappa,
1976; Jamieson and Fink, 1976). The second antibody, ARGG (Wellcome
Reagents Ltd, Beckenham, Kent) was used at a working dilution of
1 : 150 to separate the 'free' hormone from the 'bound' hormone.
A standard curve of a representative assay is shown in Figure
2.3e and the quality control data are shown in Figure 2.3f. The
standards in assays number 5 and 6 displayed a shift in the 80, 50
and 20% B/B0 values. In order to standardise the data, the values for
LHRH concentration obtained in the plasma samples assayed in assays
number 5 and 6 were divided by the ratio of the %B/BQ of the standard
curve for assays 5 and 6 and those in the other assays The interassay
coefficients of variation were found to be 21.5% and 23.6%, respectively,
using a high pool (mean 221.5 pg/ml, n=3) and a low pool (mean 36.6
pg/ml, n=4). The lower limit of sensitivity of this assay for 100 pi
samples of plasma ranged from 10-12 pg/ml.
2. 3. 4 Radioimmunoassay of PRL
Double antibody RIA kits supplied by the NIAMDD were used to
determine the concentration of PRL in rat plasma samples. The assay
has been described by Pickering (1978) and is outlined in Appendix
A.2. The hormone, rat-PRL-I-5 (NIADDK) was used for iodination
and rat-PRL-RP-1 (NIADDK) used to prepare reference standards
(range 0.5 - 64 ng/ml). The hormone specific antibodies were anti-
rat-PRL-S5 (NIADDK) used at a final dilution of 1 : 20,000. The
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at a final dilution of 1 : 150. A representative standard curve and
quality control data for the assay are shown in Figures 2.3g and 2.3h,
respectively. Using a high pool (mean 242.3 ng/ml, n=3) and a low
pool (mean 33.7 ng/ml, n=3), the interassay coefficients of variation
were 12.0% and 13.0%, respectively. The lower limits of sensitivity of
the assays for 20 pi samples of plasma ranged from 20.0- 30.0 ng/ml.
2. 3. 5 Radioimmunoassay of VIP
The VIP concentration in rat plasma was determined by RIA
based on the method described by Maletti, Besson, Bataille, Laburthe
and Rosselin (1980) and Maletti, Rostene, Carr, Sherrer, Rotten,
Kordon and Rosselin (1982), and done by Dr. W.H. Rotsztejn
(Hopital Saint-Antoine, Paris). Plasma samples collected in Edinburgh
were sent by air freight to Paris packed in dry ice in insulated poly¬
styrene containers. The samples remained frozen at all times.
The sensitivity of the assay was approximately 0.5 ng/ml.
Figure 2.3i shows a typical standard curve for the VIP assay. The
specificity of the VIP antibody was directed to a fragment of the
carboxyl-terminal and to the medium part of the VIP molecule, as
confirmed by the cross-reaction of the antibody with the VIP synthetic
fragment 10-28 (Maletti et al., 1982). There was approximately four
orders of magnitude difference in the binding capacity of the antibody
to VIP compared to the structural analogues of VIP, gastric inhibitory
peptide (GIP) and porcine peptide having N-terminal histidine and C-
terminal isoleucine-amide (PHI; Maletti et al., 1982). The inter¬
















FIGURE 2.3g: Standard curve of a representative assay for prolactin





































FIGURE 2.3i: Standard curve for a representative assay for vasoactive
intestinal polypeptide (VIP; Rotsztejn, collaborative
data).
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2. 3. 6 Radioimmunoassay of CCK and Gastrin
These assays were done by Professor G.J. Dockray (Liverpool
University). Plasma samples were sent to Liverpool packed in poly¬
styrene containers containing dry ice. The samples remained frozen
at all times. Antibodies with differing specificities for the C-terminal
pentapeptide sequence of CCK and gastrin were used (discussed in
Section 6.1). The method for the RIA of CCK and gastrin is described
in detail by Dockray and Taylor (1976) and Dockray (1980), respec¬
tively. The standard curve of a representative assay of CCK is shown
in Figure 2.3j. The standard curve of gastrin parallels that of CCK
(Dockray, personal communication). The lower limits of the sensitivity
of the CCK and gastrin assays were 20 pmol/1 and 5 pmol/1 respectively.
2.4 High Performance Liquid Chromatography (HPLC)
2. 4. 7 Introduction
Several groups have described the use of liquid chromatography
with electrochemical detection (LCED) for the measurement of plasma
catecholamines (Refshauge, Kissinger, Dreiling, Blank, Freeman and
Adams, 1974; Hallman, Farnebo, Hamburger and Jonsson, 1978;
Hjemdahl, Daleskog and Kahan, 1979; Mefford, Gilberg and Barchas,
1980). This technique has proved to be a highly selective, extremely
sensitive and also a rapid, inexpensive, non-destructive analytical
method. LCED also has the advantage of allowing the measurement of
several catecholamines and their metabolites simultaneously from one
sample. It has therefore almost replaced other assay techniques such
as the previously extensively used radioenzymatic method (Coyle and
Henry, 1973; da Prada and Zurcher, 1976; Peuler and Johnson, 1977)
which is more time-consuming and expensive per sample compared with
Concentration pmol/l
FIGURE 2.3j: Standard curve of a representative assay for chole-
cystokinin (CCK; Dockray, collaborative data).
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LCED, although smaller volumes of plasma may be used. The principles
and advantages of LCED have been extensively reviewed by Mefford
(1981). The technique consists of a simple liquid-solid extraction of
the catecholamines on alumina followed by their elution with dilute acid.
The alumina is selective for catecholamines and enables their concentra¬
tion prior to separation with liquid chromatography and subsequent
quantification by electrochemical detection.
In order for a compound to be amenable to electrochemical detec¬
tion, it must have electrochemical ability, i.e. it must undergo redox
reactions in such a way as to accommodate the loss or addition of one
or more electron. This rearrangement must occur within certain limits
of electrical potentials. These limits are 'fixed' by the electrode material
in which the electrode is placed. Carbon electrodes in aqueous solutions
were used for the analysis of catecholamines in pituitary stalk plasma.
Nearly all aromatic amines and phenols are oxidised between the potential
limits of +0.5 and +0.7 volts with regerence to an Ag/AgCl reference
electrode. The process of electrochemical oxidation converts the phenolic
compounds to quinones. A typical two electron oxidative mechanism for





The electrons are lost to the detector electrode, thus providing the
basis for detection of these compounds. The current which is derived
from these electrons is proportional to the concentration of the species
in solution (Levich, 1962). The O-methylated metabolites of the
catecholamines are more difficult to oxidase as the methoxy group must
be cleared. This requires a higher energy of activation and therefore
a higher electrochemical detection potential. These differences in
oxidation potential add selectivity and enable the differentiation between
substances which oxidise at different potentials.
2. 4. 2 Materials and Methods
(a) Standards and reagents:
Analytical reagent grade chemicals were used without further
purification. All solutions were prepared with distilled water. Stock
solutions (lOOpg/ml free base) of dopamine (DA), hydrochloride (HC1),
noradrenaline (NA) HC1, adrenaline (A) HC1, dihydroxyphenylacetic
acid (DOPAC) HC1 and the internal standard n-acetyl-dopamine (nADA)
HC1 were prepared in 0.1M hydrochloric acid and 10-6M ascorbate and
were freshly diluted on the day of the experiment. All the standards
were purchased from Sigma (Poole). Stock solutions were stable for up
to two months if stored at 4°C in the dark. Acid washed alumina
(A1203) was prepared according to Anton and Sayre (1962).
(b ) Sample preparation:
Pituitary stalk blood and jugular venous blood was collected
(Sections 2.2.5 and 2.2.6, respectively) into tubes placed on ice con¬
taining EDTA (5.4 mM/1) and ascorbic acid (50 mM/1). After centrifuga-
tion (15 min, 4°C, 600 g), the plasma was aliquoted into 100 pi aliquots
and 2 ng of nADA, the internal standard, was added to each aliquot.
The samples were then stored frozen at -40°C until analysis.
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The plasma catecholamines were concentrated and extracted with
alumina according to Hallman et al. (1979), after thawing. A summary
of the procedure is presented in Figure 2.4a. After elution of the
catecholamines from the alumina, 20 pi of supernatant or 20 pi of standard
solution containing each of the NA, A, DA, DOPAC and nADA were
injected into the column.
(c) The electrochemical detection system:
The system used was that described by Keller, Oke, Mefford and
Adams (1976), shown systematically in Figure 2.4b. The samples were
injected into the column by a Rheodyne 7125 rotary injection valve with
a 20 pi injection loop. The amines were separated by reverse pair ion
exchange chromatography on a 25 cm-long Hypersil-ODS (5p particle
size) column packed on a Magnus P6050 slurry packing unit at 5000 psi.
The injector and analytical column were mounted in a Faraday cage.
The mobile phase was 0.1M potassium dihydrogen orthophosphate buffer
containing 30 mg/1 sodium octyl sulphate, 10% HPLC-grade methanol and
0.1 mM EDTA (pH 4.0), and degassed by applying a vacuum for 2 min
then bubbling for 30 min with helium gas. This buffer was pumped at
a constant flow rate of 0.8 ml/min by a Gilson 301 pump. The effluent
then passed through a transducer cell (Bioanalytic Systems Inc., Luton,
LC-17) with a carbon paste working electrode and an Ag/AgCl reference
electrode (Figure 2.4c). The working potential was fixed at +0.6V
relative to the reference electrode. The current flow was measured by
an electronic controller unit (Bioanalytical Systems Inc., Luton, LC-17)
which amplified and converted the signal to a voltage. The chromato-




100 til plasma + 20 pi nADA (2 ng)
I thaw frozen samples
add 20 pi trichloroacetic acid




add 50 pi Na metabisulphate (IMXj
+
25 mg acid-washed alumina
vortex (5 sec)
add 400 pi EDTA (1M) Iris buffer (pH 8.6)
shake continuously for 10 min, 4°C
(f) wash A1203
x 2 with 1 ml Tris (0.5M) +
100 pi Na Metabisulphite (1M) per 100 ml water
+
x 3 with 1 ml distilled water
(g) elute catecholamines into 60 pi HC1 (0.5M)
(h) Inject 20 pi into LCED system
FIGURE 2.4a: Flowchart of the extraction procedure for plasma
catecholamines (based on Hallman et a!., 1978).
FIGURE2.4b:Aschematicdiagraofthliquidchromat graphic-electro hemic l detectorsystem.
inflow
FIGURE 2.4c: Cross-section of a BAS LC-17 transducer cell;
VV = working electrode; R = reference electrode;
A = auxiliary electrode.
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2. 4. 3 Calculations
A typical chromatogram obtained after ion-pair separation of 2 ng
each of DA, DOPAC and nADA is shown in Figure 2.4d. The retention
times using the standard buffer at a flow rate of 0.8 ml/min were found
to be approximately 7 min for DA, 10 min for DOPAC and 12 min for
nADA. A constant amount of nADA (2 ng/20pl) added to standard
solutions and (2 ng/lOOpl) aliquots of plasma before freezing, was used
as the internal standard. Measurements of the peak height of each
compound over a range of concentrations showed linearity (Figure 2.4e).
The concentration of DA and DOPAC in rat plasma samples was determined
by linear regression from the relevant standard curve, correcting for
incomplete recovery (usually 60-70%) of the internal standard. External
standards of various concentrations were run at various intervals to
determine the sensitivity of the detector.
2.5 Statistical Analyses
All the data in this thesis have been given as the mean value with
their standard error (± S.E.M.). Parametric statistical methods were
then applied. The significance of increments was determined by the
Students' paired t-test. The Students' unpaired t-test was used to
assess the significance of a difference between two means. Differences
between more than two means were compared by one-way analysis of
variance and the multiple range test for heteroscadistic means (Duncan,
1955, 1957), with the modified tables of Harter (1960).
Non-parametric statistical methods were used (Chapters III and IV)
when concentrations of LHRH in pituitary stalk blood samples were below
the lower limit of the radioimmunoassay. A value equal to the lower limit
X
FIGURE 2.4d: A representative trace from the HPLC system using
electrochemical detection. This trace shows the peaks
obtained after injection of 20 pi of an alumina extract
of pituitary stalk plasma.
Peak 1 = dopamine
Peak 2 = dihyaroxyphenylacetic acid
Peak 3 = N-acetyl dopamine (internal standard)
























FIGURE 2.4e: Standard curves for dopamine, dihydroxyphenyl
acetic acid (DOPAC) and N-acetyl dopamine (internal
standard).
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of the radioimmunoassay was assigned to the samples and the difference
between the means of the groups containing these samples was deter¬
mined by the Mann-Whitney U-test (Mann and Whitney, 1947), when
two means were compared or the Kruskal-Wallis one-way analysis of
variance by ranks (Kruskal and Wallis, 1952), when more than two
means were compared.
Differences were accepted as being statistically significant if
p <0.05.
CHAPTER III
The Relationship Between Luteinising Hormone-Releasing
Hormone (LHRH) Secretion and Pituitary LHRH
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3.1 Introduction
Gonadotrophin secretion in the male is controlled by the
negative feedback of gonadal steroids (Moore and Price, 1932; Lee,
Jaffe, Midgley, Kohen and Niswender, 1972; Kalra, Fawcett, Krulich
and McCann, 1973; Damassa, Kobashigawa, Smith and Davidson,
1976; Cheung and Davidson, 1977; Kalra and Kalra, 1979). Castra¬
tion markedly increases the release and synthesis of gonadotrophins
(Gay and Midgley, 1969; Kingsley and Bogdanove, 1973; Badger,
Wilcox, Meyer, Bell and Cicero, 1978; Nansel, Aiyer, Meinzer and
Bogdanove, 1979), decreases the hypothalamic content of LHRH
(Moguilevsky, Scacci, Debeljuk and Faigon, 1975a; Root, Reiter,
Duckett and Sweetland, 1975; Shin and Howitt, 1976; Campbell and
Ramaley, 1978; Rudenstein, Bigdeli, McDonald and Snyder, 1979;
Gross, 1980; Kalra and Kalra, 1980) and increases the number of
LHRH receptors in the anterior pituitary gland (Clayton and Catt,
1981; Frager, Pieper, Tonatta, Duncan and Marshall, 1981; Giguere,
Lefabre and Labrie, 1981). The increase in LHRH binding after
castration is due to an increase of the actual number of receptors, as
opposed to an increase in receptor affinity (Frager et at., 1979;
Clayton, Solano, Garcia-Vela, Dufau and Catt, 1980).
Treatment of castrated rats with one of three gonadal steroids,
testosterone (T), dihydrotestosterone (DHT) or 176-oestradiol (OE2),
known to be present in intact males (Ewing, Desjardins, Irby and
Robaire, 1977; Saksena, Lau and Chang, 1978; Saksena and Lau,
1979; Keel and Abney, 1980) reduced to normal, plasma LH and FSH
concentrations (Cheung and Davidson, 1977; Badger et at., 1978;
Campbell and Ramaley, 1978; Clayton and Catt, 1981), pituitary
LHRH receptor numbers (Clayton and Catt, 1981; Frager et a!., 1981)
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and hypothalamic LHRH content (Kingsley and Bogdanove, 1973;
Shin and Howitt, 1976; Campbell and Ramaley, 1978; Nansel et a!.,
1979; Rudenstein et al., 1979; Gross, 1980; K aira and K aira, 1980).
A delay of one month before treatment of castrated rats with gonadal
steroids, fully reduced plasma LH concentrations, but FSH secretion
was only partially reduced towards the values in intact animals
(Campbell and Ramaley, 1978; Conne, Scaglioni, Lang, Sizonenko and
Aubert, 1982). Treatment of long-term castrated rats with gonadal
steroids did not, however, suppress the post-castration increase in
the number of pituitary LHRH receptors or the decrease in the hypo¬
thalamic content of LHRH (Conne et at., 1982).
Although changes in hypothalamic LHRH content reflect a balance
of synthesis, release and degradation, it has been suggested that a
decrease in hypothalamic LHRH content after castration reflects an
increase in secretion of LHRH from the hypothalamus (Root et at.,
1975; Shin and Howitt, 1976; Campbell and Ramaley, 1978; Gross,
1980). The demonstration that LHRH synthesis in hypothalamic slices
incubated in vitro increased one month after castration (Moguilevsky,
Enero, Szwarcfarb and Dosoretz, 1975), concomitant with a decrease
in hypothalamic content of LHRH (Kingsley and Bogdanove, 1973;
Shin and Howitt, 1976; Campbell and Ramaley, 1978; Rudenstein
et al. , 1979; Gross, 1980; Kalra and Kalra, 1980), provides strong
evidence for an increased post-castration release of endogenous LHRH.
In addition, treatment with gonadal steroids reversed the castration-
induced reduction in LHRH content in the median eminence (Campbell
and Ramaley, 1978; Gross, 1980) and medial basal hypothalamus
(Shin and Howitt, 1976; Chen, Geneau and Meites, 1977; Kalra and
Kalra, 1980). Therefore, the negative feedback action of gonadal
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steroids appears to be mediated, at least in part, by an action on
LHRH neurones that terminate in the median eminence.
Data supporting the hypothesis that the gonadotroph response
to castration is determined largely by an increase in LHRH secretion
has recently received considerable support from investigations into
the regulation of pituitary LHRH receptors. These studies have
indicated that the interaction of endogenous LHRH with its receptor is
essential for the normal maintenance of LHRH receptors and LH secretion.
If endogenous LHRH secretion was abolished before orchidectomy,
either by a lesion of the median eminence (Clayton, Channabasavaiah,
Stewart and Catt, 1982a), subcutaneous injections of antiserum to
LHRH (Clayton, Popkin and Fraser, 1982b) or administration of a
specific antagonist to LHRH receptors (Clayton et a I. , 1982a), the
characteristic 2-fold post-castration increase in LHRH receptor number
and 10-fold increase in serum LH concentration was prevented.
Administration of LHRH or a potent LHRH agonist reversed the effects
of removal of endogenous LHRH (Clayton et a!., 1982a, 1982b).
Therefore, the post-castration increase in LHRH receptors and gonado-
trophin secretion appear to depend upon increased hypothalamic LHRH
secretion. However, estimations of the number of LHRH receptors
during the oestrous cycle in the rat (Clayton et at., 1980; Savoy-
Moore, Schwartz, Duncan and Marshall, 1980; Barkan, Regiani, Duncan
and Marshall, 1981) and hamster (Adams and Spies, 1981) showed that
when plasma gonadotrophin and LHRH concentrations were high,
pituitary LHRH receptors were reduced. Pituitary LHRH receptors
increased through late meteostrus and dioestrus in the rat, when
endogenous LHRH secretion has been shown to be low but increasing
(Sarkar, Chiappa, Fink and Sherwood, 1976). On pro-oestrous afternoon,
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however, LHRH binding declined by 50% for a 60-90 min period
(Clayton et a/., 1980; Savoy-Moore et at., 1980), at the time of a
5-6-fold increase in the LHRH concentration of pituitary stalk blood
and immediately before the pre-ovulatory gonadotrophin surge
(Sarkar et a!., 1976). The decrease in LHRH receptors at pro-
oestrus has been suggested to be due to increased occupancy of the
LHRH receptor by endogenous LHRH so that less binding occurs of
the labelled analogue of LHRH used to measure receptor number
(White and Ojeda, 1982). This hypothesis is disputed by Savoy-Moore
et at. (1980) and Barkan et at. (1981) who were unable to demonstrate
decreasing receptor binding capacity following exogenous LHRH
administration (600 ng/rat, s.c.) to adult male rats or ovariectomised
rats with OE2 implants. The most plausible explanation put forward
for the decrease in pituitary LHRH receptors, despite a marked increase
in LHRH secretion at pro-oestrus, is that LHRH 'down-regulates' its
receptors. 'Down-regulation' is a homeostatic mechanism in which the
number of hormone receptors decrease in response to elevated levels
of homologous hormone (Pollet and Levey, 1980). 'Down-
regulation' of LHRH receptors has been proposed to explain changes
in pituitary sensitivity during the oestrous cycles involving internalisa-
tion of LHRH receptors (Hazum, Cuatrecasas, Marian and Conne, 1980).
'Down-regulation' has been observed with large doses of other peptide
hormones and their receptors, for example, Angiotensin 11 has been
demonstrated to regulate the number of Angiotensin receptors on adrenal
glomerulosa cells in situations of sodium depletion (Catt, Harwood,
Aguilera and Dufau, 1979). The reason why 'down-regulation' of
LHRH receptors does not occur in the long-term castrated rats is not
yet clear.
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During lactation and in male rats with pituitary transplants
(Chapter IV), serum and pituitary levels of LH and FSH have been
found to be suppressed (McCann, Graves and Taleisnik, 1967; Ford
and Melampy, 1973; Hammons, Velasco and Rothchild, 1973; Bartke,
Smith, Micheal, Peron and Datterio, 1977; McNeilly, Sharpe, Davidson
and Frazer, 1978), pituitary LHRH receptor content was decreased
(Clayton et at., 1980; Fraser, Popkin, McNeilly and Sharpe, 1982b)
and there was diminished pituitary responsiveness to LHRH (Lu et at.,
1976a; Muralidhar, Maneckjee and Moudgal, 1977; Hodson, Simpkins
and Meites, 1978; Winters and Loriaux, 1978; Greeley and Kizer, 1979).
However, there is no direct evidence that LHRH concentrations in the
hypophysial portal vessels is reduced in the lactating rat or in the
hyperprolactinaemic male rat.
The demonstration that, in the absence of ovarian steroids, the
suckling stimulus and prolactin can effectively inhibit the post-castra¬
tion rise in gonadotrophin secretion (Smith and Neill, 1977), questions
the importance of gonadal steroids in the regulation of gonadotrophin
secretion by prolactin. Serum oestradiol (OE2) concentrations have
been found to be positively correlated with LHRH binding capacity
throughout the oestrous cycle (Savoy-Moore et at., 1980; Clayton
et at., 1980). This raises the possibility that steroid-mediated receptor
induction occurs before pro-oestrus, since a rise in circulating OE2
concentration at this stage of the cycle has been demonstrated to
initiate enhanced responsiveness of the pituitary to LHRH (Arimura
and Schally, 1971; Aiyer and Fink, 1974). There is evidence to
suggest that the potentiation of pituitary responsiveness to LHRH by
OE2 is mediated by synthesis of a protein (Kamel and Krey, 1982;
Peegel and Menon, 1982). It has been proposed that OE2 either exerts
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a direct effect on the pituitary gland to increase LHRH receptor
synthesis or acts indirectly on the hypothalamus to increase the
release of endogenous LHRH (Speight, Popkin, Watts and Fink, 1981)
which subsequently induces its own receptors in pituitary gonado¬
trophs (Clayton et ah, 1980). However, measurements of pituitary
LHRH receptors in long-term ovariectomised rats with OE2 implants
demonstrated an acute fall in pituitary LHRH receptors before the daily
afternoon LH surge, in the presence of a constant concentration of OE2
(Barkan et al., 1981). In addition, pentobarbital administration to
these rats abolished both the LH surge and the fall in pituitary LHRH
receptors while three injections of LHRH (225 ng/rat, i.v., every 30
min) given at 09.00 h, induced a marked increased in serum LH con¬
centration but did not produce a fall in LHRH binding capacity (Barkan
et ah, 1981). These data suggest that other factors, for example the
opioid peptides (Barkin, Regianis, Duncan, Papavasiliou and Marshall,
1983), secreted by the hypothalamus before the LH surge, may also
be involved in mediating the abrupt fall in LHRH receptors at pro-
oestrus. Both OE2 and androgen receptors are found in the hypo¬
thalamus and pituitary of the adult male rat (Kato, 1975; Lieberburg
and McEwen, 1977; Kalra and Kalra, 1980).
The central actions of T have been suggested to occur after it is
reduced to DHT (Massa, Stupnicka, Kniewald and Martini, 1972) or
aromatised to OE2 (Naftolin, Ryan, Davis, Reddy, Flores, Petro, Kuh,
White, Wolin and Takaoka, 1975; Figure 3.1), although the relative
importance of OE2, DHT and T in regulating LH secretion remains
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Purpose of present studies:
The main aims of the experiments described in this chapter
were to determine whether
i) the castration-induced increases in gonadotropin secretion,
number of pituitary LHRH receptors and content of LH in the
pituitary are due primarily to increased secretion of LHRH into
stalk blood;
ii) the treatment of long-term castrated rats with 0E2, DHT or
T, which suppresses LH secretion but has no effect of the
number of pituitary LHRH receptors or the pituitary content of
LH, alters the secretion of LHRH into stalk blood;
iii) OE2, DHT and T have different effects on the release of
LHRH into stalk plasma of long-term castrated rats.
3 . 2 Materials and Methods
3. 2. 7 Animals and Experimental Procedures
All the animals used were male rats of the Wistar strain which
had been maintained under the conditions described in Section 2.1.
Bilateral castration or sham-castration was carried out on 60-day old
rats under pentobarbitone (24 mg/rat), as outlined in Section 2.2.3.
All the rats were left without treatment for 30 days after surgery,
before being injected for 8 days with gonadal steroids. The steroids
injected were testosterone propionate (TP: 'Viromone', Paines and
Byrne, Middlesex) and oestradiol benzoate (OE2B: 'Benztrone',
Paines and Byrne, Middlesex) which were supplied dissolved in ethyl
oleate. 5a-dihydroxytestosterone propionate (DHTP: Steraloids Inc.,
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New Hampshire, U.S.A.) was obtained in powder form. All the
steroids were made up to the required concentration with arachis oil
(Hopkins & Williams, Essex). The doses of the steroids injected in
a volume of 0.25 ml, were 20 ug/rat/day of OE2B, 300 ug/rat/day of
DHTP and 300 jig/rat/day of TP. The two groups of control rats
(sham-castrated and control, castrated) were injected with 0.25 ml
arachis oil injections subcutaneously. The steroids or oil were injected
at 16.00 h daily, 30 days after castration. On the 9th day of treatment
the rats were divided into two groups (A and B) and the following
parameters investigated in each group:
GROUP A
(a) Peripheral plasma concentrations of LH and FSH:
The animals were decapitated and trunk blood collected into
heparinised glass tubes kept on ice. The blood was then centrifuged
at 2500 g for 15 min at 4°C and the plasma stored at -40°C until
assayed for LH and FSH concentrations (Section 2.3). The plasma
and pituitary samples (see below) were sent to be assayed by airfreight
to Dr. M.L. Aubert (University of Geneva, Switzerland), packed in
dry ice which kept them frozen at all times.
(b) Pituitary LHRH receptor content and LH concentration:
The anterior pituitary glands from the rats were dissected out on
ice immediately after decapitation, snap frozen on dry ice and stored
at -40°C. The concentration and content of LHRH receptors in crude
pituitary homogenates was determined by saturation analysis using the
method of Conne, Aubert and Sizenonko ( 1979), using a radioiodinated
superactive analog of LHRH as tracer. Two pituitary glands were
pooled to make one receptor measurement. The results are expressed
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as fmoles/mg protein (concentration) and fmoles receptor sites/
pituitary (content). The pituitary content of LH was determined by
radioimmunoassay (Section 2.3).
GROUP B
(a) Release of LHRH into pituitary stalk blood:
The hypophysial portal vessels were exposed (method in Section
2.2.5) under Althesin anaesthesia (1.0- 1.5 ml/100 g b . w.). After
cutting the pituitary stalk, blood samples were collected from the cut
end for two consecutive 30 min periods. After centrifugation (2500 g,
4°C, 15 min) the plasma was stored frozen until assayed for LHRH
(Section 2.3). The results are expressed as the concentration (pg/ml)
of LHRH in stalk plasma and the content (pg/30 min) of LHRH in stalk
blood. The values of LHRH given (Section 3.3) are the means of the
two 30 min collection periods.
(b) LH concentration in peripheral plasma:
A sample (0.5 ml) of blood was obtained from the external jugular
vein just before cutting the pituitary stalk. The plasma was stored
frozen at -40°C until the concentration of LH was determined by
radioimmunoassay (Section 2.3).
3. 2. 2 Calculations
The results were expressed as mean ± S.E.M. (n). Statistical
comparisons were made using the unpaired Students t-test. More than
two means were compared by a one-way analysis of variance and the
multiple range test for heteroscadistic means (Duncan, 1957; Harter,
1960). Non-parametric statistics were applied to determine the signif¬
icance of differences between means of LHRH concentrations in stalk
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plasma since, in some cases, the concentration of LHRH in the sample
was below the lower limit of detection of the assay (Section 2.3.3).
A value equal to the lower limit of the assay was designated to these
samples and the significance between groups determined by the Mann-
Whitney U test if two groups were compared. More than two groups were
compared using the Kruskal-Wallis one-way analysis of variance by
ranks.
The level of significance was taken as p <0.05.
3.3 Results
3. 3. 1 Experiment 7
(a) Effec ts of cas tration:
The peripheral plasma concentrations of LH and FSH and the
pituitary content of LH in control, castrated rats were significantly
(p <0.001) greater than in sham-castrated rats (Figure 3.2a). There
was no significant difference between the control, castrated rats and
the sham-castrated rats in the concentration of LHRH in pituitary stalk
plasma, or the total amount of LHRH released into stalk blood (content,
pg/30 min), Figure 3.2b. The concentration and content of LHRH
receptors in the pituitary were significantly (p <0.001) increased in
the castrate rats compared to the sham-castrate rats, Figure 3.2b.
(b) Effects of treatment with DHTP:
Treatment of castrate rats with DHTP (300 pg/rat) for 8 days
suppressed the post-castration increases in the concentrations of LH
in peripheral plasma (Figure 3.2a). The castration-induced increase
in the concentration of FSH in peripheral plasma was suppressed by
DHTP treatment but remained higher than the values in sham-castrated
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FIGURE 3.2a: The effects of castration and treatment of the castrate
rats with arachis oil (0.25 ml/rat) or 5a-dihydrotestosterone
propionate (DHTP, 300 ug/rat) for 6 days. The number
of rats in each group is shown in parenthesis. The values
given are the mean ± S.E.M. *, ** = p <0.001 when the






































FIGURE 3.2b: The effects of castration and treatment of the castrate
rats with arachis oil (0.25 ml/rat) or 5a-dihydrotestosterone
propionate (DHTP; 300 pg/rat) for 8 days. The number
of rats in each group is shown in parenthesis. The values
given are the mean ± S.E.M. Two pituitary glands were
pooled for each analysis of pituitary LHRH receptors.
*, ** = p <0.001 when the values in each parameter are
compared with each other.
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receptors and the concentration and content LHRH in stalk plasma
in castrate rats treated with DHTP were similar to the values found in
castrate rats injected with oil and significantly (p <0.001) greater than
the values in sham-castrated rats (Figure 3.2b). The changes in
the number of LHRH binding sites in the pituitary gland were not
accompanied by any alteration in the affinity constant of the LHRH
analogue (Table 3.1).
3. 3. 2 Experiment 2
Groups of rats were treated as in Experiment 1 (i.e. sham-
castrate injected with oil, castrate injected with oil and castrate injected
with DHTP) and in addition two groups of rats were castrated and
injected with either OE2B or TP. The values obtained for the parameters
investigated are shown in Figure 3.3a and 3.3b.
(a) Effects of castration:
Castration induced a significant (p <0.001) increase in concentra¬
tions of plasma LH and FSH, pituitary LH and concentration and content
of LHRH receptors in the pituitary (Figures 3.3a, 3.3b), as found in
Experiment 1. In addition, there was no significant difference between
the castrate rats and the sham-castrate rats in the content of LHRH
in stalk blood (Figure 3.3b), as found in Experiment 1.
(b) Effects of treatment with OE2B, DHTP or TP:
Treatment of castrate rats with OE2B (20 ug/rat), DHTP (300 Mg/
rat) or TP (300 jjg/rat) for 8 days completely restored the concentra¬
tion of LH in peripheral plasma to the values found in sham-castrate
rats treated with oil (Figure 3.3a). In the group of rats treated with
OE2B which were used to obtain samples of stalk blood under Althesin
anaesthesia (Figure 3.4, Group B), the concentrations of LH in peripheral
TABLE 3.1: The mean ± S.E.M. values of the affinity constant
(K^) of the LHRH agonist for LHRH binding sites
in the anterior pituitary glands of groups (n=6) of
sham-castrated and castrated rats injected for 8 days
with oil (0.25 ml/rat/day) and long-term castrated rats
injected for 8 days with 5a-dihydrotestosterone
propionate (DHTP; 300 gg/rat/day). Two anterior
pituitary glands were pooled for each estimation of




Treatment x 10 M
Sham-castrated + oil 3 1.13+0.18
Castrated + oil 3 0.99+0.09



































FIGURE 3.3a: The effects of castration and treatment of castrate
rats with oestradiol benzoate (OE2B) (20 pg/rat),
5a-dihydrotestosterone propionate (DHTP; 300 pg/
rat) or testosterone propionate (TP; 300 pg/rat)
for 8 days. Sham-castrated and control, castrated
rats were injected with arachis oil (0.25 ml/rat for
8 days. The number of rats in each group is shown
in parenthesis. The values given are the mean ±
S.E.M. *, ** = p <0.001 when the values in each
parameter are compared with each other.
FIGURE 3.3b: The effects of castration and treatment of castrate
rats with oestradiol benzoate (OE2B; 20 ug/rat),
5a-dihydrotestosterone propionate (DHTP; 300 ug/
rat) or testosterone propionate (TP; 300 ng/rat)
for 8 days. Sham-castrated and control, castrated
rats were injected with arachis oil (0.25 ml/rat) for
8 days. The number of rats in each group is shown
in parenthesis. The values given are the mean ±
S.E.M. Pituitary LHRH receptors were determined
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FIGURE 3.4: The effects of castration and treatment of castrate
rats with oestradiol benzoate (OE2B; 20 pg/rat),
5a-dihydrotestosterone propionate (DHTP; 300 pg/
rat) or testosterone propionate (TP; 300 pg/rat)
for 8 days. Sham-castrated and control, castrated
rats were injected with arachis oil (0.25 ml/rat) for
8 days. Peripheral blood samples were obtained either
after decapitation (Group A) or from the external
jugular vein under Althesin anaesthesia, just before
cutting the pituitary stalk (Group B). The number of
rats in each group is shown in parenthesis. The values
given are the mean ± S.E.M. * = p <0.001 when the
values are compared with each other in either Group A
or Group B .
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plasma collected before cutting the pituitary stalk were similar to the
values in castrate rats injected with oil, as opposed to those treated
with DHTP and TP.
The concentration of FSH in peripheral plasma was significantly
(p <0.005) suppressed, but not completely restored to sham-castrate
values by treatment with OE2B (Figure 3.3a). Neither DHTP nor TP
treatments were effective in suppressing the castration-induced increase
in the concentration of FSH in the peripheral plasma.
The increase in the content of pituitary LH induced by castration
was not suppressed by treatment with OE2B, DHTP or TP (Figure 3.3a).
The concentration and content of LHRH in stalk plasma was not
altered by treatment of castrated rats with OE2B, DHTP or TP, and the
values were similar to those in sham-castrate rats (Figure 3.3b).
The content and concentration of pituitary LHRH receptors remained
elevated despite treatment with OE2B, DHTP or TP (Figure 3.3b).
However, out of the three steroids injected, OE2B was the most effective
in suppressing the post-castration rise in the number of pituitary LHRH
numbers.
3.4 Discussion and Conclusions
These studies support previous findings that secretions from the
testes maintain an inhibitory influence on plasma concentrations of the
gonadotrophins (Kalra et al., 1973; Damassa etal., 1976; Badger
et a!., 1978), the pituitary content of LH (Gay and Midgley, 1969;
Conne et a!., 1982) and the number of LHRH receptors in the pituitary
(Frager etal., 1979; Clayton et al. , 1980; Conne et al., 1982). In
agreement with other studies (Campbell and Ramaley, 1978; Conne
et a!., 1982), treatment of long-term castrated rats with the gonadal
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steroids, OE2B or TP, completely suppressed the post-castration rise
in plasma LH concentrations, despite the continued elevation in pituitary
LH content and pituitary LHRH receptors (Figures 3.3a, 3.3b). In
addition, the present studies also showed that treatment with DHTP,
a 5a-reduced metabolite of TP, produced similar effects to TP on the
changes induced by long-term castration in the hypothalamic-pituitary
axis, supporting that theory that the conversion of TP to DHTP is
important for TP to exert its negative feedback effects (Martini, 1976;
Kalra and Kalra, 1980; McEwen, 1980; Martini, 1982). The demonstra¬
tion that TP or DHTP was ineffective in completely reducing the con¬
centration of plasma FSH to the values intact rats (Figure 3.3a),
supports the suggestion that testicular inhibin is also necessary for
the maintenance of tonic, low concentrations of plasma FSH (Setchell,
Davies and Main, 1977; Morris and Jackson, 1978; Franchimont,
Verstraelen-Proyard, Hazee-Huelstein, Renard, Demoulin, Bourguignon
and Hustin, 1979). Although in the experiments in this chapter (Figure
3.3a), OE2B was completely effective in suppressing the post-castration
rise in plasma FSH concentrations, the plasma concentrations of OE2B
likely to occur by the subcutaneous injection of 20 pg/rat would be
considerably higher than the concentrations of plasma OE2B (20-45 pg/
ml) that occur in the intact male rat (Butcher, Inskeep and Pope, 1978;
Saksena et al., 1978; Saksena and Lau, 1979; Keel and Abney, 1980).
The relative importance of OE2 in suppressing FSH secretion is therefore
not clearly established.
The post-castration rises in plasma gonadotropin secretion,
pituitary LH synthesis and the number of pituitary LHRH receptors
cannot, on the basis of the present studies, be attributed to increased
secretion of LHRH into pituitary stalk blood (Figure 3.3). The marked
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depletion of the LHRH content in the median eminence and mediobasal
hypothalamus induced by castration (Shin and Howitt, 1976; Conne
et ah, 1980; Gross, 1980; Kalra and Kalra, 1980) may therefore not
be due to increased release of LHRH. Whether short-term castration
increases LHRH secretion into stalk blood remains to be investigated.
The first suggestion that an increased secretion of LHRH occurred
after castration was based on the demonstration that hemi-pituitaries
superfused with portal vessel blood from castrate rats induced greater
concentrations of LH in the superfusate than portal blood from intact
male rats (Ben-Jonathan, Mical and Porter, 1973). Direct measurements
of LHRH concentrations in pituitary stalk blood under pentobarbitone
anaesthesia, an anaesthetic which blocks the pro-oestrus LHRH surge
(Sarkar et ah, 1976), did not show a significant difference between
intact and castrate rats (Eskay, Mical and Porter, 1977). LHRH in
stalk plasma in the present experiments (Figures 3.2b, 3.3 ) was
collected under Althesin anaesthesia, an anaesthetic which does not
completely block the pro-oestrus LH surge, although it is reduced
(Sarkar et ah, 1976). Therefore, it is possible that the reasons that
castration did not induce an increase in LHRH secretion (Figures 3.2b,
3.3b) were that in the male rat, Althesin anaesthesia and the trauma of
surgery done to expose the portal vessels, masked any increases in
LHRH secretion. However, using Althesin anaesthesia and similar surgery
to expose the portal vessels, Sarkar and Fink ( 1980) and Sherwood and
Fink (1980) demonstrated that ovariectomy increased LHRH release
into stalk blood.
The secretion of a constant amount of LHRH into stalk blood in
r
intact and castrate rats was unexpected, firstly, in view of the numeous
studies (Section 3.1) which suggest that endogenous LHRH regulates
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the number of pituitary LHRH receptors, and, secondly, present
results (Figures 3.2b, 3.3b) and those by Conne et al. (1982) showed
that castration induced an increase in the number of pituitary LHRH
receptors. Since the number of pituitary LHRH receptors remained
elevated even after steroid treatment (Figures 3.2, 3.3b; Conne et aI.,
1982), it appears that prolonged elevations of gonadotrophin secretion,
and possibly other changes induced by long-term castration, prevent
down-regulation of LHRH receptors, which may require elevated LHRH
release. However, since in fact there was no increase in LHRH release
in the castrate rats (Figures 3.2b, 3.3b), pituitary LHRH receptor
numbers remained elevated. This hypothesis is supported by the report
that immunoneutralisation of LHRH but not treatment with TP was
effective in suppressing the castration-induced increase in pituitary
LHRH receptors (Aubert, Conne, Nawrati, Lang and Sizonenko, 1981).
In conclusion, the measurement of the release of LHRH into stalk
plasma in long-term castrated rats in the experiments described in this
chapter has shown that the removal of the inhibitory influence of the
testes, which increases the release of LH and FSH, the synthesis of
LH and the number of LHRH receptors in the pituitary, is not accom¬
panied by an increase in the release of LHRH. Furthermore, the
suppression of post-castration increases in plasma LH and FSH concentra¬
tions by OE2B, DHTP or TP cannot be attributed to a decrease in the
release of LHRH into stalk plasma, as there was no significant change
in the release of LHRH into stalk plasma after injections of these gonadal
steroids.
CHAPTER IV
Effects of Long-Term Hyperprolactinaemia, Castration
and Testosterone Replacement on Dopamine (DA) and Luteinizing
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4.1 Introduction
Hyperprolactinaemia has been implicated in the pathogenesis
of human infertility (Bohnet, Dahlen, Wuttke and Schneider, 1976;
Quigley, Judd, Gilliland and Yen, 1979; Evans, Cronin and Thorner,
1982). Between 13-30% of women with secondary amenorrhea have
increased plasma PRL concentrations (Franks, Murray, Jequier, Steele,
Nabarro and Jacobs, 1975). Infertility and absence of cyclic ovarian
activity during the immediate post-partum period in mammals is also
directly associated with increased PRL concentration in the circulation
(McNeilly, 1980).
The mechanism(s) responsible for the anti-fertility effects of
hyperprolactinaemia are not fully understood. Experimental and
lactational hyperprolactinaemia in the rat are accompanied by decreased
plasma and pituitary gonadotrophin concentrations (Ford and Melampy,
1973; Bartke, Smith, Micheal, Peron and Dalterio, 1977; Smith and
Neill, 1977; McNeilly, Sharpe, Davidson and Fraser, 1978). Hyper¬
prolactinaemia also significantly delayed and attenuated the character¬
istic post-castration increases in plasma LH and FSH and pituitary LH
concentration (Grandison, Hodson, Chen, Advis, Simpkins and Meites,
1977; Smith and Neill, 1977; Winters and Loriaux, 1978; McNeilly,
Sharpe and Fraser, 1980a). An increase in plasma PRL concentration,
induced by pituitary implants, has also been reported to prevent the
increase in pituitary LHRH receptor number after castration orovariectomy
and on the morning of pro-oestrus (Clayton and Bailey, 1982c; Marchetti
and Labrie, 1982), as well as the decrease in hypothalamic LHRH content
after castration (Grandison et a/., 1977). In addition, a reduction in
pituitary LH release in response to exogenous LHRH administration has
been reported to occur in the lactating rat (Lu, Chen, Grandison,
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Huang and Meites, 1976; Muraldhar, Maneckjee and Mougdal, 1977;
Smith, 1982) and in intact male rats and castrated rats (Winters and
Loriaux, 1978; Greeley and Kizer, 1979; Tresguerres and Esquifino,
1981), which suggests that PRL also acts at the pituitary level to
alter LH release by reducing pituitary responsiveness to LHRH.
During lactation and pathological hyperprolactinaemia, the LH pulse
frequency has been demonstrated to be significantly reduced (Bohnet
et a!., 1975). All these data are consistent with reduced endogenous
LHRH secretion in the hyperprolactinaemic condition together with an
alteration in the responsiveness of the pituitary gland to LHRH.
The inhibitory effect of hyperprolactinaemia on the post-castration
LH rise may result from increased dopamine (DA) turnover induced by
PRL in the hypothalamus. DA turnover in the tuberinfundibular (TIF)
system was accelerated by systemic or intracerebroventricular injection
of ovine PRL (Hokfelt and Fuxe, 1972; Gudelsky, Simpkins, Mueller,
Meites and Moore, 1976; Annunciato and Moore, 1978) and by hyper¬
prolactinaemia induced either by anterior pituitary transplants under the
kidney capsule (Olson, Fuxe and Hokfelt, 1972; Hohn and Wuttke, 1978;
Morgan and Herbert, 1980) or by subcutaneous implants of pituitary
tumour tissue (Perkins, Westfall, Paul, MacLeod and Rogol, 1979).
In addition, DA receptor activation has been reported to inhibit LH
release (Fuxe and Hokfelt, 1969; Drouva and Gallo, 1977). The DA
agonist, 2crbromoergocriptine (CB-154), completely reversed the
inhibitory effects associated with pituitary transplants, on pituitary
LHRH receptor numbers and gonadotrophin secretion (Marchetti and
Labrie, 1982). Moreover, specific dopamine receptor antagonists (e.g.
Pimozide) increased LHRH concentration in stalk blood, while blockers
of DA synthesis (e.g. a-methyl-p-tyrosine) decreased LHRH release
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(Sarkar and Fink, 1981). A decrease in DA turnover in the TIF
neurones at pro-oestrus has been proposed to result in the removal
of an inhibitory dopaminergic influence on LHRH neurones in the median
eminence (Ahren, Fuxe, Hamberg and Hokfelt, 1971; Fuxe, Hokfelt
and Nilsson, 1972). This removal of the inhibitory effect on LHRH
release is proposed to result in the LHRH surge on pro-oestrus (Ahren
etal., 1971; Fuxe et al., 1972).
Although plasma concentrations of testosterone did not differ
significantly in intact controls and hyperprolactinaemic rats (Bartke
et al., 1977; McNeilly, 1980), the presence of the gonads, but not the
adrenal gland, appears to be necessary for PRL to exert an inhibitory
effect on gonadotrophin secretion (McNeilly et al., 1980). Furthermore,
PRL increased the sensitivity of the hypothalamus to negative feedback
effects of gonadal steroids on gonadotrophin secretion (McNeilly et al.,
1978, 1980; Marchetti and Labrie, 1982). Administration of oestradiol-
17g to ovariectomised rats with pituitary transplants has been reported
to increase further the plasma PRL concentrations and potentiate the
f€cepW
inhibitory effects of the pituitary transplant on pituitary LHRH^content
and gonadotrophin secretion (Marchetti and Labrie, 1982).
Purpose of present study:
The present study was undertaken to test the hypotheses:
i) that the increased concentrations of plasma gonadotrophins after
castration are due to increased release of LHRH and decreased
release of DA into pituitary stalk blood, which can be reversed
by testosterone (T) administered by silastic implants;
ii) that long-term hyperprolactinaemia reduces the secretion of LHRH
and increases the secretion of DA into pituitary stalk blood;
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iii) that the suppression of the post-castration rise in plasma
gonadotropin secretion in the hyperprolactinaemic rat is due
to a reduction in the secretion of LHRH into stalk blood in hyper¬
prolactinaemic rats compared with that in control rats;
iv) that the hyperprolactinaemic rat is more sensitive to the
negative feedback effects of T at the level of the hypothalamus,
as seen by the changes in the concentration of LHRH in stalk
blood in castrated rats with and without T implants.
4. 2 Materials and Methods
4. 2. 7 Animals and Treatments
Adult male rats (130-150 days old, 240-280 g b.w.) of the inbred
PVG strain were used in all experiments. The animals were divided
into two groups; animals in one group had two anterior pituitary
glands transplanted under the kidney capsule under ether anaesthesia,
while animals in the other group were used as control animals. After
28 days the two groups of rats were divided into the following groups:
i) intact, untreated controls;
ii) castrated, untreated group;
iii) castrated, implanted with 10 mm T capsules;
iv) castrated, implanted with 30 mm T capsules.
The T capsules were implanted subcutaneously in the back of the
animals at the time of castration, under ether anaesthesia. Metal
clips were used to suture all surgical cuts.
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4. 2. 2 Collection of Blood Samples
Blood samples were collected from the rats 14 days after the
implantation of testosterone capsules. The rats were administered
Althesin (0.5- 1.5 ml/100 g b.w.) and the hypophysial portal vessels
exposed as described in Section 2.2.5. After an intravenous injection
of heparin (2500 IU/rat in 0.5 ml volume), a 1.0 ml sample of blood was
obtained from the external jugular vein. The pituitary stalk was then
cut and blood samples collected for 30 min periods before, during and
after the application of an electrical stimulus to the median eminence.
The stimulus was applied for 30 min by placing a unipolar platinum
electrode on the surface of the median eminence. The stimulus parameters
consisted of 30 sec trains of biphasic square wave pulses of 60 Hz, 1 mA
peak to peak and 1 msec duration (Section 2.2.7). These parameters
have been shown to be optimum for LH release (Jamieson and Fink, 1976).
Pituitary stalk blood samples of 10-20 pi were collected alternately
every 30-45 sec into two sets of tubes kept on ice. One set of tubes
contained Trasylol (20 KIU/1) and EDTA (5.4mM/l) into which the
blood was collected and immediately mixed. These samples were centri-
fuged at 2500 g for 15 min at 4°C at the end of the collection period
of 30 min. The plasma was divided into 100 pi aliquots and n-Acetyl
dopamine (2 ng in 20 pi 0.1N HC1) added before the samples were
stored at -40°C. The concentration of DA and one of its metabolites,
dihydroxyphenylacetic acid (DOPAC) in these samples was subsequently
determined by HPLC (Section 2.4). Blood samples collected into the
second set of tubes and the peripheral blood samples were centrifuged
at 2500 g for 15 min at 4°C. The plasma was stored at -40°C until
analysed for LH, FSH, PRL and LHRH by double antibody radioimmuno¬
assay (Section 2.3).
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4. 2. 3 Treatment of Pituitary Grafts
At the end of the collection of pituitary stalk blood the vascularisa-
tion of the pituitary transplants was verified by examination of the
transplant under the kidney capsule using the dissecting microscope.
The rats were perfused with Indian ink, the kidney with the trans¬
planted pituitary dissected out and kept in buffered formaldehyde until
embedded in paraffin wax (Appendix A5). Serial sections (20 pm thick)
of the kidney and pituitary transplant were cut. Some sections were
stained with the orange fuchsin (Appendix A5; Slidders, 1961) green
(OFG) stain and some were left unstained and examined under the
optical microscope.
4. 2. 4 Calculations and Statistics
The concentrations of DA, DOPAC and the hormones LHRH, LH,
FSH and PRL in plasma samples from each group of rats was expressed
as the mean ± S.E.M. The amount of LHRH and DA released into stalk
blood during each 30 min collection period was calculated by multiplying
the concentration of LHRH or DA by the volume of stalk blood collected.
This value is referred to as the content. The Student's t-test was
used to determine differences between two means. When more than two
means were compared, an analysis of variance and multiple range test
(Duncan, 1957; Harter, 1960) was used. In cases where the value of
LHRH determined by radioimmunoassay was below detection, the value
equal to the lower limit of the assay was assigned and the difference
between groups determined by non-parametric statistics, using either
the Mann-Whitney or Kruskal-Wallis test. The level of significance
was taken as p <0.05.
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4.3 Results
4. 3. 1 Experiment 7
(a) Concentrations of LH, FSH and PRL in peripheral plasma and
LHRH secretion into pituitary stalk plasma:
- Effects of pituitary transplants
The implantation of pituitary transplants into intact rats for
42 days induced about a 2-fold increase in the peripheral plasma
concentration of PRL (Figure 4.1). Hyperprolactinaemia was
associated with a significant (p <0.05) decrease in the concentration
of plasma FSH (Figure 4.1). The concentration of LH in peripheral
plasma (Figure 4.1) and the release of LHRH into pituitary stalk
plasma (Figures 4.2a, 4.2b) was not significantly altered by implantation
of pituitary transplants compared to control rats.
Electrical stimulation of the ME of all the animals induced a signif¬
icant (p <0.05) increase in the release of LHRH into stalk plasma in
the control rats (Group A) and the rats with pituitary transplants
(Group B) (Figures 4.2a, 4.2b). The concentration and content of
LHRH in stalk plasma of control rats and rats with pituitary transplants
were of a similar magnitude during the period of stimulation. During
the post-stimulation period, the concentration and content of LHRH in
stalk blood were approximately equal to the values measured in the pre-
stimulation period (Figures 4.2a, 4.2b). The volume of pituitary stalk
blood collected during each 30 min period is shown in Table 4.1.
Electrical stimulation of the ME of two groups (intact, control and
castrate, hyperprolactinaemic with 30 mm T implants) only
induced a significant (p <0.05) increase in the mean volume of stalk
blood collected. However, there was no significant difference between

























FIGURE 4.1: Peripheral plasma concentration of LH, FSH and PRL
in control rats (Group A) and rats with two anterior
pituitary glands transplanted under the kidney capsule (Group B).
The values shown are the mean ± S.E.M.; peripheral blood samples
were collected under Althesin anaesthesia, just before the pituitary
stalk was cut to collect stalk blood.
T10 = 10 mm and T30 = 30 mm testosterone implants.
*, ** = p <0.05 when the values in Group A are compared to Group B
and when plasma PRL concentrations in intact and castrated rats in


















EJ castrate + T-jq
[D castrate+ T3q
a • pre-stimulation





























FIGURE 4.2a: The concentration of LHRH in pituitary stalk plasma
collected under Althesin anaesthesia from control rats
(Group A) and rats with pituitary transplants (Group B)
before, during and after electrical stimulation of the
median eminence. The values given are the mean ±
S.E.M. (n).
Tio = 10 mm and T30 = 30 mm testosterone implants.
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FIGURE 4.2b: The content of LHRH in pituitary stalk blood of control
rats (Group A) and rats with pituitary transplants
(Group B), under Althesin anaesthesia, before, during
and after electrical stimulation of the median eminence.
The values given are the mean ± S.E.M. (n).
T10 = 10 mm and T3 0 =30 mm testosterone implants.
* = p <0.05 when the values are compared with each
other, within Group A or Group B.

















































































































The values of LHRH in stalk plasma of the individual rats in the
group with pituitary transplants is shown in Table 4.2. Rat number 3
had a similar concentration and content of LHRH during the pre-stimula-
tion period to rats 1 and 2, but on stimulation of the ME an increase in
the release of LHRH did not occur despite an increase in the flow of
stalk blood seen in all the rats, which suggested that all rats had
received an electrical stimulus. In addition, rat number 4 had a
significantly (p <0.05) higher concentration and content of LHRH during
the pre-stimulation period than the other rats. In view of the small
number of animals in this group, a further group of 6 animals with
pituitary transplants was studied (Experiment 2).
Table 4.3 shows the mean ± S.E.M. dose of Althesin that was
required to induce anaesthesia before surgery to expose the pituitary
stalk vessels. For rats with pituitary transplants the dose of Althesin
required was almost half that required for the control male rats, and is
comparable to the doses required to induce deep anaesthesia in female
rats.
Effects of castration
Castration for 14 days induced a significant (p <0.05) and equi¬
valent increase in the concentration of LH and FSH in peripheral plasma
of both control rats and rats with pituitary transplants (Figure 4.1).
Plasma PRL concentrations in the control group (A) and in the group
with pituitary transplants (B) were significantly (p <0.05) decreased
by castration when compared to values in intact animals.
There was no difference in the concentration or content of LHRH
in pituitary stalk plasma after castration of the control rats or the rats
with pituitary transplants (Figures 4.2a, 4.2b).















































TABLE 4.3: Comparison of the doses of Althesin (ml/100 g body
weight) required to induce anaesthesia for surgery to
collect pituitary stalk blood from male rats of the PVG
strain (controls and hyperprolactinaemic rats) and female
rats of the Albino Wistar strain (at 16.00 h on pro-
oestrus or oestrus). Values given are mean ± S.E.M.
* = p <0.05 when the values are compared with each
other.
Group n











Pro-oestrus 8 246.0 ± 8.0




Electrical stimulation of the ME of castrated, control rats induced
a significantly (p <0.05) lower release of LHRH into stalk plasma
compared with that in intact, control rats (Figures 4.2a, 4.2b). This
difference in the release of LHRH during stimulation of the ME between
the castrated and intact rats was not seen in the rats with pituitary
transplants or after administration of T to rats in Group A or Group B.
- Effects of testosterone implants
Testosterone (T) implants of 10 mm lengths did not suppress the
post-castration rises in plasma LH and FSH in either the control or
hyperprolactinaemic rats. However, the 30 mm implants of T were
effective in restoring plasma LH concentrations to values in intact rats,
in both the control group and the group of animals with pituitary
transplants. The T implants (10 mm or 30 mm lengths) had no effect
on the concentration of PRL in peripheral plasma (Figure 4.1) and
LHRH in stalk plasma (Figures 4.2a, 4.2b) in either the control rats
(Group A) or those with pituitary transplants (Group B) compared with
that in intact rats.
Electrical stimulation of the ME of the rats with T implants produced
a significant (p <0.05) increase in the release of LHRH into stalk plasma
compared with that before stimulation (Figures 4.2a, 4.2b). The
increase in LHRH concentration in stalk plasma of castrated rats with
10 mm and 30 mm implants of T was equal to that in intact control rats
and hyperprolactinaemic rats. However, the LHRH content in stalk
blood of control rats with 30 mm implants of T was significantly (p <0.05)
lower than in intact, control rats during the stimulation period.
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(b) DA and DOPAC secretion into pituitary stalk plasma:
The concentration of DA in peripheral plasma was undetectable
(<100 pg/ml) in all groups of rats.
The concentrations (Figure 4.3a) and content (Figure 4.3b) of
DA and DOPAC in pituitary stalk blood from intact, control rats was
similar to those of rats castrated for 14 days and rats with chronic
hyperprolactinaemia (pituitary transplanted rats; Figure 4.1).
Implantation of implants of T into castrated rats had no effect on either
the concentration or content of DA or DOPAC in pituitary stalk plasma.
Electrical stimulation of the median eminence did not alter the
release of DA into stalk plasma, but there was a significant (p <0.05)
increase in DOPAC concentrations and content during stimulation
compared to values before stimulation in intact, control rats.
4. 3. 2 Experiment 2
(a) Concentrations of LH, FSH and PRL in peripheral plasma:
The concentrations of LH, FSH and PRL in peripheral plasma of
groups of intact, control rats and intact rats with pituitary transplants
are shown in Figures 4.4 and 4.5. The values obtained in Experiment 1
(Figures 4.1 and 4.2) and a mean of the values from Experiments 1 and
2 are also shown.
The concentration of plasma PRL was significantly (p <0.05)
higher in the rats with pituitary transplants than in the control rats
in Experiment 2, as found in Experiment 1. In contrast to Experiment 1,
the hyperprolactinaemia induced by the pituitary transplants in Experi¬
ment 2 was associated with a significant (p <0.05) decrease in the plasma
concentration of LH. The plasma LH concentrations in the combined
mean of the two experiments was not significantly different in the

























FIGURE 4.3a: The contentration of dopamine and dihydroxyphenyl-
acetic acid (DOPAC) in pituitary stalk plasma of intact
rats, castrated rats with and without testosterone
implants and rats with pituitary transplants, measured
by HPLC with electrochemical detection. The blood
samples were collected under Althesin anaesthesia for
30 min periods before and during electrical stimulation
of the median eminence.
Tio = 10 mm and T3o = 30 mm testosterone implants.
























FIGURE 4.3b: The content of dopamine and dihydroxyphenyl-acetic
(DOPAC) in pituitary stalk blood of intact rats,
castrated rats with and without testosterone implants,
and rats with pituitary transplants, measured by HPLC
with electrochemical detection. The blood samples were
collected under Althesin anaesthesia for 30 min periods
before and during electrical stimulation of the median
eminence.
Tio = 10 mm and T30 = 30 mm testosterone implants.

































































FIGURE 4.4: Peripheral plasma concentrations of PRL, LH and FSH
in groups of control rats and rats with pituitary trans¬
plants. Blood samples were collected under Althesin
anaesthesia in two separate experiments. The values
given are the mean ± S.E.M. (n) obtained in each experi¬
ment and a mean of the combined experiments. The con¬
centration and content of LHRH in the stalk blood of
these groups of rats is shown in Figure 4.5.
* = p <0.05 when the values within each parameter are



























































FIGURE 4.5: The concentration and content of LHRH in pituitary
stalk blood of control rats and rats with pituitary trans¬
plants. Blood samples were collected under Althesin
anaesthesia in two separate experiments. The mean ±
S.E.M. (n) values in each experiment and the combined
mean of the experiments is given. The peripheral plasma
concentrations of PRL, LH and FSH in these rats are
shown in Figure 4.4.
* = p <0.05 when the values are compared with each
other.
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The plasma FSH concentration of the control rats in Experiment 2
was not significantly different from the control rats in Experiment 1
(Figure 4.4), but, in contrast to Experiment 1, hyperprolactinaemia
did not suppress plasma FSH concentrations. The mean of the combined
experiments showed that plasma FSH concentrations were suppressed
by hyperprolactinaemia (Figure 4.4).
(b) LHRH concentration in pituitary stalk plasma:
The mean concentration and content of LHRH in stalk plasma
of the rats in Experiment 1 or the mean of the combined experiments
(1 + 2; Figure 4.5) were not altered by the implantation of pituitary
transplants compared with that in control rats.
As in Experiment 1, electrical stimulation of the median eminence
of the rats in Experiment 2 induced a significant increase in the stalk
plasma concentration and content of LHRH in control rats and rats with
pituitary transplants (Figure 4.6). Although the increase in LHRH
concentration in stalk plasma in rats with pituitary transplants was
significantly (p <0.05) greater than in the control rats, this difference
was not seen when the contents of LHRH during the stimulation period
were compared.
4. 3. 3 Some Observations on the Pituitary Crafts
Examinations under the dissecting microscope (Figure 4.7a) showed
that the pituitary grafts were well vascularised around 42 days after
implantation under the kidney capsule, when pituitary stalk blood samples
were collected. Wax-embedded sections of the kidney and the pituitary
grafts taken from rats that had been perfused with Indian ink (Figures
4.7b, 4.7c) also confirmed that the pituitary transplants were vascularised
after implantation. Some cell death occurred in the pituitary grafts,
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FIGURE 4.6: The concentration and content of LHRH in stalk blood
of control rats and rats with pituitary transplants before,
during and after electrical stimulation of the median
eminence, under Althesin anaesthesia. The values
shown are the mean ± S.E.M.
*, ** = p <0.05 when the values within each parameter
are compared with each other.
FIGURE 4.7a: The anterior pituitary transplant 42 days after
implantation under the kidney capsule, as seen under
the dissecting microscope. The pituitary transplant is well-vascularised
(blood vessels indicated by arrows).
FIGURE 4.7b: Transverse section of the pituitary transplant (AP)
which was transplanted under the kidney (K) capsule.
Blood vessels containing indian ink with which the animal was perfused
before removing the kidney are indicated by arrows.
FIGURE 4.7c: Transverse section of the pituitary transplant at a
high magnification showing indian ink in blood vessels
(indicated by arrows).
FIGURE 4.7d: An unstained section of the pituitary transplant.
Arrows indicate dead tissue (yellow) in the pituitary
which was transplanted 42 days earlier.
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4.4 Discussion and Conclusions
Pituitary transplants under the kidney induced an approximately
2-fold increase in plasma PRL concentrations and suppressed the
release of pituitary gonadotropins, as shown previously (Bartke
et al., 1978; McNeilly ef at., 1978; Winters and Loriaux, 1978). The
plasma concentration of PRL induced by the pituitary transplants are
at the lower range of those found in post-partum lactating rats (Lu,
Chen, Grandison, Huang and Meites, 1976b) and were therefore within
the physiological range. The post-castration rise in plasma LH and
FSH was inhibited by hyperprolactinaemia, in agreement with the
findings of Grandison et at. (1977), McNeilly et at. (1978), Winters and
Loriaux (1978) and Greeley and Kizer (1979).
The implantation of T capsules into castrated rats suppressed
the post-castration rise of plasma LH and FSH in the hyperprolactin-
aemic rats and in the control rats as previously reported (McNeilly
et at., 1978, 1980). The plasma T concentrations achieved by the
capsules of T in control and hyperprolactinaemic rats have been
reported to be 2.1 ± 0.2 v. 1.8 + 0.1 ng/ml for the 10 mm implants
and 4.0 ± 0.2 v. 5.0 ± 0.3 ng/ml for the 30 mm implants (McNeilly et at.,
1980). The data in Figure 4.1 therefore suggest that plasma T con¬
centrations greater than or equal to 4 ng/ml are required to completely
suppress the post-castration rises of plasma LH and FSH. This
plasma T concentration is considerably higher than the value of 1.6
ng/ml found by Damassa, Kobashigawa, Smith and Davidson ( 1976) to
maintain LH concentrations at or below those found in intact animals.
The plasma concentrations of T in intact and hyperprolactinaemic intact
rats have been reported to be 8.3 + 0.4 and 3.7 ± 0.4 ng/ml respec¬
tively (McNeilly et at., 1980). The fact that the 10 mm implants of T
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were ineffective in reducing plasma LH or FSH concentrations to
intact values in the hyperprolactinaemic rats compared to the control
rats does not support the hypothesis that hyperprolactinaemia sensitises
the hypothalamic-pituitary axis to the negative feedback effects of
testosterone (McNeilly et at., 1980b, 1983). The reason why the 10 mm
implants of T did not inhibit the post-castration rises in plasma LH and
FSH in the hyperprolactinaemic rats (Figure 4.1) is not clear since
the plasma concentrations of PRL in the rats used in this study (Figure
4.1) were similar to the values of plasma PRL reported by McNeilly
et at. (1980a), although the basal plasma concentrations of LH and FSH
of the hyperprolactinaemic rats (Figure 4.1) were overall lower than in
the studies by McNeilly et at. (1980b).
The release of LHRH into pituitary stalk plasma was not altered
significantly, either by inducing hyperprolactinaemia or by castration
(Figures 4.2a, 4.2b). Therefore, neither the suppression of gonado-
trophin secretion induced by hyperprolactinaemia nor the post-castration
rises in gonadotrophin secretion can be attributed to a decrease and
increase, respectively, in the release of LHRH into stalk blood. An
increase in the concentration of LHRH in pituitary stalk blood has been
reported to occur in ovariectomised rats that were also adrenalectomised
(Sherwood and Fink, 1980). In the adult male rat it has been demon¬
strated that the gonads are required for PRL to exert an inhibitory
influence on pituitary LH and FSH release (Grandison et a!., 1977;
Winters and Loriaux, 1978; McNeilly et at., 1980a). The role of the
adrenal gland in modulating gonadotrophin secretion in the hyper¬
prolactinaemic rat is still controversial (Bartke et al., 1977; Greeley
and Kizer, 1979; McNeilly et at., 1980a; Weber, Ooms and Vreeburg,
1982). However, removal of the testes or replacement of T in castrated
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rats did not alter the concentration of LHRH release in stalk plasma
(Figures 4.2a, 4.2b). In addition, the rats with hyperprolactinaemia
were not more sensitive to the feedback effects of T, as assessed by the
LHRH concentration in stalk plasma.
Electrical stimulation of the ME of castrated, control rats did not
increase the concentration of LHRH in stalk plasma to intact, control
values. This significant (p <0.05) difference between the castrated
and intact control rats in the release of LHRH after electrical stimula¬
tion was not seen in the hyperprolactinaemic rats, suggests that PRL
changes the response of the LHRH neurones to castration may sensitize
LHRH neurones to input from electrical stimulii in castrated rats.
The hypothalamic content of LHRH does not differ between intact,
control rats and rats with pituitary transplants (McNeilly et at., 1978).
However, the demonstration that castration induced a decrease in hypo¬
thalamic content of LHRH (Shin and Howitt, 1976; Badger, Wilcox,
Meyer, Bell and Cicero, 1978) which was reversed by replacement of T
in the castrated rats (Shin and Howitt, 1976; Kalra and Kalra, 1978)
suggests that the reason for less release of LHRH into stalk plasma
of castrated rats following electrical stimulation of the ME, may be that
there is less LHRH available for release in the castrated, control rats.
The number of LHRH receptors in the anterior pituitary gland
was reduced below normal in rats immunised against LHRH (Fraser,
Popkin, McNeilly and Sharpe, 1982b) and in rats with hyperprolactin¬
aemia induced either by transplantation of pituitary glands for 98 days
(Fraser et al., 1982b) or by suckling in the lactating rat (Clayton
et at., 1980). From these studies it has been proposed that a reduction
in endogenous LHRH secretion accompanies the decrease in the number
of LHRH receptors in the pituitary gland of hyperprolactinaemic rats
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(Clayton et at., 1980; Fraser et at., 1982b). This view, however, is
not substantiated by the demonstration that the release of LHRH into
not
pituitary stalk blood of hyperprolactinaemic rats wasAsignificantly
different from control rats (Figure 4.5).
The secretion of DA into pituitary stalk blood was not increased
by long-term hyperprolactinaemia or castration compared to intact
controls (Figures 4.3a, 4.3b). These concentrations of DA were
significantly (p <0.05) higher than those previously published by
Ben-Jonathan, Oliver, Weiner, Mical and Porter (1977) and Gudelsky
and Porter (1980) who, using pentobarbitone anaesthesia and a radio-
enzymatic assay, found that the DA concentrations in pituitary stalk
were only 0.2-0.6 ng/ml in intact and castrated rats, and 1.1 ng/ml
in rats given PRL by intracerebroventricular injections. The results
presented here are the first data on DA concentrations in pituitary
stalk plasma collected under Althesin (an anaesthetic that does not
suppress the pre-ovulatory LHRH surge; Sarkar et al., 1976), and
measured using HPLC with electrochemical detection. The higher
concentration of DA measured in the present studies shows that pento¬
barbitone anaesthesia result in lower plasma DA concentrations than
those found under Althesin anaesthesia.
The lack of a significant difference in the DA concentration in
pituitary stalk plasma of hyperprolactinaemic rats has also been
reported by Cramer, Parker and Porter (1979a), who found that the
DA concentration in pituitary stalk plasma of female rats bearing
anterior pituitary transplants were similar to dieoestrus control rats.
Electrical stimulation of the ME did not alter the release of DA into stalk
plasma in any of the groups of rats, although DOPAC release was
increased. Direct electrical stimulation of the ME has been reported
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(Fekete, Herman, Kanyicska and Makar, 1980) to reduce the DA
content of the ME, although ME stimulation did not alter the plasma
PRL concentrations in the study by Fekete et at. (1980).
A recent report (Weber, de Greef, de Koning and Vreeburg,
1983) that male rats bearing PRL- and adrenocorticoid (ACTH)-
secreting pituitary tumours showed an increased rate of secretion of
DA and a decreased rate of secretion of LHRH into stalk plasma
suggests that a significant increase in plasma PRL as well as ACTH
may be necessary to observe changes in DA and LHRH release. Adrenal-
ectomised, tumour-bearing rats did not show the decreases in plasma
LH and FSH or LHRH secretion seen in intact rats (Weber et at., 1983).
Furthermore, the plasma concentrations of PRL induced by the tumours
are 12-fold greater than those found in rats with pituitary transplants
(Figure 4.1; Bartkeefo/., 1977; McNeilly et al., 1980b), post¬
partum lactating rats (Whitworth, Grosvenor and Mena, 1981) or after
electrical stimulation of the mammary nerve trunk of lactating rats
(de Greef, Plotsky and Neill, 1981). The physiological relevance of
the study by Weber et al. (1983) is therefore debatable.
Hyperprolactinaemia sensitized the brain to the anaesthetic effects
of the steroid, Althesin (Table 4.3). The response to the anaesthetic
effects if Althesin has been found to differ between male and female
rats and appeared to be due mainly to plasma oestrogen concentrations
(Fink, Sarkar, Dow, Dick, Borthwick, Malnick and Twine, 1982).
Elevated concentrations of oestradiol in the circulation would induce
high plasma PRL concentrations (Ratner, Talwalker and Meites, 1963;
Meites and Clemens, 1972; Gudelsky, Nansel and Porter, 1981).
Therefore, the sex difference in the response to Althesin (Fink et aI.,
1982) cannot be due solely to increased plasma concentrations of oestrogen,
but is probably due to elevated plasma concentrations of PRL.
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The morphology of the pituitary grafts 15, 45 and 90 days after
implantation under the kidney capsule has been examined by Everett
(1954); Aguado, Alvial and Rodriguez (1977, 1981). Vascularisation
of the transplanted pituitary gland, observed at around 42 days after
implantation (Figures 4.7a, 4.7b), has been observed as early as
8 days after implantation (Everett, 1954), although some cell death
was visualised in the implants (Figure 4.7d).
Electron microscopical studies on the pituitary grafts showed that
the number of LH and FSH cells had decreased 45 days after implanta¬
tion of the pituitary grafts compared to implantation for 15 days
(Aguado et al., 1981). The number of prolactin cells in the pituitary
transplants 45 days after implantation was significantly less than at
either 15 or 90 days after implantation, although the prolactotrophs
displayed hypertrophied organelles which is indicative of high secretory
activity (Aguado etal., 1981).
The main conclusions that can be drawn from the studies described
in this chapter are that,
i) the post-castration rises in plasma gonadotrophins cannot be
attributed to an increased release of LHRH or a decreased release
of DA into pituitary stalk blood compared to control rats, although
electrical stimulation of the median eminence of castrated rats
induced lower LHRH release than in control rats;
ii) T administration to control rats or hyperprolactinaemic rats had
no effect on the concentration of LHRH in stalk plasma which
suggests that the negative feedback effects of testosterone on
gonadotrophin secretion, in castrated control rats or in castrated
hyperprolactinaemic rats, cannot be attributed to a suppression
of LHRH release into stalk blood;
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iii) long-term hyperprolactinaemia did not alter the secretion of
LHRH or DA into stalk blood although pituitary gonadotrophin
secretion was suppressed, compared to control rats;
iv) the suppression of the post-castration rises in plasma gonado-
trophins in hyperprolactinaemic rats was not due to a reduction
in the secretion of LHRH into stalk blood in hyperprolactinaemic
rats compared to control rats.
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5.1 Introduction
5. 7. 7 Formation and Distribution of Oestrogen Metabolites
The exact neuroendocrine mechanisms underlying the biphasic
regulation of pituitary gonadotrophin and PRL secretion by oestrogens
are still not fully understood. There is evidence that suggests the
involvement of oestrogen metabolites. The biotransformation of
oestrogens in mammals has been demonstrated to be almost exclusively
limited to oxidative reactions (Figure 5.1a). The first step involving
oxidation of the 17g-hydroxy group of oestradiol to the ketone oestrone
is followed by competitive hydroxylations in the five carbon D ring
or in the aromatic A ring (Fishman, Bradlow and Gallagher, 1960).
The ring D hydroxylation is predominantly at the 16 a-position, forming
oestriol (Marrian, 1930) and 16 a-hydroxyoestrone (Marrian, Loke,
Watson and Panattoni, 1957). The major end-products of the com¬
petitive ring A hydroxylation at either the C-2 or C-4 position are,
respectively, the 2- and 4-hydroxyoestrogens (Fishman, Cox and
Gallagher, I960; Ball and Knuppen, 1978; Emons, Hoppen, Ball and
Knuppen, 1980). The term "catechol oestrogen" (CAE) is applied to
these hydroxylated metabolites of oestrogen which have the 18C structure
of oestrogens with a phenolic hydroxyl group at C-3 and an additional
one at C-2 or C-4, resulting in a catechol group (an aromatic ring
bearing two hydroxyl groups) at one end of the oestrogen molecule
(Figure 5.1b). The 2-hydroxyoestrogens, 2-hydroxyoestradiol and
2-hydroxyoestrone will be referred to as CAE2 and CAE!, respectively'*.
The catechol oestrogens are partially O-methylated to 2-methoxy-































FIGURE5.1b:Formulaefthecatecholgroup,catech lamin s,oes adiol-173and2-hydroxyo s radiol (catecholoestradiol,CAE2)showingthstructu lsimilarityof2-hydr xyoestradiolt boththecatecholaminesandoestradi -173.
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identical with the enzyme responsible for the O-methylation of the
catecholamines (Kraychy and Gallagher, 1957; Ball, Knuppen, Haupt
and Breuer, 1972; Hoffman, Paul and Axelrod, 1980a). It has been
demonstrated that CAE2 is an effective inhibitor of both tyrosine
hydroxylase (TH) (Lloyd and Weisz, 1978; Foreman and Porter, 1980),
the rate-limiting enzyme in catecholamine biosynthesis (Levitt, Spector,
Sjoerdsma and Udenfriend, 1965), and COMT, an enzyme involved in
the metabolism of the catecholamines (Ball et at., 1972; Breuer and
Koester, 1974). Inhibition of the activity of these enzymes by micro-
molar concentrations of CAE2 has been found to depend on the
"catechol" part of the molecule rather than the aliphatic side chain
(Lloyd and Ebersole, 1980; Lloyd and Weisz, 1978). Although the
enzymes, TH and COMT, from steroid-target areas of the brain (e.g.
hypothalamus, amygdala) are not more sensitive to inhibition by CAE2
than other areas of the brain investigated (e.g. striatum), the
inhibition of enzyme activity by CAE2 was comparable to that of equi-
molar levels of dihydrophenylalanine (DOPA), the precursor of
endogenous catecholamines, when subsaturating levels of the endogenous
cofactor tetrahydrobiopterin were used (Lloyd and Ebersole, 1980).
In a recent study, Parvizi and Wuttke (1983) reported that CAEX and
CAE2 reduced catecholamine turnover in the anterior medial hypo¬
thalamus and pre-optic area in castrated male and female rats. These
interactions with key enzymes in the aminergic system have been
postulated to act as a "biochemical link" between the oestrogens and
the neurotransmitters found to be most directly involved in the hypo¬
thalamic control of gonadotrophin and PRL release (MeCann,
Ojeda, Fawcett and Krulich, 1974; Weiner and Ganong, 1978;
Barraclough and Wise, 1982).
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The formation of the catechol oestrogens, CAEX and CAE2 is
catalysed by oestradiol-2-hydroxylase which is widely distributed
in body tissues, although the highest activity has been found to occur
in the liver (King, 1961; Barbieri, Canick and Ryan, 1978; Hoffman,
Paul and Axelrod, 1980b). Neither the ovary, a site of oestradiol
synthesis, nor the virgin uterus, a major oestradiol target, had
significant oestradiol-2-hydroxylase activity. The discovery that
this enzyme is active in the brain and pituitary gland of man (Ball
and Knuppen, 1978) and rats (Fishman and Norton, 1975; Ball,
Haupt and Knuppen, 1978; Hoffman et a!., 1980b) has stimulated
speculation that the transformation of oestrogens to catechol oestrogens
was involved in the physiological regulation of gonadotrophin and PRL
release by oestrogens. This concept received support from subsequent
demonstrations that the catechol oestrogens are present in the pituitary
and hypothalamus in concentrations at least tenfold higher than the
parent oestrogens (Paul and Axelrod, 1977). In addition, CAE2 has
been shown to compete with oestrogens for binding to soluble oestrogen
receptors in the anterior pituitary and hypothalamus (Davies, Naftolin,
Ryan, Fishman and Siu, 1975; Clarke and Findlay, 1980), as well as
with dopaminergic ligands for dopamine receptors in rat anterior
pituitary membranes (Schaeffer and Hseuh, 1979).
5. 7. 2 Catechol Oestrogens and PRL Release
A role for CAE2 as a dopamine antagonist which removes
dopaminergic inhibition of PRL release has been proposed to account
for the observation that oestrogens stimulate PRL secretion (Chen
and Meites, 1970; Frantz, Kleinberg and Noel, 1972; de Lean, Garon,
Kelly and Labrie, 1977). CAE2 administration has been reported to
suppress PRL release in immature rats (Barbieri, Todd, Morishita,
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Ryan, Fishman and Naftolin, 1980) and stimulate PRL release in hypo-
gonadal women (Adashi, Casper, Fishman and Yen, 1980), ovariectomised
rats (Yanai and Nagasawa, 1979), male rats bearing atrial cannulae
(Shin, Bates and Jellinck, 1981) and 25-day old female rats (Rodriguez-
Sierra and Blake, 1982a). CAEX on the other hand, suppressed PRL
secretion in normal young women (Fishman and Tulchinsky, 1980) and
oestrogen-primed post-menopausal women (Adashi, Rakoff and Fishman,
1979; Schinfeld, Tulchinsky, Schiff and Fishman, 1980), adult male
rats bearing oestradiol implants (Shin et at., 1981) and inhibited the
pre-ovulatory PRL surge in cycling rats (Katayama and Fishman, 1982).
In vitro studies showed that CAE2, like dopamine, inhibited PRL
release from the superfused rat pituitary gland (Linton, White, de
Tineo and Jeffcoate, 1981) and both CAEX and CAE2 inhibited the
growth of PRL-secreting tumours (Lambert, Nagy, Utterlinden and
MacLeod, 1982). Normal PRL synthesis by the pituitary gland has been
found to be inhibited by CAEX while CAE2 stimulated PRL synthesis
and release from male rat pituitary glands and inhibited release from
female rat pituitary glands (Lambert et at., 1982).
5. 7. 3 Catechol Oestroqens and LH Secretion
Studies on the effect of the catechol oestrogens on gonadotrophin
release has also produced a vast amount of conflicting data. The
demonstration that CAEX induced a dose- and time-dependent rise in
serum LH concentration in immature male rats (Naftolin, Morishita,
Davies, Todd, Ryan and Fishman, 1975) provided the first evidence for
a biological action of the catechol oestrogens on a physiological parameter.
The primary oestrogens, oestradiol and oestrone, lowered LH and FSH
in this model (Morishita, Adachi, Naftolin, Ryan and Fishman, 1976).
This positive feedback effect of CAEj in the male rat after acute
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administration has since then been challenged (Rodriguez-Sierra and
Blake, 1980b). In addition, a potent inhibition of LH release by
CAEi and CAE2 has been demonstrated in 35-40-day old male rats
(Rodriguez-Sierra and Blake, 1980b), suggesting that these catechol
oestrogens could instead play a role in the negative feedback effect
on LH secretion. In ovariectomised, oestrogen-primed rats the
administration of CAEi and 4-hydroxyoestradiol in the morning
potentiated the cyclical release of LH and FSH in the afternoon
(Gethmann and Knuppen, 1976; Ball, Emons, Klingebiel, Gruhn and
Knuppen, 1981). Continuous administration for up to 72 h of a
number of oestrogen metabolites to 22-day old ovariectomised rats,
by means of implanted osmotic pumps, showed that CAE2 and 4-hydroxy-
oestrone induced a suppression of plasma LH in morning samples,
2-methoxyoestrone had no effect, while CAEX produced a statistically
significant increase in plasma LH after 48 hours of infusion (Martucci
and Fishman, 1979). The stimulation of LH secretion by CAEX sug¬
gested that CAEX may be involved in the positive feedback effect on
gonadotrophin secretion in the female rat. However, a recent study
demonstrated that CAE2, not CAEi, induced a surge in LH secretion
48 hours after administration to 25-day old female rats (Rodriguez-
Sierra and Blake, 1982b). The administration of CAEx, CAE2 or
4-hydroxyestrone together with oestradiol to ovariectomised ewes
failed to alter the negative feedback action of oestradiol on LH secretion
(Clarke and Findlay, 1980), which suggests that these catechol
oestrogens lack anti-oestrogenic properties in this model. In the
adult castrated rat, 4-hydroxyestradiol induced a potent decrease in
plasma LH concentration while CAE2 had no effect even at a high dose,
although CAE2 inhibited the suppression of LH release by 4-hydroxy-
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estradiol and oestradiol (Foreman, 1980; Parvizi, Ellendorf and Wuttke,
1981). Acutely administered CAEx to hypogonadal women inhibited
the release of LH and FSH provided they were oestrogen-primed
(Adashi et al., 1979).
5. 7. 4 Purpose of the Present Study
From the above account, it is clear that a firm conclusion cannot
be reached regarding the role of the catechol oestrogens in neuro¬
endocrine reproductive mechanisms. At the time this thesis was
begun (October 1979) it seemed reasonably therefore, to carry out
controlled studies to establish whether CAEX or CAE2
(i) modulated the release of LH and PRL;
(ii) exerted oestrogen-like effects on the uterus
and ovaries;
(iii) altered the release of LH into peripheral
plasma by modulating the release of LHRH
into pituitary stalk blood.
The two models in which these effects of the catechol oestrogens
were investigated were the immature male rat (Section 5.2) and the
immature female rat treated with pregnant mare serum gonadotrophin,
to induce ovulation (Section 5.3). On completion of the studies on
the effects of CAEi and CAE2 on LH and PRL release and the effects
of CAE2 on uterine and ovarian weights, it was not possible to obtain
the required amounts of pure catechol oestrogens. Therefore, the
effect of CAEx and CAE2 on the release of LHRH into pituitary stalk
blood was not investigated as originally planned.
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5.2 The Effects of the Catechol Qestrogens on LH and PRL Secretion
in the Immature Male Rat
5. 2. 7 Materials and Methods
All experiments were carried out using male Albino Wistar COBS
(Charles River Ltd, Margate, Kent) which were aged 35 d and had
been maintained under conditions described in Section 2.1 for one
week. Groups of rats were injected s.c. with 0.25 ml of either the
vehicle, CAEx, CAE2, oestradiol (OE2) or oestrone (OE^. The steroids
were purchased from Sigma (Poole). Due to the exceptional instability
of the catechol oestrogens they were stored in powder form under
nitrogen and protected from light. The catechol oestrogen to be
injected was made up to the required concentration in propylene
glycol containing 0.1% ascorbic acid, immediately before use.
The animals were decapitated for the collection of trunk blood
and the anterior pituitary, 6 h after treatment (18.00 h). Blood
samples were centrifuged at 4°C and stored frozen until assayed for
LH and PRL by RIA (described in Section 2.3).
The protein concentration of the anterior pituitary homogenates
was estimated by the Lowry, Rosenbrough, Farr and Randall (1951)
method (Appendix A.3) and the amount (ng) of LH per pg protein
calculated.
The data were analysed by one-way analysis of variance, followed
by the multiple range test (Duncan, 1957; Harter, 1960) to determine
the significance of the differences between the various treatments.
5. 2. 2 Results
(a) Plasma LH concentrations:
The plasma LH concentration 6 h after s.c. injections of four
doses (10 pg, 50 pg, 100 pg and 200 pg) of OEx, OE2, CAEx. CAE2 or
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the vehicle are shown in Figure 5.2a. There was no statistically
significant difference in plasma LH concentrations after either OEi or
OE2 administration compared to the concentrations in vehicle treated
control animals. All doses of CAEi and CAE2 injected induced a
significant (p <0.05) increase in plasma LH concentration compared
to the control rats. The maximum LH concentration was seen after a
single injection of CAE!. The dose-response experiment showed that
peak elevation occurred with the 10 pg dose of CAEX while increasing
doses produced smaller rises. A similar effect on plasma LH levels
after CAE2 administration was also seen.
Changes in plasma LH concentration 2, 6, 24 and 48 h after the
administration of CAE2 (50 gg) are shown in Table 5.2a. A 10-fold
increase in plasma LH release occurred within 2 h which was maintained
for as long as 48 h (duration of experiment).
TABLE 5.2a: Peripheral plasma concentration of PRL and LH
(ng/ml) in 35-day old male rats at various intervals
after a subcutaneous injection of 50 gg 2-hydroxy-
oestradiol (CAE2) or 0.25 ml oil. Values are given
as mean ± SEM (n).
Peripheral plasma
LH concentration PRL concentration
(ng/ml) (ng/ml)
Oil ( 0. 25 ml /rat)
6 h 2.4 ±0.4 (29) 138.0 ±36.0 (8)
24- U 2.0 ±0.4 (8) 235.0 ±26.0 (9)
4-8 K 1.4 ±0.8 (8) 126.0 ±88.0 (D
(50 ug/rat)
2 h 27.3 ±5.2 (9) 223.0 ± 8.0 (9)
6 h 11.1 ±1.2 (17) 80.0 ± 21.0 (9)
24 h 19.8 ±3.2 (9) 177.0 ±84.0 (9)
48 h 15.7 ±1.9 (8) 176.0 ±93.0 (9)
FIGURE 5.2a: LH concentrations in peripheral plasma and anterior
pituitary gland and PRL concentrations in peripheral
plasma from 35-day old rats 6 h after injections of
various doses of 2-hydroxyoestradiol (CAE2),
oestradiol (OE2), 2-hydroxyoestrone (CAEi) or
oestrone (OEi) or the vehicle (control). Values








(b) Pituitary LH content:
Figure 5.2a shows anterior pituitary LH content (ng LH/pg
protein) 6 h after the injection of various doses of the steroids and the
vehicle. Injections of CAE2 (100 pg) and OEX(50 pg) produced a
significant (p <0.05) decrease and increase, respectively, in pituitary
LH content compared to the value in vehicle-treated control animals.
There was no other significant difference in pituitary LH content
between any of the treatment groups.
(c) Plasma PRL concentration:
The effect of subcutaneous injections of the steroids and the
vehicle on PRL release 6 h later is shown in Figure 5.2a. Injection
of the primary oestrogens OE! and OE2 stimulated PRL release; the
increase in plasma PRL concentration was significantly (p <0.05)
greater than in vehicle-injected control animals after the highest dose
(200 pg) of QE2 and the lowest dose (10 pg) of OEi.
None of the four doses of CAEX injected 6 h previously produced
a significant change in plasma PRL concentrations compared with
those in vehicle-treated control animals. Only the 100 pg dose of
CAE2 significantly (p <0.05) stimulated PRL release.
Table 5.2a shows the peripheral plasma PRL concentration at
various time intervals after the injection of CAE2 (50 pg). Although
this dose of CAE2 produced a significant (P <0.05) increase in LH
secretion compared to oil-treated control animals, it produced no
significant changes in plasma PRL concentration, either 2, 6, 24 or
48 h after its administration.
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5. 2. 3 Discussion and Conclusions
These results are the first to support the study by Naftolin
et at. (1975) in which 50 and 100 ug doses of CAEX elevated serum
LH by 4-7 fold. In addition, the results presented in this section
demonstrated that CAE2, another naturally occurring catechol oestrogen,
at similar doses to CAEX also stimulated LH release. The failure of
CAE2 to stimulate LH secretion in experiments with pre-pubertal male
rats (Rodriguez-Sierra and Blake, 1980, 1982b) and castrated male
rats (Foreman, 1980; Parvizi et al., 1981) raised the possibility that
the increase in plasma LH concentration demonstrated by Naftolin
et al. (1975) was stress-induced. This seemed likely in view of the
fact that their animals were anaesthetised by inhalation of a 50%
02 : CO2 mixture and blood samples were obtained by cardiac puncture.
In the study presented here, the rats were decapitated as in the
studies by Rodriguez-Sierra and Blake (1980, 1982b), in which catechol
oestrogens (100 ug doses) either did not alter LH release or else
reduced plasma LH concentrations. The reason for this discrepancy
between the results obtained by different workers is not clear.
Plasma LH concentrations were determined at various intervals
after the subcutaneous injections of CAE2 (50 ug; Table 5.2a).
Within 2 h a 10-fold increase in plasma LH concentration occurred,
compared to vehicle-treated controls. Plasma LH concentration remained
higher than controls up to 48 h after a single injection of CAE2 (50 ug).
The half-life of CAEX and CAE2 in plasma is 180s and 90s, respectively
(Kono, Merriam, Brandon, Loriaux and Lipsett, 1980). Therefore,
it is unlikely that the injected CAE2 remained in the circulation for
48 h. However, since the purity of the catechol oestrogens supplied
by Sigma (Poole) was not checked, it can be argued that the stimulatory
effects of these metabolites of the oestrogens is due to contamination
of the catechol oestrogen preparations with the parent oestrogen.
Neither OEx nor OE2 significantly altered plasma LH concentrations
compared with those in vehicle-treated control animals. It is unlikely,
therefore, that contamination of the catechol oestrogen preparation
OEx or OE2 would significantly affect the potency of CAEX and CAE2
to stimulate LH release.
The finding that OEx and OE2 administration did not alter the
plasma LH concentration in 35-day old male rats (Figure 5.1c) was
also observed by Naftolin et al. (1975). Administration of an intra¬
venously injected bolus of CAE2 (100 pg) to chronically castrated adult
rats did not alter the plasma LH concentration, but it was able to
inhibit the suppression of LH secretion by OE2 (Franks, Maclusky,
Naish and Naftolin, 1981). In addition, OE2 did not alter LH release
from superfused male rat pituitary gland (Linton et al., 1981). Although
it has been shown that OE2 is a potent inhibitor of LH secretion in the
long-term castrated rat (Swerdloff and Walsh, 1973; Franks et al.,
1981), the suppression of LH secretion in the intact adult male (Verjan,
de Jong, Cooke, van der Molen and Eik-Nes, 1974; van Beurden,
Mulder, de Jong and van der Molen, 1977; Franks et al., 1981) is not
a consistent finding (Tcholakian, Chowdhury and Steinberger, 1974).
The physiological role of OEx in modulating LH secretion is not
yet fully known. In studies on pre-pubertal male rats similar to
those described in this section (in which OE^^ had no effect on plasma
LH concentration), OEj^ (100 pg) injected s.c. reduced serum LH
concentration 6 h later but this effect was not observed 24 or 48 h
later (Rodriguez-Sierra and Blake, 1982b). Plasma concentrations
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of both OEx and LH found to be elevated in post-menopausal women
and in women with polycystic ovarian syndrome (Sitterii
and MaeDonald, 1974; Rebar, Judd, Yen, Rakoff, Vandenberg and
Naftolin, 1976), suggesting a possible link between QEX and LH.
The mechanism by which CAEX and CAE2 stimulate the release
of LH secretion has not been resolved. The demonstration that CAE2
(10" 7 to 10-10mol/l) did not significantly alter the release of LH
from superfused rat pituitary glands (Linton et at., 1981) suggests
that CAE2 did not act at the pituitary level. The pituitary content
of LH determined 6 h after injections of CAEX, CAE2, OE^^ or 01^ were
similar to vehicle-injected control rats (Figure 5.2a) which suggests
that pituitary LH synthesis was not increased despite the marked
increase in pituitary LH release induced by CAEX and CAE2 (Figure
5.2a). An alternative mechanism by which CAEX and CAE2 may
stimulate the release of LH could be by increasing the sensitivity of the
pituitary to LHRH. Hseuh, Erickson and Yen (1979) showed that
CAE2 increased the sensitivity of cultured pituitary cells taken from
ovariectomised rats, to LHRH-induced LH release. CAE2 was less
effective than OE2 while CAE x had no effect on the sensitivity of the
pituitary gonadotrophs to LHRH (Hseuh et a!., 1979). These studies
by Hseuh et al. (1979) do not explain why QE2 did not alter plasma
LH concentrations and why CAEX stimulated LH release in the 35-day
old rats (Figure 5.2a). The possibility that the catechol oestrogens
increase the release of LHRH into pituitary stalk blood and so stimulate
LH release remains to be investigated.
A physiological role for CAEX in PRL release in the pre-pubertal
male rat appears to be unlikely. Doses up to 200 pg CAE1 did not
significantly alter PRL secretion compared to vehicle-treated controls
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(Figure 5.2a), in agreement with other similar studies (Rodriguez-
Sierra and Blake, 1982). In contrast, CAE 1 has been shown to
suppress PRL in normal young women (Fishman and Tulchinsky,
1980) and in oestrogen-primed post-menopausal women (Schinfield
et al., 1980). Administration of CAE2 (100 Mg/rat),OE2 (200 pg7rat)
andOE1(l0 pg/rat) significantly increased PRL concentrations in
peripheral plasma (Figure 5.2a). A stimulatory effect on PRL
secretion by CAE2 and OE-l in the pre-pubertal male rat has been found
in recently published studies (Rodriguez-Sierra and Blake, 1982b).
Although Rodriguez-Sierra and Blake (1982b) found OE2 did not alter
PRL release, there is evidence from several studies that OE2 stimulates
PRL release (Frantz, Kleinberg and Noel, 1972; MacLeod;
1976; De Lean, Ferland, Drouin, Kelly and Labrie, 1977) and from
anterior pituitary cell cultures (Raymond, Beaulieu and Labrie, 1978).
Since CAE2 has the capacity to compete with dopaminergic ligands
for dopamine receptors in the anterior pituitary (Schaeffer and Hseuh,
1979), it is possible that CAE2 stimulated PRL release by preventing
dopamine from inhibiting PRL release from the pituitary (Shaar and
Clemens, 1974; Neill, 1980). This proposal is, however, not
supported by experiments showing that exposure of superfused male
rat pituitary glands to CAE2 alone or with dopamine reduced PRL
secretion by 51-60% (Linton et at., 1981). In addition, it has been
argued that the delayed effect (2-4 hours) of CAE2 on PRL concentra¬
tion (Adashi et at., 1980; Shin et a!., 1981) and the relatively small
magnitude of the response suggest that CAE2 does not act in the same
manner as known dopamine antagonists (e.g. metoclopramide: Juda,
Lazarus and Smythe, 1976). Alternatively, a hypothalamic site of
action of CAE2 to inhibit DA synthesis is also possible. A decrease in
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DA turnover in the anterior medio-basal hypothalamus and preoptic
area after CAE2 administration to gonadectomised rats has been
associated with the increase PRL secretion induced by CAE2 (Parvizi
and Wuttke, 1983). CAE2 has also been shown to inhibit the activity
of tyrosine hydroxylase in the hypothalamus, at physiological concentra¬
tions of CAE2 (Lloyd and Weiz, 1978). This would reduce the synthesis
of dopamine and therefore the dopaminergic inhibition of PRL. The
ability of CAE2 to alter catecholamine synthesis significantly would
depend on two main conditions. Firstly, that CAE2 had access to the
appropriate neuronal sites and, secondly, that a mechanism existed for
concentrating CAE2 in catecholamine neurones. These conditions are
necessary since CAE2 is very labile and rapidly o-methylated by the
COMT in hypothalamic extracts (Breuer and Koester, 1974). It has been
demonstrated that high concentrations of CAE2 as well as the enzyme
which converts OEjto CAE2 exist in the hypothalamus (Fishman and
Norton, 1975; Paul and Axelrod, 1977) and that the DA neurones in
the TIF region, but not the substantia nigra, can concentrate tritiated
OE2 (Pfaff and Keiner, 1974; Stumpf, Sar and Keefer, 1975). The two
conditions mentioned above are, therefore, fulfilled which suggests
that CAE2 could be stimulating PRL release by acting at the hypothalamus.
The duration of the effect of CAE2 may be controlled by the degree of
access of catechol oestrogens to COMT. The methylated metabolites or
OEj^ and OE2 do not inhibit tyrosine hydroxylase activity (Foreman and
Porter, 1980), suggesting that these steroids could act as reservoirs
of the catechol oestrogens.
In conclusion, the studies presented in this section showed that
CAEi stimulated LH secretion while CAE2 stimulated both LH and PRL
secretion in the pre-pubertal male rat. This demonstrates that the
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enzymatic conversion of OEx and OE2 to 2-hydroxylated derivatives does
not produce inactive metabolites.
5.3 The Effect of Acute Catechol Oestrogen Administration to Immature
Female Rats Treated With Pregnant Mare Serum Gonadotrophin
(PMSG)
5. 3. 7 In troduction
Several studies suggest that the catechol oestrogens may play
a role in inducing hormonal changes (Fishman, 1976; Gelbke,
Ball and Knuppen, 1977; Paul, Hoffman and Axelrod, 1980). The
formation of CAE* and CAE2 is catalysed by oestradiol-2-hydroxylase,
a microsomal cytochrome P450-dependent mono-oxygenase (Gelbke
et al., 1977; Paul, Axelrod and Diliberto, 1977). Radioenzymatic
measurements of the activity of oestradiol-2-hydroxylase in the brain
of female rats during the oestrous cycle showed a sharp rise in activity
occurred at pro-oestrus, just before the ovulatory LH surge (Fishman,
Norton and Krey, 1980). The enzyme activity in the liver remained
unchanged throughout the cycle. Measurements of plasma CAEX
concentrations during the human menstrual cycle demonstrated that a
6 - fold increase occurred at ovulation (Ball, Gelbke and Knuppen,
1975), suggesting that a specific increase in oestradiol-2-hydroxylase
activity occurred at ovulation. These cyclic changes in enzyme activity
in conjunction with evidence for a positive feedback effect of exogenous
CAE2 on pituitary LH release (Naftolin et at., 1975; Gethman and
Knuppen, 1976; results presented in Section S. 1.3) raises the pos¬
sibility that endogenous CAE2 is involved in the physiological induction
of the pre-ovulatory LH surge. There is evidence that oestradiol-2-
hydroxylase activity in the brain and liver of male rats also responds
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to hormonal manipulation. Castration induced a reversible fall in
enzyme activity in both the brain and liver while cytochrome P450-
inducers (e.g. barbiturates) had no effect (Hoffman et al., 1980b).
Using cultured pituitary gonadotrophs it has been demonstrated
that CAE2, but not CAEX, sensitises the cultures to LHRH although
CAE2 was less potent than either OEj or QE 2 (Hseuh et o/., 1979). This
suggests that the metabolismof OE2 to CAE2 (Figure 5.1a) could be
important in prolonging its effect whereas the conversion of QE2 to CAEX
may be important in terminating its activity.
The administration of catechol oestrogens to adult female rats
reduced fertility and prevented the development of oestrous cycles
in neonatal female rats (Parvizi and Naftolin, 1977). The effects of
CAEX and CAE2 administration to the neonatal female rats resembled
those seen in androgenised female rats (Barraclough, 1961), suggesting
that these catechol oestrogens cause defeminisation. Evidence sug¬
gesting that the catechol oestrogens could act as endogenous anti-
oestrogens include the demonstration that CAE2 competes with QE2 for
soluble oestrogen receptors in the pituitary and hypothalamus (Davies
et al., 1975; Clarke and Findlay, 1980) and inhibit oestrogen-elicited
accumulation of hypothalamic cAMP (Paul and Skolnick, 1977).
The timing of the first gonotrophin surge in pre-pubertal rats
treated with PMSG has been demonstrated to depend on the capacity
of the ovaries to secrete E2 in the form of a surge (Wilson, Horth,
Endersby and McDonald, 1974). There was a positive correlation
between the dose of PMSG, the peak concentration of plasma OE2 and
the average number of ova shed (Wilson et a!., 1974). Plasma OE2
concentrations reached a maximum 42-52 h after PMSG treatment and
then fell significantly (Wilson et a!., 1974). Both the pre-ovulatory
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surge of LH and the time of ovulation have been shown to be advanced
by up to 24 h by the simultaneous administradion of PMSG and OE2
(Park and Zarrow, 1971) . This stimulatory effect of OE2 was used to com¬
pare the effects of CAEi and CAE2 in the PMSG-treated 39-day old female
rat. In the immature female rat treated with PMSG, the hormonal changes
(Park and Zarrow, 1971; Sorrentino, Reiter, Lee and Schalch, 1972; Wilson
et at., 1974; Sarkar and Fink, 1979) and neural pathways that mediate the
neuroendocrine signal for ovulation (Quinn and Zarrow, 1965; Sorrentino
et al 1972) are similar to those in the adult female rat (Everett, 1964;
Halasz and Pupp, 1965; Koves and Halsz, 1970; Butler and Donovan, 1971;
Fink, 1979). However, unlike the adult female rat, no significant increase
in pituitary responsiveness to LHRH appears to occur in PMSG-4;reated rats
(Sarkar and Fink, 1979) and this may explain, at least in part, the fact that
the LH surge in PMSG-treated rats is only about a third that of the spontan¬
eous surge at puberty (Wilson et aL, 1974; Sarkar and Fink, 1979).
Purpose of present study:
The aim of the experiments described in this section was to deter¬
mine the effects of CAE2 on PMSG-induced ovulation compared to the
effects of OEx and OE2 by measuring the magnitude of the pre-ovulatory
LH surge and plasma PRL concentrations. In addition, the effects of
the oestrogens and CAE2 on the reproductive tract were compared by
determining the weights of the uterus and ovaries.
5. 3. 2 Materials and Methods
Female Wistar rats (Charles River, U.K.) were obtained on day
24 of life and kept on a lighting schedule of 14 hours light (lights on
between 06.00 h and 20.00 h). At 11.00 h on day 30 the rats were
injected subcutaneously (s.c.) with either 20 iu PMSG ("Folligon",
Intervet Laboratories Ltd, Cambridge) or 0.9% saline. On day 31, 28 h
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later, the rats were injected with either 2.5 ug OE2, 2.5 ug QEa, 50 ug
CAE2 or the vehicle (propylene glycol containing 0.01% ascorbic
acid), in a volume of 0.25 ml by an s.c. injection given at 16.00 h.
At 17.00 h on day 32, blood samples (0.3 ml each) were collected from
the external jugular vein under ether. The plasma obtained was kept
frozen at -20°C until assayed for LH and PRL by radioimmunoassay
(Section 2.3). On the morning of day 33, between 08.30 h and 10.00 h
the animals were decapitated. The uteri were removed and stripped
of adhering fat and connective tissue. Any fluid present was expressed
then the uteri were blotted and weighed.
Differences between the mean values of the five groups were
compared by analysis variance and the multiple range test for hetero-
scedastic means and unequal numbers of replicates (Duncan, 1957;
Harter, 1960). Values of p <0.05 were considered as significant.
5. 3. 3 Results
(a) Effects on plasma hormone concentrations:
The concentration of LH and PRL in peripheral plasma samples
obtained at approximately 17.00 h on day 32 after various injections
on day 30 and 31 are shown in Table 5.3a.
A single injection of 20 iu PMSG produced a significant (p <0.05)
increase, 56 h later, in plasma LH concentrations compared to those
in the other groups. The administration of 50 |ig CAE2 28 h after an
injection of 20iu PMSG significantly (p <0.05) blocked this increase
in plasma LH concentration. Plasma LH concentrations in animals treated
with saline followed by either OE2 or CAE2 were similar to each other
and significantly lower (p <0.05) than those in animals treated with
PMSG followed by saline. In 4 out of 12 rats the injection of 2.5 ug
OE1 stimulated a marked increase in plasma LH concentration (mean +
TABLE 5.3a: Plasma LH (ng/ml) and PRL (pg/ml) concentrations,
mean ± SEM (n) at approximately 17.00 h in groups
of 32-day old female rats, subcutaneously administered
either 20 iu PMSG, saline, 2.5 gg oestradiol-17 3 (QE,2),
2.5 gg oestrone(QEi) or 50 gg CAE2 on day 30 and 31
as indicated. Blood samples were obtained, under ether
anaesthesia, from the external jugular vein.
Peripheral plasma
LH concentration PRL concentration
Day 30 Day 31 (ng/ml) (pg/ml)
PMSG (20iu) Saline (0.25 ml) 131.5 + 18.7 (16) 387.0 + 42.0 (D
Saline (0.25 ml) CAE2 (50gg) 12.9 + 4.4 (17) 271.0 + 78.0 (3)
PMSG (20iu) CAE2 (50gg) 27.1 + 6.7 (ID 145.0 + 79.0 (3)
Saline (0.25 ml) OE2 (2,5gg) 5.9 + 2.3 (16) 251.0 + 100.0 (3)
Saline (0.25 ml) OEx (2.5gg) 49.7 + 22.3 (12) 291.0 + 114.0 (5)
TABLE 5.3b: Plasma LH concentration in individual rats 25 h after























SEM = 142.9 ± 34.1 ng/ml); in the other 8 rats plasma LH concentra¬
tions remained low (mean ± SEM = 4.3 ± 0.2 ng/ml). The plasma LH
concentrations in the individual rats injected with 2.5 ug OEj^ are shown
in Table 5.3b.
There was no significant difference between any of the groups
with respect to the plasma PRL concentrations (Table 5.3a).
(b) Effects on the reproductive tract:
Table 5.3c shows the weights (mg) of uteri and ovaries of 33-day
old female rats treated with PMSG, saline or steroids. A significant
(p <0.05) increase in uterine weight occurred after the injection of
20iu PMSG compared with that of any of the other treatments. The
injection of 2.5 ngOE, in animals previously injected with saline resulted
in an increase in the weight of the uterus which was significantly
(p <0.05) less than after injecting 20iu PMSG followed by saline and
significantly (p <0.05) greater than after injecting saline followed by
50 ug CAE2. The uterotrophic effect of 20 iu PMSG injected on day 30
was significantly (p <0.05) reduced by the injection of 50 ug CAE2 on
day 31. The mean weight of the uterii in the group of rats treated with
both 20 iu PMSG and 50 ug CAE2 was approximately the same as that in
animals injected with saline followed by 2.5 ug Ex.
Table 5.3c shows that treatment of 30-day old rats with 20 iu
PMSG significantly (p <0.05) increased the weight of the ovaries
compared to any of the other treatments. The injection of 50 ug CAE2
28 h after 20iu PMSG given on day 30 produced a significantly (p <0.05)
greater increase in ovarian weight compared with that of treatment with
20iu PMSG alone. The administration of 50 ug CAE2 or 2.5 ug OE2
produced an equivalent increase in the weight of the ovaries. This
was significantly (p <0.05) greater than that after injecting 2.5 ug OEi
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TABLE 5.3c: The weight (mg) of uterii and ovaries of 33-day old
female rats administered after 20iu PMSG, saline, 2.5
Mg oestradiol-173 {(OB2),2.5 Mg oestrone (OEi) or 50 Mg
CAE2 on day 30 and 31 as indicated. Values are given
as mean ± SEM (n).
Treatment ... . , . . ... . , . .Weight of uterus Weight of ovaries
Day 30 Day 31 (mg) (nig)
PMSG (20iu) Saline (0.25 ml) 155.9 ± 12.7 (18) 63.8 + 3.5 (19)
Saline (0.25 ml) CAE2 (50ug) 64.9 ±13.7 (74; 24.6 + 3.1 (74;
PMSG (20iu) CAE2 <50Mg) 91.4 ± 7.0 (15) 95.3 + 11.4 (15)
Saline (0.25 ml) OE2 (2.5Mg) 112.2 ±12.2 (13) 28.8 + 6.2 (12)
Saline (0.25 ml) OE i ( 2.5Mg) 98.8 ± 12.0 (12) 18.1 + 2.3 (11)
and significantly (p <0.05) less than the mean ovarian weight produced
by injection of 20 iu PMSG alone or followed by 50 ug CAE2.
5. 3. 4 Discussion and Conclusions
Administration of 20 iu PMSG to pre-pubertal female rats induced
an increase in the circulating LH concentration approximately 56 h
later had a uterotrophic effect, increased the weight of the ovaries
and induced ovulation. These effects of PMSG are in agreement with
previous findings (e.g. Park and Zarrow, 1971; Wilson et al., 1974;
Sarkar and Fink, 1979). Experiments described in this section demon¬
strated that while 2.5 Mg OE2 had a potent uterotrophic effect, it was not
as effective as PMSG in inducing the release of LH and increasing
ovarian growth in immature female rats. In contrast, 2.5 Mg OEx
produced plasma LH concentrations which were about 9-fold greater
than those produced by OE2. The uterotrophic activity of OEx was
equivalent to that of OE2. These results provide new data on the
oestrogenic nature of OEx and are firs± t° demonstrate a stimulation
of LH release by OEx.
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The principal metabolite of OE2, CAE2, which was more potent
than 0E2 in increasing plasma LH concentrations, suppressed the plasma
LH surge induced by PMSG. Franks, Ball, Naftolin and Ruf (1980)
have demonstrated that administration of doses of CAE2 up to 100 pg
did not alter the time of ovulation or the number of ova induced by
PMSG. Therefore, the magnitude of the suppression of the pre-ovulatory
LH surge induced by PMSG after CAE2 administration does not apparently
affect the ability of PMSG to induce ovulation.
The biological action of the catechol oestrogens was initially
distinguished by their lack of uterotrophic activity (Gordon, Cantrall,
Cekleniak, Albers, Maner, Stolar and Bernstein, 1964). CAEX and
CAE2 were found to retain less than 0.1% of the uterotrophic activity
of their parent compounds and this was attributed to their reduced
binding to uterine OE2 receptors (Martucci and Fishman, 1976). In
later studies, wax pellets (Martucci and Fishman, 1979) or miniature
osmotic pumps (Jellinck, Davis, Krey, Luine, Roy and McEwen, 1979)
were used to infuse CAEX at a rate of approximately 25 pg/day. These
studies as well as those in which CAEX were injected daily (Kono et a!.,
1981) demonstrated that CAEX did not have any significant uterotrophic
activity. The low uterotrophic effect of CAE2 was confirmed in the
studies described (Section 5.2.3, Table 5.3c). In addition, these
studies (Table 5.3c) provide the first evidence that CAE2 inhibit the
uterotrophic activity of PMSG .
CAEx administered to adult rats at noon on pro-oestrus has been
demonstrated to abolish the pre-ovulatory PRL surge (Katayama and
Fishman, 1982). After CAE2 administration, in contrast, the plasma
PRL concentration 12-15 h before ovulation (Table 5.2) was not
significantly different from QE,- or PMSG-treated rats. This suggests
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that CAEi and CAE2 differ in their effects on PRL release. In
addition, CAE2 has an equipotent effect to its parent oestrogen in
inducing PRL release.
In conclusion, data from experiments on pre-pubertal female rats
showed that CAE2 induced a larger rise in the pre-ovulatory LH surge
than its parent oestrogen, although its uterotrophic activity was lower
thanOE2. CAE2 also reduced the uterotrophic effect of PMSG as well
as the magnitude of the pre-ovulatory LH surge induced by PMSG.
Whether the changes in plasma LH concentration produced after CAE2
administration are brought about by modulation of the release of LHRH
into pituitary stalk blood remains to be investigated.
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0.1 Introduction
Cholecystokinin (CCK) was originally isolated from hog intestine
as a 33-amino acid peptide (Jorpes and Mutt, 1973). It strongly
stimulates gall bladder contraction and release of digestive enzymes
(e.g. amylase) from the exocrine pancreas (Jorpes and Mutt, 1973;
Mutt, 1980; Williams, 1980). The presence of a CCK-like gastro¬
intestinal peptide has also been demonstrated in the central nervous
system. Gastrin-like material in brain extracts of several vertebrates
was first described by Vandergaegen, Signeau and Gepts (1975).
Studies using immunological techniques combined with fractionation
procedures have indicated that this gastrin-like material is distinct
from heptadecapeptide gastrin and is identical to the biologically active
carboxy terminal octapeptide of CCK (CCK-8) (Dockray, 1976; Muller,
Straus and Yalow, 1977; Dockray, Gregory and Hutchison, 1978;
Rehfeld, 1978; Robberecht, Deschodt-Lanckman and Vanderhaeghen,
1978). Subsequent studies have demonstrated that while CCK exists
in at least five forms in the brain (viz. a component larger than CCK-39,
components similar in size to CCK-33, CCK-12, CCK-8 and a smaller
molecular form), the predominant form is CCK-8 (60-70%) and approxi¬
mately 15% is CCK-33 (Muller et al. , 1977; Dockray et at., 1978;
Larsson and Rehfeld, 1979; Rehfeld, Gottermann, Larsson, Emson
and Lee, 1979; Lamers, Morley, Poitras, Sharp, Carlson, Hershman
and Walsh, 1980; Ryder, Eng, Straus and Yalow, 1981). The partial
amino acid sequence of CCK-33 is shown in Figure 6.1a. CCK-8 in
the brain is formed by selective endopeptidase cleavage of CCK-33
(Deschodt-Lanckman, Bui, Noyer and Christopher, 1981; Straus,
Malesci and Yalow, 1981) and since this enzyme system is more efficient
in the brain than the gut (Eng, Shiina, Straus and Yalow, 1982), there
I I
FIGURE 6.1a: Partial amino acid sequence of CCK 22-33. Area in j j
represents the area of homology with gastrin (G).






FIGURE 6.1b: Antigenic determination of two COOH-terminal specific
antisera, L48 and 1296. Antiserum L48 raised to
CCK-8 coupled to bovine serum albumin has a 50 times
higher affinity for CCK-8 and G-17 than G-4 and G-5.
Antiserum 1296 cross-reacts about 20 times more with







is very little CCK-33 in the brain. In the gut, on the other hand,
there are roughly equal amounts of CCK-8 and CCK-33 (Rehfeld,
1978; Dockray, 1980). The major form of CCK in peripheral nerves,
such as those innervating pancreatic islets, has been reported to be
C-terminal tetrapeptide (CCK-4) which is common to gastrin (Figure
6.1) (Rehfeld, Larsson, Gottermann, Schwartz, Hoist, Jensen and
Morley, 1980), although Dockray and Gregory (1980) have disputed
the existence of free CCK-4 in the pancreas. CCK has structural
and functional homologies to gastrin. Their identical C-terminal
sequence is responsible for their biological activity while the rest of
each molecule modifies activity quantitatively and determines relative
potencies for various targets (Rehfeld, 1981). These
ivwiMurkO
characteristics together with immunocytochemical and radioA chemical
studies of the occurrence of gastrin and CCK in different vertebrate
species suggest these two peptides have evolved from a common
ancestral molecule (Larsson and Rehfeld, 1977; Dockray, 1979).
The development of a range of antisera specific for different
sequences of CCK and gastrin has enabled the use of immunohisto-
chemical methods to localise these peptides in the brain (Innes, Correa,
Uhl, Schneider, Snyder, 1979; Larsson and Rehfeld, 1979; Loren,
Alumet, Hakanson and Sundler, 1979; Vanderhaeghen, Lotstra, De
Mey and Giles, 1978) and gut (Dockray, 1976; Buffa, Solicia and Go,
1976; Rehfeld et al., 1979).
6. 7. 7 CCK and the Pituitary
Gastrin-17 and gastrin-34 have only been located in the pig
pituitary gland (Rehfeld, 1978) although the pituitary of several other
species including the rat has been surveyed (Beinfeld, Meyer and
Brownstein, 1980). Substantial amounts of CCK-like immunoreactivity
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have been shown to be present in fibres in the pars nervosa (PN)
(Loren etal., 1979; Vanderhaeghen et al., 1980; Beinfeld, Meyer
and Brownstein, 1980) but not in the pars intermedia (PI) or pars
distalis (PD). Section of the pituitary stalk resulted in the disappear¬
ance of CCK from the PN while destruction of both paraventricular
nuclei resulted in a 60% fall in PN CCK (Beinfeld et al., 1980). It
has therefore been suggested that CCK in the PN originates in neuronal
cell bodies in or near the paraventricular nuclei, and that these
neurones project to the PN by way of the median eminence. Presumably
40% of the CCK in the PN originates in supraoptic nucleus where, as
in the paraventricular nucleus, CCK cell bodies have been seen to
coexist with oxytocin (Loren et al., 1979; Vanderhaeghen et al.,
1980). The reduction of CCK content of PN under physiological
conditions such as lactation and hypernatremia, which stimulate oxytocin
and vasopressin release, respectively, suggests CCK may be co-secreted
with oxytocin and vasopressin (Beinfeld et al., 1980). Scattered CCK
cell bodies and fibres have been seen in all hypothalamic nuclei except
the mammillary bodies (Vanderhaeghen et al., 1980; Loren et al.,
1979).
Numerous CCK immunoreactive fibres have been found in the
external layer of the median eminence of dogs (Vanderhaeghen, Lotstra,
Vierendeels, Gilles, Deschepper and Verbanck, 1981), rats (Vanderhaeghen
etal., 1980; Hokfelt, Elde, Fuxe et al., 1978; Loren etal., 1979;
Anhut, Meyer and Knepel, 1983) and frogs (Larsson and Rehfeld, 1977).
The distribution of CCK within the hypothalamo-hypophysial system
suggests that CCK could have a role in control of pituitary secretion.
There is evidence that both CCK-8 and gastrin alter the release
of a number of hormones from the anterior pituitary. Central administra-
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of CCK-8 and gastrin stimulated the release of growth hormone (GH)
and inhibited the release of thyrotropin (TSH) and luteinizing hormone
(LH) (Vijayan, Samson and McCann, 1978a, 1979a),. The release of
follicle-stimulating hormone (FSH) was not altered by either CCK or
gastrin. Prolactin (PRL) release was stimulated by CCK-8 and
inhibited by gastrin (Vijayan et at., 1978a, 1979a),. The modulation of
LH, PRL and GH release by CCK-8 and gastrin appear to be by way
of a hypothalmic action rather than a direct action on the pituitary
while the stimulation of TSH by gastrin has been attributed to an
effect of gastrin on the hypothalamus and pituitary (Vijayan et al.,
1978a). Intravenous injections of CCK-8 and gastrin into rats, or the
incubation of hemi-pituitaries with these peptides, did not produce
the changes in the release of anterior pituitary hormones seen after
intraventricular administration, except for the inhibitory effect of
gastrin on TSH release (Vijayan et a!., 1978$, 1979a). Presumably
CCK-8 in ng doses and gastrin in ug doses injected intravenously
acted to inhibit the release of LHRH and TRH which resulted in reduced
circulating levels of LH and TSH. There is evidence in humans that
CCK can decrease the TSH response to TRH (Morley, 1981), suggesting
this may be a mechanism by which CCK modulates anterior pituitary TSH
concentrations. CCK has also been demonstrated to reverse the
inhibitory effect of somatostatin on GH release in monolayer cultures
of a GH tumour cell line (Morley, Melmed, Briggs, Carlson, Hershman,
Solomon, Lamers and Damassa, 1979). This may explain the finding
that intravenous injection of CCK to humans increased GH secretion
(Domschke, Lux and Domschke, 1980), an effect not seen when gastrin
is administred to rats by the same route (Vijayan et al., 1978a).
Intracerebroventricular and intraperitoneal injections of crude CCK
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extracts lead to pronounced increases in plasma corticosterone levels
in intact but not hypophysectomised rats (Fekete, Bokor, Penke,
Kovaes and Telgdy, 1981; Itoh, Hirota, Katsuura and Odaguchi,
1981).
6. 7. 2 CCK and the Brain (Other than Hypothalamus)
Substantial concentrations of CCK have also been found in
brain areas outside the hypothalamus except for the pons, medulla
and cerebellum; the highest concentrations were in the cortex and
striatum (Brownstein et at., 1981; Innis ef al., 1979; Vanderhaeghen
et al., 1980). In the ventral tegmental area and in the zona compacta
of the substantia nigra, CCK immunoreactivity has been demonstrated
to coexist in a subpopulation of dopamine-containing neurons that
project to the amygdala and cortex (Innes et al., 1979; Hokfelt,
Skirbol, Rehfeld, Goldstein, Markey and Dann, 1980; Meyer, Beinfeld,
Oertel and Brownstein, 1981). The degeneration of these cell bodies
and terminals may explain the diminution of CCK and its receptors in
the basal ganglia and cortex in Huntington's disease (Hokfelt et al.,
1980; Emson, Rehfeld, Langerin and Rossor, 1980; Hays, Meyer
and Paul, 1981) and has been taken as evidence that CCK may be
involved in extrapyramidal function. Numerous CCK-containing cell
bodies and nerve terminals have also been localised throughout the
hippocampus (Loren et al., 1979; Handelmann, Meyer, Oertel and
Beinfeld, 1981), in several amygdaloid nuclei, the mesencephalon and
medulla oblongata (Innes et a!., 1979; Loren et al., 1979;
Vanderhaeghen et al., 1980). Several major pathways, such as the
medial forebrain bundle and the stria terminalis, contain CCK immuno-
reactive fibres.
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(ob/ob) mice (Straus and Yalow, 1979; Saito, Williams and Goldfine,
1981) and normal mice after a 2-5 day fast (Straus and Yalow, 1980).
Fasting in mice also increased the number of CCK receptors in the
olfactory lobe and hypothalamus (Saito et al. , 1981). These studies
relating CCK levels and CCK receptor numbers to fasting have, how¬
ever, not been confirmed by other workers (Lamers et al., 1979; Ho
and Hansky, 1979; Schneider, Monohan and Hirsch, 1979; Oku,
Glick, Shimonura, Inoue, Bray and Walsh, 1980).
6. 7. 3 Interactions between CCK and Monoaminergic Neurones
Evidence that CCK can alter monoamine levels in various brain
areas suggests another mechanism by which CCK could regulate
anterior pituitary hormone release. Intraventricular administration
of CCK antiserum has been found to decrease the dopamine (DA)
and noradrenaline (NA) content of the hypothalamus, mesencephalon,
amygdala and septum, while an increase in DA and a decrease in NA
content occurred in the striatum (Kadar, Fekete, Lonovics and
Telegdy, 1981). In the same experiments, the 5-HT content of
mesencephalon, amygdala and septum was reduced, and increased in
the striatum. The reduction in DA content has been attributed to
a decrease in DA synthesis due to an inhibition of tyrosine hydroxyl¬
ase activity, while the sulfate ester on the tyrosine residue of the CCK
molecule (Figure 6.1a) has been found to inhibit the production and
release of DA at the nerve terminal (Itoh and Katsuura, 1981). The
failure of CCK-8 to interfere with the behavioural effects of apomorphine
and haloperidol (Itoh and Katsuura, 1981) supports a presynaptic site
of action to explain the antagonism of DA by CCK-8. The inhibition of
DA by CCK-8 may explain the PRL-release stimulating action of CCK-8
(Section 6.1.1, Vijayan et al. , 1979). There is evidence that CCK and
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Administration of CCK has been reported to produce a variety
of effects on central nervous function. For example, intracerebro-
centricular administration of CCK-8 (20-250 ng) induced dose-related
hypothermia and hypoglycaemia (Katsuura, Hirota and Itoh, 1981;
Morley, Levine and Lindbland, 1981). The hypothermia was antagon¬
ised by throtrophin releasing hormone (TRH: Katsuura et al., 1981)
and similar in magnitude to that produced by equimolar doses of neuro¬
tensin (Yehuda and K'astin, 1980). Pharmacological doses (150-100 pg/
kg) CCK administered parentally have been shown to induce sedation,
catalepsy, ptosis and inhibition of rearing activity in mice (Zetler,
1980a; Katsuura and Itoh, 1982). CCK-8 and the frog skin decapeptide,
caerulein (which shares seven of eight residues with CCK-8) delayed
the onset of convulsions that followed the administration of strychnine,
penetetrazol, picrotoxin and bicuculline (Zetler, 1980b). Intraventricular
CCK-8 (400-1800 ng) markedly suppressed L-dopa-induced behavioural
effects in rats (Katsuura and Itoh, 1982) and antagonised the potentia¬
tion of L-dopa by TRH (Metcalf and Dettmar, 1981).
The satiety produced by introduction of food into the intestine
can be mimicked by either systemic injections of CCK and its analogs
(Gibbs, Young and Smith, 1973; Houpt, Anika and Wolff, 1978) or by
injections of CCK into the cerebral ventricles (Della-Ferra and Baile,
1979) and ventromedial hypothalamus (Stern, Cudillo and Kruper, 1976).
CCK-antibody injected into the cerebral ventricles stimulated feeding
in sheep but not in rats (Della-Ferra, Baile, Schneider and Grinken,
1981) while continuous injections of picomole quantities of CCK-8 into
the cerebral ventricles of sheep decreased feeding (Della-Ferra and
Baile, 1979). The concentration of CCK and the number of CCK
receptors were reduced in the cerebral cortex of both genetically obese
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DA co-exist in the same neurons (Innes et al., 1979; Hokfelt et a!.,
1980; Meyer et al., 1981) and that schizophrenia may be related to
an excess of central dopaminergic neuronal activity (Mackay
and Crow, 1980; Snyder, 1982). This has led to speculation that
CCK-8 could also act as an anti-psychotic agent and by decreasing
central dopaminergic transmission, have a therapeutic effect in
schizophrenia. It has been claimed that an analog of CCK-8 was
beneficial in a large proportion of patients suffering from schizophrenia
for 2-27 years (Itoh and Katsuura, 19810. This study has not yet
been confirmed.
6. 7. 4 Purpose of Present Study
Whether CCK and gastrin play a major role in modulating the
release of hormones from the anterior pituitary is still largely undecided.
However, in view of the localisation of these peptides in brain areas
which project to the median eminence and the demonstration that CCK
can be released from hypothalamic synaptosomes by depolarisation
(Pinget, Straus and Yalow, 1978; Sheppard, Klaff, Hudson and
Tyler, 1980; Dodd, Edwardson and Dockray, 1980), the aims of the
present study were to determine:
1. whether the concentrations of CCK and gastrin in
pituitary stalk blood were greater than in the
peripheral circulation;
2. whether electrical stimulation of various areas of the
brain known to contain immunoreactive CCK-gastrin-
like material modulated the release of CCK or gastrin
into stalk plasma, since electrically-stimulated release
of a substance provides indirect evidence for physio¬
logical release of that substance;
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3. to what extent the peripheral sources of CCK and
gastrin, notably the gastric antrum, contributed
to the concentrations of CCK and gastrin measured
in stalk plasma.
To avoid problems with immunological cross-reactivity in radio¬
immunoassay procedures to determine the concentrations of CCK and
gastrin in plasma and tissue samples, antisera (L/48 and 1296)
prepared with differing specificities for mid- and C-terminal regions
were used (Figure 6.1b). These antisera do not, therefore, cross-
react with the inactive NH3-terminal fragments (Dockray and Walsh,
1975; Dockray, Vaillant and Hutchison, 1981).
6.2 The Effect of Electrical Stimulation of Various Brain Areas on
CCK and Gastrin Release into Pituitary Stalk Blood
6. 2. 7 Methods
(a) Animals: Adult male rates of the Albino Wistar COB strain were
used in all experiments (180-200 g body weight). Urethane (1 g/kg
b.w.) administered intraperitoneally was used to induce anaesthesia.
Pituitary stalk blood was collected as described in Section 2.2.5 for
consecutive periods of 30 min each before, during and after the applica¬
tion of the electrical stimulus. Peripheral blood samples were collected
from the external jugular vein before the pituitary stalk was cut and
at the end of each 30 min period of pituitary stalk blood collection.
All blood samples were collected into tubes kept on ice and containing
EDTA (5.4 mM/1 blood) and Trasylol (5 K1U/1). The plasma was
stored frozen at -40°C and sent to Dockray (Liverpool) packed in dry
ice. The samples remained frozen until assayed.
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(b) Implantation of electrodes and stimulation parameters: Bipolar
glass-insulated platinum electrodes were prepared and implanted as
described in Section 2.2.7 under Avertin anaesthesia. The electrode
tips were 1 mm apart for implantation in the suprachiasmatic nucleus
(SCN), ventral hippocampus (VH) and amygdala (AMY) and para¬
ventricular nucleus (PVN). For the preoptic area (POA) and dorsal
hippocampus (DH), electrodes with tips separated by 2 mm were
implanted. The co-ordinates used were taken from de Groot's atlas
(1959) and are shown in Table 6.2a.
TABLE 6.2a: Co-ordinates used for the implantation of electrodes
with reference to the stereotaxic co-ordinates
described by de Groot (1959).
Brain
Co-ordinates
area Anterior Ventral Lateral
AMY 5.4 -2.5 3.5
POA 7.8 -1.5 1.0 —
PVN 6.4 -1.3 0.3
SCN 7.4 -2.3 0.5 -
DH CO o +2.0 1.5













All the rats implanted with electrodes appeared healthy and
were feeding and drinking 4-5 days after electrode implantation when
pituitary stalk blood samples were obtained.
For stimulation of the median eminence (ME), a unipolar glass-
insulated platinum electrode was placed on the surface of the ME just
before heparin was injected and the pituitary stalk cut.
The parameters of the electrical stimulus used were those shown
to produce the optimum release of LH (Fink and Aiyer, 1974; Jamieson
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and Fink, 1976); trains (30 sec on; 30 sec off) of biphasic square
wave pulses with a frequency of 60 Hz, duration of 1 msec and amplitude
of 500 pA (1 mA peak-to-peak). The electrode was left in place for
the duration of the entire experiment. At the end of each experiment
the heads were fixed in 10% formalin. Subsequently, serial frozen
sections of the brain were prepared, stained with Cresyl fast violet
and examined (Section 2.2.7).
(c) Radioimmunoassay and calculations: The concentration of CCK
and gastrin in plasma samples was determined by radioimmunoassay
using antibodies with differing specificities for the COOH-terminal of
these two peptides (Dockray, 1980; Dockray, Vaillant and Hutchison,
1981; Section 2.3; Figure 6.1b). The sensitivity of the CCK assay
was 20 pmol/1 and for gastrin it was 5 pmol/1.
Radioimmunoassays using the two antibodies L48, which reacts
almost equally with gastrin and CCK, and 1296, which is specific for
the N-terminus of gastrin-17 and reacts poorly with CCK, were done
simultaneously on all the samples. Since the CCK concentration in
peripheral plasma is <10 fmol/ml, the difference between L48 and 1296
was used to determine the concentration of hypothalamus-derived CCK
in pituitary stalk plasma.
The content (concentration x volume/unit time) of CCK and
gastrin in pituitary stalk blood collected over a 30 min period was
calculated. The significance of differences between means was deter¬
mined by the unpaired t-test. The differences between more than two
means was determined by analysis of variance and the multiple range
test (Duncan, 1957; Harter, 1960).
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6. 2. 2 Results
(a) Characteristics of CCK in pituitary stalk blood: Figure 6.2a
shows that serial dilutions of pituitary stalk plasma yielded a displace¬
ment curve which had a slope similar to the standard curve obtained
with synthetic CCK-8. Gastrin in rat plasma diluted in parallel with
standard gastrin (Dockray, unpublished data).
The mean ± SEM CCK concentration in pituitary stalk blood in
unstimulated control rats was significantly (p <0.05) greater than the
CCK concentration in peripheral plasma (Table 6.2b)
TABLE 6.2b: The effect of Trasylol (5 KIU/1) and EDTA (5.4 mM/1)
addition to whole blood on CCK concentration (pmol/1)
in peripheral and pituitary stalk plasma, and CCK
content (fmol/30 min). Values are given as mean ± SEM;
n=7 in each group.









75.00 ± 13.0 221.40 ± 35.0
Content
(-Fmol/30 min) 31.00 ± 18.0 208.40
+ 58.0
Rapid enzymatic degradation of CCK occurred if blood samples
were simply collected into cold tubes kept on ice and frozen at 20°C
until assayed (Table 6.2b). The addition of EDTA (5.4 mM/1) and
Trasylol (5 KIU/1) to whole blood at the time of collection was found




















FIGURE 6.2a: Inhibition of binding curves in the CCK radioimmunoassay
for synthetic CCK-8, pituitary stalk plasma, and plasma
containing synthetic CCK-8 (collaborative data, Dockray).
The lower limit of the assay was 0.5 pmol/l.
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in both peripheral and pituitary stalk plasma was significantly
(p <0.05) higher after EDTA and Trasylol addition.
(b) The effect of electrical stimulation of the brain on CCK and
gastrin release into pituitary stalk blood: Sections of the rat
brain showing the positions of the electrodes are shown in Figure 6. 2b.
Stimulation of all areas except AMY, DH and VH produced a marked
increase in the depth of respiration.
Cholecystokinin: The yalues of CCK (pmol/1) in peripheral and
pituitary stalk plasma collected before, during and after the applica¬
tion of an electrical stimulus to various brain areas are shown in
Figure 6.2c. Details of these data, including the number of rats in
each group, are presented in Table 6.2c. Peripheral plasma 'control'
values refer to the CCK concentration of the blood obtained from the
external jugular vein shortly before the pituitary stalk was cut in
order to collect pituitary stalk blood. The 'control' group listed in
the column of the brain areas stimulated refers to the group of rats
which were not implanted with electrodes and did not receive any
electrical stimulation.
Pituitary stalk plasma CCK concentration was significantly
(p <0.05) higher than peripheral plasma in the unstimulated 'control'
group of rats, both before ('control' sample) and 30 min after ('pre-
stimulation' sample) the pituitary stalk was cut (Table 6.2c). Over
the next hour of collection, the CCK concentration of both pituitary
stalk plasma and peripheral plasma was found to fall progressively.
Electrical stimulation did not produce any statistically significant
differences in the CCK concentration of peripheral plasma compared to
the prc-stimulation period in any of the groups.
FIGURE : Coronal sections of the rat brain taken from de Groot's
atlas (1959) showing positions of the electrode tips (•)
. 2b(i) -n t^e f0p0Wing areas:
A3.0 dorsal and ventral hippocampus (HPC)
A5.4 central amygdaloid nucleus (AME)
A6. 2 paraventricular nucleus (PVH)
A7.4 suprachiasmatic nucleus (SC)
A7.8 preoptic nucleus (POA)
Abbreviations
AAA anterior amygdaloid area
AH anterior hypothalamic area




MFB medial forebrain bundle





ACE central amygdaloid nucleus












FIGURE 6.2b(ii): Representative photomicrographs of brain
sections (A - F) showing positions of electrode
tracts in the dorsal and ventral hippocampus,
central amygdaloid nucleus, paraventricular




C. Central Amygdaloid Nucleus
E. Suprachiasmatic Nuclei
FIGURE 6.2c: CCK concentration (pmol/1) in peripheral Hi and
pituitary stalk plasma j j
a = peripheral plasma samples before stalk sectioned
b = pre-stimulation period
c = stimulation period (indicated by a bar)
d = post-stimulation period

























TABLE6.2c:heCCKconcentration(pg/ml)i peripherallasma ditu t rys lkplasmab fo e,during andfterelectricalstimulationofvariousbr inar a( eeFig e6.2f bbr v tions). The'control'group(C)rep esentsunstimulatedats.Peripheral'co trol'amplesr obtainedbeforthepituitarys lkwasc .Thv luesagiv nm a±SEM;t numberofratsie chgroupsivenp renth sis. Brain areaControlPeripheralplasma Pre-stimStimPost-stim
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(6)
20.0 20.0(2) 98.0 280.0(2) 60.0 42.0( ) 29.0
(1)




































219.0± 06. 73.6±16 0 36.0 66.3±4 0
(5) (1) (3)




The application of the stimulus to the ME, POA, SCN and DH
produced a slight increase in CCK release into pituitary stalk blood.
These increments in CCK concentration and content over 30 min were
not., however, significantly different from the values found in
pituitary stalk plasma during the pre-stimulation period in each group.
Similarly, a reduction of CCK concentration and content in pituitary
stalk blood on electrical stimulation of the PVN was not statistically
significant. Less marked reductions of CCK concentration in pituitary
stalk plasma, thought not statistically significant, were also seen on
stimulation of the AMY and VH. However, in the unstimulated control
group (C) there was also a reduction (although not significant) in the
content and concentration of CCK pituitary stalk blood over the three
successive 30 min collection periods. This suggests that a time-related
decline of CCK release into pituitary stalk blood occurs after the
pituitary stalk has been cut. The amount of CCK released into pituitary
stalk blood over a 30 min period (content, -fmol/30 min) for each group
is represented in Figure 6.2d. These values reflect the changes in
CCK concentration (pmol/1) in pituitary stalk blood seen in these
groups.
The volume of pituitary stalk blood collected together with CCK
concentration and content/30 min are shown in Table 6.2d. The volume
of blood was increased by 200-300 pi in all groups in which an electrical
stimulus was applied to the brain. In the unstimulated group, by
comparison, a fall of a similar volume occurred in the second 30 min
period of pituitary stalk blood collection.
FIGURE 6.2d: CCK content (-fmoI/30 min) of pituitary stalk plasma
samples collected for 30 min periods before, during
and after electrical stimulation of various brain
areas (see Figure 6.2b for abbreviations used).
a = pre-stimulation period
b = stimulation period (indicated by bar)





























































































































































































































Gastrin: Gastrin concentrations were measured in the same
plasma samples as those used to measure CCK from groups of rats in
which the electrical stimulus was applied to the ME, POA or SCN.
The data obtained from this experiment are shown in histogram form
(Figure 6.2e) while additional details, such as the number of rats
per group, are given in Table G.2e.
Though the concentration of gastrin in pituitary stalk blood
collected during the pre-stimulation period was found to be higher
than in peripheral plasma, this difference was not statistically signifi¬
cant .
Electrical stimulation of the ME, POA or SCN had no appreciable
effect on the concentration or content/30 min of gastrin in pituitary
stalk blood, while the increase in peripheral plasma concentration was
also not statistically significant.
The mean ± SEM volume of pituitary stalk blood collected and
the concentration and content (30 -fmol/min) of gastrin in these
samples is shown in Table 6.2f. Changes in gastrin content (-fmol/30
min) are shown graphically in Figure 6.2f. There were no significant
differences in pituitary stalk blood volumes or increments in these
volumes in each group.
6. 2. 3 Discussion and Conclusions
The first criteria for defining a substance as a releasing factor
in the hypothalamo-hypophysial axis is that its concentration in portal
vessel blood should be greater than in the peripheral circulation
(Harris, 1972). The second requirement is that the substance should
be extractable from the hypothalamus, stalk and median eminence.












FIGURE 6. 2e: Gastrin concentration (pmol/l) in peripheral and
pituitary stalk plasma.
b = pre-stimulation period
c = stimulation period (indicated by bar)
d = post-stimulation period
Pituitary stalk blood was collected for 30 min periods
(see Figure fi.2b for abbreviations used).



















































































































FIGURE 6. 2f: Gastrin content (-fmol/30 min) of pituitary stalk
plasma samples collected for 30 min periods before,
during and after electrical stimulation of various
brain areas (see Figure 6.2b for abbreviations used)
a = pre-stimulation period
b = stimulation period (indicated by bar)
c = post-stimulation period
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these values were indeed significantly (p <0.05) greater than peripheral
blood (Tables 6.2b and 6.2c), 'control' group. Although gastrin
concentration in pituitary stalk blood was also greater than peripheral
blood, the difference was not statistically significant. The presence
of immunoreactive CCK-8 in the hypothalamus, stalk and median eminence
has been confirmed by several studies, mentioned in the Introduction
to this Chapter. The concentration of CCK in the hypothalamus is
approximately 250 pmol/g which is only about 50 pmol/g more than found
in the jejunum and about half as much as in the cerebral cortex
(Dockray, 1982). It has been shown that the predominant form of
CCK in the brain is CCK-8 (Muller et al., 1977; Dockray et a!., 1978;
Rehfeld et al., 1980; Ryden et al., 1981). The presence of CCK-8
in pituitary stalk blood suggests that this is also the major form
released. These data receive support from the fact that CCK-8 was
released from synaptosome fractions isolated from the hypothalamus,
cortex, striatum and thalamus in response to depolarisation (Dodd
et al. , 1980; Sheppard et al., 1980). The sulfated form of CCK-8 is
more active than the non-sulfated fragments (Fekete et al., 1980;
Saito et al., 1981). Immunoreactive gastrins have been found in
pituitary extracts only (Rehfeld, 1978) and include a large component
as well as G-34 and G-17. The immunoreactive forms of CCK or gastrin
in pituitary stalk blood were not determined. There is no published
evidence demonstrating the release of gastrin from nerve endings.
Therefore, CCK, but not gastrin, appears to fulfil the first two criteria
to establish them as releasing factors.
Further investigations to demonstrate that these peptides could
have physiological roles as neurotransmitters or neuromodulators in
the hypothalamic-pituitary system, along the lines used to establish
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LHRH as a releasing factor (Fink and Jamieson, 1976; Eskay, Mical
and Porter, 1977) produced some interesting and unexpected results.
Electrical stimulation of several brain areas shown to contain immuno-
reactive CCK cell bodies and nerve fibres was coupled with measure¬
ments of the peptide in portal vessel blood, to provide direct evidence
for a relationship between increased activity of these neurones and
release of CCK. Since blood flow in portal vessels increases with
stimulation (Fink and'Jamieson, 1976) and pituitary stalk blood col¬
lections are likely to be contaminated with blood from sources other
than portal (Fink and Harris, 1970), the concentration provides an
unreliable estimate of the amount of the substance released. Data from
studies on the effects of electrical stimulation are therefore also
evaluated on the basis of increments in content.
The stimulus parameters were the same as those found to be
optimal for the release of LH (Jamieson and Fink, 1976) and similar to
that found to be optimal for oxytocin release in the rabbit (Harris,
Manabe and Ruf, 1969) and suckling induced release of oxytocin,
which is produced by a burst of about 50 Hz in the supraoptic hypo¬
physial system (Wakerly and Lincoln, 1973). Due to constraints on
time and expense, an extensive study to determine the optimum
parameters for CCK release was not undertaken. However, a marked
increase in depth of respiration with a fall in respiratory rate (Fink
and Jamieson, 1976) was observed on stimulation of POA, SCN, PVN
and ME, suggesting these brain areas were stimulated on application
of the stimulus.
The absence of a statistically significant difference in the con¬
centration of CCK and gastrin in pituitary stalk blood on electrical
stimulation of any of the selected brain areas, suggests that these
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peptides are not physiologically released into the hypophysial portal
vessel circulation. The data suggest that electrical stimulation of the
ME, SCN, POA and DH merely slowed down the drop in CCK levels
that are found after cutting the pituitary stalk. The concentration of
CCK in peripheral plasma in the unstimulated 'control' group was
significantly (p <0.05) greater than in any of the other groups. A
wide range of CCK concentrations was found in the stimulated groups.
This variability could be attributed to a phasic release of CCK as well
as a post-operative alteration in the release of CCK.
Interpretation of the differences in CCK and gastrin levels in
pituitary stalk blood on stimulation of several areas of the brain is
made difficult by the fact that intrinsic connections of these peptide-
containing cell bodies and fibres are still not clear. The fact that
electrical stimulation of the POA, SCN and ME did not alter gastrin
values was not surprising in view of the lack of immunohistochemical
evidence for the presence of gastrin in these areas. However, the
absence of a significant increase in CCK release into pituitary stalk
blood on stimulation of the ME, despite evidence for the presence of
CCK-immunoreactive fibres in the external layer of the ME (Hokfelt
ef al., 1978; Lorenefo/., 1979; Vanderhaeghen etal., 1980), was
unexpected and is difficult to explain. It has been demonstrated that
a large proportion of CCK fibres from the PVN and a smaller proportion
from the SCN project to the external layer of the median eminence
(Larsson and Rehfeld, 1977; Loren ef al., 1979; Beinfeld ef a!.,
1980). The absence of an increase in CCK release into pituitary stalk
blood on stimulation of the ME, PVN and SCN could be due to the fact
that there are no CCK nerve terminals originating from the PVN or
SCN that terminate on hypophysial portal vessels. There is evidence
138.
that CCK is released from nerve terminals (Pinget et aI., 1978;
Sheppard et al., 1980) by a calcium-dependent depolarisation (Rehfeld
et al., 1979; Dodd et al., 1980). Therefore, despite the fact that in
order to collect pituitary stalk blood the pituitary stalk was cut, it is
unlikely to have been an appreciable release of CCK into the blood
samples collected from the severed fibres to the posterior pituitary.
Electrical stimulation of the POA, which has been demonstrated to
contain CCK immunoreactivity (Loren et al., 1979; Vanderhaeghen
et al., 1980), also did not alter the release of CCK into pituitary stalk
blood. The recent finding that the CCK content of the hippocampus
was unchanged by knife cuts which disrupted its afferent and efferent
connections (Handelmann et al., 1981) suggests that CCK immuno¬
reactivity is intrinsic to this area. The fact that electrical stimulation
of either the DH or the VH did not alter the CCK concentration in
pituitary stalk blood shows that there is no direct projection of CCK
neurones in the hippocampus to the ME.
These experiments do not rule out the possibility that electrical
stimulation of one of these areas could influence stimulation-induced
release from a different area. For example, hippocampal stimulation
reduced LHRH output induced by stimulation of the POA (Chiappa,
Fink and Sherwood, 1977). In addition, the CCK immunoreactive fibres
and cell bodies in the amygdala (Innes et at., 1979; Loren et al., 1979;
Vanderhaeghen et a!., 1980) probably project to areas other than the
hypophysial portal vessels. Knife cuts that separated amygdala from
the caudate reduced the CCK content in the caudate by 30% (Meyer
et al. , 1981), indicating that the caudate was one of the areas to which
CCK fibres from the amygdala project.
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In conclusion, although these data show that CCK-8 concentra¬
tion in pituitary stalk blood is significantly (p <0.05) greater than in
peripheral blood, the role of CCK-8 as a physiological releasing factor
is doubtful. Electrical stimulation of several brain areas that have
been demonstrated to contain CCK-immunoreactivity did not alter the
release of CCK-8 into pituitary stalk blood. The gastrin concentration
of pituitary stalk blood is not significantly higher than peripheral
blood. Electrical stimulation of the PVN, SCN and ME did not alter
these levels of gastrin. It is possible that the optimal parameters for
the release of CCK and gastrin were not used.
6.3 Changes in Plasma CCK and Gastrin with Gastric Antrectomy
6. 3. 7 Introduction
The series of experiments described in this section were carried
out after those described in Section 6.2. Since circulating gastrin
originates almost exclusively from the antrum and duodenum (Malstrom,
Stadil and Rehfeld, 1976; Dockray, 1979), whereas the brain i
is the main source of CCK in the mammalian system (Dockray, 1976;
Rehfeld, 1978), and since serum gastrin concentrations are reduced
more than 10-fold by duoantrectomy (Rehfeld, Stadil, Baden and
Fischerman, 1975), changes in values of peripheral and portal vessel
blood CCK and gastrin after duoantrectomy were studied. The fact
that CCK shares the biologically active COOH-terminal amino acids
with gastrin (Figure 6.1) and that the radioimmunoassay used to measure
CCK and gastrin values involves using antibodies with differing speci¬
ficities for these two peptides (Figure 6.1), suggests that experimental
reduction of gastrin would lower the total effective cross reaction in
the assay.
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6. 3. 2 Methods
(a) Animals and treatments:
Male rats (180-200 g) of the Albino Wistar COB strain were
used in all experiments. Urethane (1 mg/kg i.p.) or Althesin (1ml/
100 g) were used to induce anaesthesia. Pituitary stalk blood was
collected as described in Section 2.2.5 during three consecutive 30 min
periods before, during and after the application of an electrical stimulus
to the ME (as in Section 6.2.1). Peripheral blood samples were col¬
lected from the external jugular vein. All blood samples were collected
on ice into tubes containing EDTA 5.4 (mM/1) and Trasylol (5 KIU/1).
The plasma was frozen until assayed for CCK and gastrin by radio¬
immunoassay (Section 2.3). The lower limit of the CCK assay was 20
pmol/1 and for gastrin it was 5 pmol/1.
Gastric antrectomy and vagotomy were carried out as described
in Section 2.2.4, approximately 1 h before samples of peripheral and
portal blood were collected. To determine the time course of the
clearance of CCK and gastrin from peripheral plasma after antrectomy,
external jugular venous samples (0.4-0.5 ml) were collected at frequent
intervals before and from 5 min up to 90 min after the removal of the
antrum.
(b) Calculations:
The concentrations of CCK and gastrin in the plasma were
determined by radioimmunoassay (Section 2.3). The content (concentra¬
tion x volume per unit time) of CCK was calculated for pituitary stalk
blood. The significance of the differences between means was assessed
by the paired and unpaired students' t-test.
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6. 3. 3 Results
(a) Changes in circulating CCK and gastrin concentrations after
gastric antrectomy:
Figure 6.3a shows that within the first 5 min there was a 48%
reduction in the plasma concentration of gastrin and a 51% reduction
in the plasma concentration of CCK; after 5 min, CCK values remained
undetectable (<20 pmol/1). Since blood samples were not collected
during the fast phase- (0-5 min) of the clearance of the peptides, the
half-life cannot be accurately calculated. The concentration of both
CCK and gastrin before antrectomy was 46% and 40% lower, respectively,
under Althesin compared with urethane anaesthesia (Figure 6.3a).
Urethane anaesthesia was therefore used in all other experiments
described in this Chapter.
(b) CCK and gastrin release into pituitary stalk blood after gastric
antrectomy and electrical stimulation of the median eminence:
Table 6.3a shows the gastrin and CCK concentration of peripheral
and pituitary stalk blood sampled for 30 min periods, beginning 1 h
after gastric antrectomy. Removal of the antrum significantly (p <0.05)
reduced circulating gastrin levels by half during the pre-stimulation
period. Pituitary stalk blood gastrin concentrations were lowered even
more dramatically (p <0.05); gastrin content of pituitary stalk blood
was also significantly (p <0.05) lower after removal of the antrum.
This suggests that the gastric antrum is a major source of gastrin
measured in both peripheral and pituitary stalk blood.
The effect of antrectomy on circulating CCK concentration was
almost as great as for gastrin. The concentrations of CCK in samples
of peripheral blood samples taken before ME stimulation were reduced
significantly (p <0.05). The reduction in CCK content of pituitary
FIGURE 6.3a: CCK and gastrin concentration in the peripheral
circulation before and up to 90 min after the removal
of the gastrin antrum. Blood samples were collected from
the external jugular vein under Urethane or Althesin
anaesthesia. Groups of 5 rats each were used. The
lower limit of the assays were 20 pmol/1 for CCK and
5 pmol/1 for gastrin.
TABLE6.3a:
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stalk blood was less marked, but CCK content of stalk blood was
significantly (p <0.05) lower after antrectomy.
Electrical stimulation of the ME did not significantly alter the
release of gastrin into pituitary stalk plasma or peripheral plasma
either in the intact group or 90-120 min after the removal of the antrum.
Similar results were obtained for CCK concentrations, though there was
a significant (p <0.05) increase with ME stimulation in pituitary stalk
plasma content over the 30 min period in the intact group (Table 6.3a).
After removal of the antrum, this difference was not found. However,
a significant (p <0.05) reduction in pituitary stalk plasma CCK content/
30 min was found after antrectomy.
(c) Changes in CCK release following vagotomy compared to gastric
antrectomy
In order to rule out the possibility that removal of vagal release
of CCK (Dockray, 1981) or the trauma of surgery on removal of the
gastric antrum accounted for the reduced values of CCK found after
antrectomy, the concentration and content of CCK was determined
after cutting the vagii by cutting the oesophagus (Method; Section
2.2.4).
Table 6.3b shows that cutting the vagii had no significant effect
on the CCK concentration in pituitary stalk blood compared with the
values in control animals. Antrectomy, on the other hand, significantly
(p <0.025) reduced CCK concentration in the peripheral circulation,
as found in the experiments described in Section 6.3.3b. Pituitary
stalk plasma concentration was reduced by 65% and the CCK content
of pituitary stalk blood collected over 30 min was reduced by 76% after
gastric antrectomy.
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TABLE 6.3b: The effect of antrectomy or cutting the oesophagus on
CCK concentration (pmol/1) and content (f mol/30 min)
in peripheral and pituitary stalk plasma compared to
intact controls. Values are given as mean ± SEM;
* and ** p <0.05 when plasma CCK concentration after




Peripheral plasma - 6
Pituitary stalk plasma 6
Oesophagus cut
Peripheral 9
Pituitary stalk plasma 7
Antrectomy
Peripheral 8




**134.70 ±24.0 76.70 ±21.0
78.30 ±14.0
125.50 ± 23.0 82.54 ±28.0
* 34.10 ±7.0
** 46.30 ±9.0 20.04 ±4.0
6. 3. 4 Discussion and Conclusions
These results provide strong evidence that a large proportion of
the CCK and gastrin in pituitary stalk blood originates from the gastric
antrum. The first series of experiments (Section 6.3.3a) demonstrated
that removal of the antrum reduced the peripheral plasma concentration
of both gastrin and CCK by approximately 50%. An equivalent reduction
of both CCK and gastrin was unexpected in view of the fact that the
gastric antrum is known to be the major source of gastrin (Malstrom
et al., 1976), while the chief source of peripheral CCK is the intestines
(Jorpes and Mutt, 1973; Larsson and Rehfeld, 1979) which were left
untouched in this experiment.
That a statistically significant (p <0.05) decrease in CCK and
gastrin released into pituitary stalk blood also occurred after gastric
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antrectomy was demonstrated by the second series of experiments
(Section 6.3.3b). Electrical stimulation of the ME did not significantly
alter the release of CCK or gastrin either in the intact group or after
removal of the antrum. This suggests that even after removal of the
peripheral source of CCK and gastrin, an electrical stimulus applied to
the brain does not increase the release of the peptides into hypophysial
portal vessel circulation; the lack of a significant effect of ME stimula¬
tion on the release of these peptides cannot be due to a masking of
the effect due to peripheral release of CCK and gastrin.
The results of the third series of experiments (Section 6.3.3c)
confirmed that gastric antrectomy consistently lowered the peripheral
plasma CCK concentration and content/30 min of pituitary stalk plasma
by 65-75%. In addition, these experiments showed that removal of the
antrum rather than the trauma of surgery or sectioning of the vagii,
which have been demonstrated to release CCK (Lundberg et al., 1978;
Dockray et a!., 1981), could account for the decrease in CCK concentra¬
tion in peripheral and pituitary stalk plasma.
The demonstration that CCK concentration in plasma are reduced
after gastric antrectomy suggests that either the antibodies used in
the radioimmunoassays used to measure the concentrations of these
peptides did not differentiate between the two structurally similar
peptides, gastrin and CCK, or that the gastric antrum does in fact
release a large amount of CCK. These experiments underline the
difficulties that arise in interpreting data from investigations of a
complex association between central and peripheral peptide pools.
However, the measurement of CCK and gastrin concentrations after
antrectomy provide evidence that suggests that CCK and gastrin
measured in pituitary stalk plasma originate largely from the periphery.
CHAPTER VII
Vasoactive Intestinal Polypeptide (VIP) in Rat
Pituitary Stalk Blood: Investigations into the Effects
of Electrical Stimulation of Various Brain Areas and
Possible Changes During the Rat Oestrous Cycle
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7.1 Vasoactive Intestinal Polypeptide (VIP) in Rat Pituitary Stalk
Blood: Effects of Electrical Stimulation of Brain Areas Containing
Immunoreactive VIP
7. 7. 7 Introduction
Vasoactive intestinal polypeptide (VIP) is a 28-amino acid residue
polypeptide, first isolated from porcine duodenum (Said and Mutt, 1970).
It. has powerful hypotensive and vasodilatory effects and has been found
in large quantities throughout the mammalian digestive system, from
the oesophagus to the rectum (Polak, Pearse, Garaud and Bloom, 1974;
Larsson, Fahrenkrug, Schaffalitsky de Muckadell, Syndler, Hakanson
and Rehfeld, 1976; Besson, Laburthe, Bataille, Dupont and Rosselin,
1978; Hutchison, Dimaline and Dockray, 1981). In the rat, the highest
concentration of VIP in the gut occurs between the duodenum ( 1676 ±
186 ng/g of tissue) and the colon (1214 ± 214 ng/g of tissue) with
smaller amounts (180 ± 26 ng/g of tissue) in the pancreas (Besson
et al. , 1978). Immunohistochemical studies show that VIP immuno-
reactivity is present in gastrointestinal nerves and formsa major part of
the nervous system intrinsic to the gut wall (Larsson et al., 1976).
In addition, vagal nerve stimulation induces VIP release in vivo
(Fahrenkrug, Galbo, Hoist, Schaffalitzky de Muckadell, 1978) and
in vitro from the isolated perfused stomach (Pederson, O'Dorisio, Howe,
Mclntoch. Mueller, Brown and Cataland, 1981).
Immunoreactive VIP has also been demonstrated in neurones of the
peripheral and central nervous system by immunohistochemical and radio¬
immunoassay techniques (Larsson et al. , 1976; Besson, Rotsztejn,
Laburthe, Epelbaum, Beaudet, Kordon and Rosselin, 1979a; Loren,
Emson, Fahrenkrug, Bjorklund, Alumets, Hakanson and Sundler, 1979b;
Roberts, Woodhams. Bryant, Crow, Bloom and Polak, 1980; Sims,
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Donald, Hoffman, Said and Zimmerman, 1980; Hokfelt, Schultzberg,
Lundberg, Fuxe, Mutt, Fahrenkrug and Said, 1982; Fahrenkrug
and Emson, 1982). Based on light microscopic immunohistochemical
studies, the distribution of VIP in the rat and mouse brain can be
divided into four major systems (Sims et ah, 1980). These include:
1. An intracerebral cortical system (Fuxe, Hokfelt, Said and Mutt,
1977; Besson et al., 1979a; Sims et ah, 1980). VIP immunoreactivity
has been demonstrated in all regions of the cortex including the
limbic cortex and subiculum (Kohler, 1982). The highest concentra¬
tion of VIP in the brain is found in the occipital cortex (Besson
et ah , 1979a).
2. An area of extremely dense fibres and terminals between the stria
terminalis and its bed nucleus (Loren, 1979b; Roberts et ah, 1980;
Sims et ah, 1980). These fibres also appear to form a VlP-con-
taining pathway which links the amygdaloid complex with the hypo¬
thalamus (Roberts et ah, 1980; Sims et ah, 1980; Palkovits,
Besson and Rotsztejn, 1981).
3. A system originating in the midbrain central grey (Larsson et ah,
1976; Fuxe et ah , 1977; Loren et ah , 1979b; Sims et ah , 1980;
Marley, Emson, Hunt and Fahrenkrug, 1981).
4. A hypothalamic system with cell bodies localised primarily within
the basal portion of the suprachiasmatic nucleus, medial preoptic
area and anterior hypothalamus, with only a few VIP-containing
fibres in the median eminence (Larsson et al. , 1976; Fuxe et al.,
1977; Loren et ah, 1979b; Samson. Said and McCann, 1979;
Roberts et al. , 1980; Sims et ah , 1980; Card, Brecha, Karten
and Moore, 1981; Rostene, Leranth, Maletti, Mezey, Besson, Eiden,
Rosselin and Palkovits, 1982).
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So far, no group has detected VIP in the cerebellum (Besson
et al. , 1978; Loren et al., 1979; Sims eta/., 1980). VIP has been
detected in the pars nervosa of the dog but not several other mammalian
species, by Van Noorden, Polak, Bloom and Bryant (1979) and in the
rat by Samson et at. ( 1979). However, radioimmunological investiga¬
tions by Besson et at. ( 1978) and immunohistochemical studies by Loren
et at. (1979) have been unable to demonstrate VIP in the pars nervosa
of the rat.
The selective distribution of VIP in the brain, its presence in
nerve terminals and its calcium-dependant release from synaptosomes
from the cerebral cortex and hypothalamus (Giachetti, Said, Reynolds
and Koniges, 1977; Emson, Fahrenkrug, Schaffalitsky de Muckadell,
Jessel and Iversen, 1978) and rat brain cortex and amygdala slices
(Besson, Rotsztejn, Poussin, Lhiaubet and Rosselin, 1982), as well as
a specific enzyme system which degrades this peptide in the brain
(Keltz, Straus and Yalow, 1980), all suggest a role for VIP as a neuro¬
transmitter or neuromodulator in the brain. Furthermore, VIP has a
potent excitatory effect on neurones of the hippocampus, cerebral
cortex, preoptic area, septum and midbrain central grey neurons
(Phillis, Kilpatrick and Said, 1978; Dodd, Kelly and Said, 1979;
Haskins, Samson and Moss, 1982) and binds to specific VIP receptors
found only in VIP-rich areas of the brain (Deschodt-Lanckman,
Robberecht and Christophe, 1977; Taylor and Pert, 1979; Staun-
Olsen, Ottsen, Bartels, Nielsen, Gammeltoft and Fahrenkrug, 1982).
In addition, the presence of immunoreactive VIP in the limbic system,
in several hypothalamic nuclei and their linking pathways, as well as
high concentrations of VIP in hypophysial portal vessel blood (Said
and Porter, 1979; Shimatsu, Kato, Matsushita, Katakami, Yanaihara
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and Imura, 1981) suggest that VIP may play a role in neuroendocrine
regulation.
Purpose of the present study:
The main aims of the experiments described in this section were
to determine:
1. whether the release of VIP into pituitary stalk blood
is modulated by electrical stimulation of various areas
of the brain known to contain immunoreactive VIP;
2. the effect of complete removal of the gut on the con¬
centration of VIP in pituitary stalk blood to assess
the contribution of VIP in the peripheral system to
the stalk blood concentrations.
7.1.2 Materials and Methods
(a) Animals:
Adult male VVistar COB rats weighing 180-200 g were used in the
experiments described in this section. Urethane (1 mg/kg b.w.) was
administered intraperitoneally to induce anaesthesia. In the first
series of experiments, pituitary stalk blood was collected (method
described in Section 2.2.5) over consecutive 30 min periods before,
during and after the application of the electrical stimulus to the brain.
Peripheral blood samples from the external jugular vein were obtained
before the pituitary stalk was cut and at the end of each 30 min period
of pituitary stalk blood collection. In the second series of experiments
the peripheral blood samples were obtained from the external jugular
vein before and at 30 min intervals after the removal of the gut.
Pituitary stalk samples were collected for a 30 min period which
began 30 min after the gut was removed. The blood samples were
collected into tubes kept on ice; the tubes contained Trasylol (5000
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KlU/ml). The plasma was kept frozen at -40°C until packed in dry
ice and sent by airfreight to Paris to be assayed for VIP. The samples
remained frozen at all times.
(b) Implantation of electrodes and stimulation parameters:
The methods used to prepare and implant the bipolar glass-
insulated platinum electrodes are described in Section 2.2.7. Implanta¬
tion of the electrodes was carried out under Avertin anaesthesia, 4-5
days before collection of pituitary stalk blood samples. All the rats
appeared healthy at the time of stalk blood collection. Electrodes
were implanted in the amygdala (AMY), the suprachiasmatic nucleus
(SCN), preoptic area (POA), paraventricular nucleus (PVN), ventral
hippocampus (VH) and dorsal hippocampus (DH). The co-ordinates
used were based on de Groot's atlas (1959) and are given in Table 6.2a.
The median eminence (ME) was stimulated by way of a unipolar glass-
insulated platinum electrode which had been placed on the surface of
the ME with the aid of a micro-manipulator, after exposure of the portal
vessels and removal of brain membranes, just before heparin was
injected and the pituitary stalk cut. In all cases, the stimulus was
applied for 30 min and consisted of biphasic square wave pulses in
trains of 30 sec on and 30 sec off. frequency of 60Hz, amplitude of
500 mA (1mA peak-to-peak) and pulse duration of 1 msec. The
parameters of the electrical stimulus used were those shown to produce
the optimum release of LH (Fink and Aiyer, 1974; Jamieson and Fink,
1976). The electrodes were left in place until the end of the experiment
when rats were decapitated. The head was trimmed and fixed in
buffered formalin. After decalcification of the skull the electrodes
were carefully removed. The brain was frozen, serial sections were
cut, stained with cresyl fast violet and placement of the electrodes
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determined (Section 2.2.7). Brain sections indicating the positions
of the electrode are shown in Figure 6.2b.
(c) Radioimmunoassay and calculations:
VIP immunoreactivity in the plasma samples was measured by a
specific radioimmunoassay, as described in Section 2.3, according to
the method of Maletti, Rostene, Carr, Scherrer, Rotten, Kordon and
Rosselin ( 1982). The specificity of the VIP antibody was directed to
a fragment of the carboxyl-terminal and the medium part of the molecule,
as indicated by the cross-reaction of the antibody with the synthetic
fragments 10-28 of VIP (Maletti et at., 1982).
The concentration of VIP in the plasma samples was expressed
in pg/ml. In addition, the content (concentration x volume per 30 min)
was calculated for the pituitary stalk blood samples. The significance
of differences between means was determined by the paired or unpaired
t-test as appropriate. The differences between more than two means
was determined by analysis of variance and Duncan's multiple range
test for heteroscadistic means (Duncan, 1957; Harter, 1960).
7. 7. 3 Results
(a) Characteristics of VIP in pituitary stalk blood:
The mean (± SEM) concentration of VIP in pituitary stalk plasma
was significantly (p <0.001) greater than the concentration in peripheral
plasma (Table 7.1a) before stimulation of any brain areas. The VIP
content in pituitary stalk plasma in the 30 min collection period was
423 ± 68 pg/30 min.
Degradation of VIP during the collection period was found to be
effectively minimised by the addition of the peptidase inhibitor, Trasylol
(5000 Kill/ml whole blood) at the time of collection of the samples
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TABLE 7.1a: VIP peripheral and pituitary stalk plasma from adult
male rats showing the effect of Trasylol addition (5000
KlU/ml) to whole blood. Values given are mean + SEM
(n). *p <0.001 when peripheral and pituitary stalk
plasma VIP concentration was compared.
Peripheral plasma Pituitary stalk plasma
With Trasylol:
Concentration (pg/ml) 452.9 + 124.6 (8)* 1281.0 + 157.6 (7)*
Content (pg/30 min) 422.4 + 68.6 (7)
Without Trasylol:
Concentration (pg/ml) 321.4 + 48.8 (6) 552.8 ± 119.7 (6)
Content (pg/30 min) 328.8 + 66.5 (5)
(Table 7.1a). The VIP concentration in pituitary stalk plasma without
Trasylol was approximately 60% of the concentration in samples to which
Trasylol had been added. Peripheral plasma VIP concentrations were
not significantly decreased in the samples without Trasylol.
(b) Effect of electrical stimulation on VIP concentrations in peripheral
plasma and pituitary stalk plasma:
VIP concentrations in peripheral and pituitary stalk plasma before,
during and after the application of an electrical stimulus to various
areas of the brain are shown in Table 7.1b and represented in histogram
form in Figure 7.1a. Peripheral 'control' values represent VIP concentra¬
tions in the peripheral circulation before the pituitary stalk was cut in
order to collect pituitary stalk blood.
(i) Peripheral plasma VIP concentration
The VIP concentration in peripheral plasma varied considerably
between groups. In the group of rats with electrodes in the POA, the













































































































































peripheral plasma VIP concentration was 3 times greater (p <0.05)
than in the group of rats in which was not implanted or stimulated
(the 'control' group). All the other groups had peripheral plasma
VIP concentrations similar or lower than the unstimulated 'control'
group. Cutting the pituitary stalk slightly lowered the peripheral
plasma VIP concentration in all groups. Electrical stimulation produced
no statistically significant changes in the peripheral plasma VIP con¬
centration of any of the groups compared to the concentration in the
unstimulated 'control' group.
(ii) Pituitary stalk plasma VIP concentrations
The VIP concentrations in pituitary stalk plasma within the
different groups also showed considerable variability (pre-stimulation
values, Table 7.1c). Electrical stimulation of seven areas of the brain
did not produce any statistically significant changes in the VIP con¬
centration of the pituitary stalk plasma (Figure 7.1a).
The amount of VIP released into pituitary stalk plasma over the
30 min before stimulation, 'content' in Table 7.1c, showed a similarly
large intra-group variation as found for VIP concentration. Stimula¬
tion of the different areas of the brain produced no statistically signifi¬
cant changes in pituitary stalk plasma VIP content (Figure 7.1b).
The volumes of pituitary stalk blood collected over each 30 min
period are shown in Table 7.1c. An increase in blood flow was found to
occur in all groups on application of the electrical stimulus. The relative
increments in blood volume varied according to the area stimulated.
However, there were no significant differences between groups after
stimulation in terms of the blood volumes or increments in blood volumes.



























































































































































































FIGURE 7.1b: VIP content (pg/30 min) of pituitary stalk plasma
samples collected for 30 min periods before, during
and after electrical stimulation of various brain
areas (see Figure 7.1a for abbreviations used).
a = pre-stimulation period;

































(c) VIP concentration in pituitary stalk blood after removal of the gut:
Table 7. Id shows that removal of the gut from the lower end of
the oesophagus up to and including the rectum, significantly (p <0.01)
decreased the concentration of VIP in peripheral plasma compared to
intact controls. Within 30 min the VIP concentration in peripheral
plasma fell significantly (p <0.01) and continued to fall over the next
60 min. There was no significant difference in the peripheral VIP
concentration of the intact controls compared to the experimental group,
before the gut was removed.
The concentration (pg/ml) and content (pg/30 min) of VIP in
pituitary stalk blood was not significantly altered by removal of the gut
(Table 7. Id).
7. 7. 4 Discussion and Conclusions
The significantly (p <0.05) higher concentration of VIP in pituitary
stalk blood compared to the peripheral circulation suggests a preferential
release of VIP of central origin occurs into the hypophysial portal
vessel circulation. This conclusion received support from the fact
that the VIP concentration in the pituitary stalk concentration was not
significantly altered by removal of the gut, which is the main source of
VIP in the peripheral circulation (Polak et al., 1974; Larssen et al.,
1976; Bessonefo/., 1978; Hutchison et al., 1981; Table 7.Id).
This allows for a possible involvement of VIP in the control of anterior
pituitary function. Electrical stimulation of several regions that have
been demonstrated to contain VIP-immunoreactivity produced no
significant change in the VIP concentration of pituitary stalk blood
(Figure 7. la).








Intactcontrols: Concentration(pg/ml) Content(pg/30mi )
5
15.4+3.0*9 1±4.02 92.4*139 87.41 5 74.6±11 568 2+7.
Cutremoved: Concentration(pg/ml) Content(pg/30mi )
911.8±.27 60.7*11.7.5.3*25 58.87 118 7
38.9±6.722 87 1
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Electrical stimulation of the central nucleus of AMY did not change
VIP concentrations in peripheral or pituitary stalk plasma (Figure 7.1a).
There is immunohistochemical evidence that VIP immunoreactive fibres
in the stria terminalis and its bed nucleus form a major pathway linking
the AMY and the hypothalamus (Fuxe et al., 1977; Roberts et al.,
1980; Sims et al. , 1980) and unilateral transection of the stria terminalis
produced a significant fall in VIP content of the SCN and AMY (Palkovits
et al., 1981). There is, however, no published evidence that VIP
fibres from the AMY project to the portal vessels.
VIP-containing cell bodies in the hippocampal complex are located
mainly around the subicular complex (Loren et al., 1969; Roberts
et at., 1981; Kohler, 1982). Electrical stimulation of either the DH
or the VH produced no change in the VIP concentration of pituitary
stalk plasma (Figure 7.1a). This suggests that VIP fibres from the
hippocampal complex do not project to the portal vessels. Indeed,
immunohistochemical studies showed that while VIP-containing fibres
were distributed throughout the complex, their processes could not be
traced for any great distances and appeared to be intrinsic to the hippo¬
campus (Loren eta!., 1980; Roberts et al. , 1980; Kohler, 1982).
Electrical stimulations of the PVN, POA, ME or SCN produced no
significant change in the VIP concentration of pituitary stalk plasma
(Figure 7.1a). The SCN has been demonstrated to contain a dense
population of VIP cell bodies and a rich supply of VIP-containing fibres
(Loren eta!., 1979; Sims et al., 1980; Card et al., 1981). A
moderately dense VIP fibre system has been found in the ventral border
of the PVN and in the POA (Sims et al. , 1980; Card et al., 1981).
While there is immunohistochemical evidence for the presence of a few
scattered VIP fibres in the ME (Roberts et al., 1980: Sims et al. ,
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1980; Hokfelt et al. , 1982), the fact that electrical stimulation of
the SCN, PVN, POA or ME did not alter VIP release into stalk plasma
suggests that there is no significant VIP-innervation of the portal
vessels originating from these areas. From experiments involving
anterolateral deafferentation of the medial basal hypothalamus (Besson
et a!., 1979a), transection of the periventicular VIP fibres from the
SCN (Rostene et at., 1982) and bilateral lesions of the SCN (Rotsztejn,
personal communication), it has been proposed by Rotsztejn and his
colleagues (Rostene et a!., 1982) that VIP fibres in the ME originate
either from the medial basal hypothalamus (arcuate or ventromedial
nucleii) or from caudal projections.
The regional overlap of VIP distribution with a number of peptides
suggests that VIP may have a neuromodulatory role in the brain (Sims
et al., 1980; Card et a!., 1981). Iontophoretic application of VIP
has been reported to alter the electrical activity of POA neurones
whose axons project to the ME (Haskins et al., 1982). VIP was found
to be excitatory when applied to cell bodies of the rat hippocampus of
the CA1 region (Dodd et al. , 1979). Although intraventicular injections
of VIP have been reported to stimulate the release of LH in ovariectomised,
conscious rats (Vijayan, Samson, Said and McCann, 1979b), VIP had no
effect on LH release from monolayer cultures of gonadotrophs (Denef,
Hautekeete and Dewals, 1978) or from enriched preparations of pituitary
cells (Rotsztejn et at., 1980a). The incubation of VIP with ME synapto-
somes has been reported to stimulate the release of LHRH (Samson,
Burton, Reeves and McCann, 1981). VIP was, however, ineffective in
stimulating the release of LHRH from incubated esson,
Rotsztejn and Ruberg, 1979b; Vijayan et at., 1979b; Samson, Snyder,
Said and McCann, 1980; Drouva, Epelbaum, Tapia-Arancibia, Laplante
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and Kordon, 1981), in contrast to its ability to inhibit the release of
another hypothalamic peptide, Somatostatin (Epelbaum, Tapia-Arancibia,
Besson, Rotsztejn and Kordon, 1979). While these data support a role
for VIP in the hypothalamus as a neuromodulator and suggest an
indirect involvement of VIP in the regulation of some adenohypophysial
hormones, the ability of VIP to act directly at the pituitary level to
stimulate the release of PRL (Ruberg, Rotsztejn, Arancibia, Besson
and Enjalbert, 1978; Shaar, Clemens and Dininger, 1979; Gourdji,
Bataille, Vauclin, Grouselle, Rosselin and Tixier-Vidal, 1979;
Rotsztejn, Benoist, Besson, Beraud, Bluet-Pajot, Kordon, Rosselin
and Duval, 1980a) suggests that the greater secretion of VIP into
pituitary stalk blood compared to peripheral blood (Figures 7.1a and
7.1b; Said and Porter, 1979; Shimatsu et a!., 1981) has a physiological
function. The role of VIP as a putative PRL-releasing factor is dis¬
cussed in Section 7.2. A recent report that 5-HT injections into the
ventricles stimulated VIP release into pituitary stalk blood (Shimatsu,
Kato, Matsura, Katakami, Yanaihara and Imura, 1982) provides strong
support for the hypothesis that the stimulatory effect of 5-HT on PRL
secretion is due to the release of a PRL-releasing factor rather than
inhibition of dopamine release into pituitary stalk blood (Clemens,
Rousch and Fuller, 1978; Lamberts and MacLeod, 1978; Pilotte and
Porter, 1981). Therefore, although it has been shown (Table 7. Id)
that VIP in the periphery does not make a significant contribution
to the concentration of VIP measured in pituitary stalk blood and the
origin of VIP in stalk blood is not yet resolved, it is likely that high
concentrations of VIP are involved in the modulation of PRL secretion.
The presence of VIP in cerebrospinal fluid (CSF; Fahrenkrug,
Schaffalitsky de Muckadell and Fahrenkrug, 1977) does raise the
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possibility that tanycyctes (special ependymal cells present in large
numbers in the median eminence) may transport VIP, amongst other
substances, from the CSF to pituitary stalk portal vessels (Knigge and
Scott, 1970). However, the role, if any, of tanycytes in transporting
substances between the CSF and pituitary stalk vessels is unclear
(Bergland and Page, 1979; Mezey and Palkovits, 1982). It is
also possible that the optimal parameters for the release of VIP were
not used in this study (Figure 7.1a, Section 7.1.2) and that is why
there was no significant difference in the concentration of VIP in stalk
plasma after electrical stimulation of the brain. Finally, a VIP-like
peptide, PHI (PHI-27; the peptide (P) having NH2-terminal histidine
(H) and COOH-terminal isoleucine (I) amide and 27 amino acid residues)
has been found in the external layer of the ME (Hokfelt, Fahrenkrug,
Tatemoto, Mutt, Werner, Hulting, Terenius and Chang, 1983).
Although the cross-reactivity of PHI with the VIP-antibody used in
the experiments described in this section is fairly low (Maletti et ah,
1982), it is possible that part of immunoreactivity in stalk blood
attributed to VIP, is due to PHI.
7. 2 VIP in Pituitary Stalk Blood: Concentration During the Rat
Oestrous Cycle
7. 2. 7 Introduction
It has been established for nearly a decade that the hypothalamic
tripeptide, thyrotrophin-releasing hormone (TRH) is a potent stimulator
of PRL secretion (Bowers, Friesen, Hwang, Guyda and Folkers, 1971;
Jacobs, Snyder, Wilber, Utiger and Daughaday, 1971; Tashijan,
Barowsky and Tensen, 1971; Valverde, Chieffo and Reichlin. 1972). The
absence of an increase in plasma thyrotrophin (TSH) concentrations in
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post-partum women in whom suckling induced high concentrations of
PRL in the circulation (Gautvik, Tashijan, Kourides, Weintraub,
Graeber, Maloof, Suzuki and Zuckerman, 1974), raised the possibility
of the existence of a PRL-releasing factor (PRF) distinct from TRH.
Pharmacological and experimental manipulations (Section 1.4.3) have
confirmed that TRH can stimulate the release of PRL in vitro and in
vivo (Jackson and Reichlin, 1974; Boyd, Spencer, Jackson and
Reichlin, 1976; Meites and Sonntag, 1982). However, while
anti-TRH serum induced a 50% fall in plasma PRL concentrations in
the rat (Koch, Goldhaber, Firemen, Zor, Shaw and Tal, 1977) but not
in the ewe (Fraser and McNeilly, 1982a), hypothalamic extracts do
possess PRF activity that cannot be attributed to TRH (Boyd et al.,
1976; Szabo and Frohman, 1976; Grosvenor and Mena, 1980).
Moreover, the dose of TRH required to induce the release of PRL is
relatively high (Meites and Sonntag, 1982).
There is growing evidence to support the role of VIP as a PRF.
The evidence includes the following:
i) VIP stimulated the release of PRL from enriched preparations of
normal PRL-secreting cells (Rotsztejn et a!., 1980a), rat hemi-
pituitaries in vitro (Ruberg et at., 1978; Shaar et a!., 1979; Samson
et al. , 1980) and normal human pituitary tissue (Malarkey, O'Dorisio,
Kennedy and Cataland, 1981).
ii) Intraventricular and intravenous injections of VIP stimulated
the release of PRL in vivo in various species (Kato, Iwasaki, Abe,
Yanaihara and Imura, 1978; Vijayan et al. , 1979b; Bataille, Talbot,
Milhaud, Mutt and Rosselin, 1981; Frawley and Neill, 1981).
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iii) The presence of immunoreactive VIP in nerve endings of the
mediobasal hypothalamus (Emson et al., 1978; Besson et al.,
1979a),in prolactotrophs (Morel, Besson, Rosselin and Dubois, 1982)
and in high concentrations in pituitary stalk blood (Section 7.1; Said
and Porter, 1979; Shimatsu et al. , 1981).
iv) The existence of VIP receptors in human and rat PRL-secreting
cells (Nicosia, Spada, Borghi, Cartelazzi and Gianattasio, 1980;
Rotsztejn et al., 1980a).
v) The stimulation of cAMP accumulation by low doses of VIP in the
pituitary gland (Deschodt-Lanckman et al., 1977; Quik, Iversen
and Bloom, 1978; Borghi, Nicosia, Giachetti and Said, 1979; Rotsztejn,
Dussaillant, Nobou and Rosselin, 1981) and in rat clonal PRL cells
(Gourdji et al., 1979) together with PRL release from the rat clonal
PRL cells (Gourdji et al. , 1979). While the PRL-stimulating action of
VIP was additive to TRH, the accumulation of cAMP was not (Gourdji
et al., 1979; Enjalbert, Arancibia, Ruberg, Priam, Bluet-Pajot,
Rotsztejn and Kordon, 1980).
Apart from a direct effect of VIP on pituitary cells to stimulate
the release of PRL, it has been proposed that VIP blocks the inhibitory
effect of dopamine on PRL release. This was suggested by the demon¬
stration that VIP significantly attenuated the inhibition of PRL release
by dopamine from cultured pituitary cells (Kato et al., 1978). Moreover,
L-dopa the precursor of dopamine inhibited the release of PRL by
VIP in anaesthetised rats (Kato et al. , 1978) and dopamine agonists
specifically inhibited the activation of cAMP in the pituitary by VIP
(Onali, Schwartz and Costa, 1981). The blockade of dopamine receptors
with neuroleptics did not modify VIP-induced PRL release (Enjalbert
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et a!., 1980) which suggests that VIP does not act at dopamine
receptors.
The physiological factors that control the release of VIP are
for the most part speculative and still largely under investigation.
Studies in developing rats showed that at puberty an increase in the
content of VIP in the brain preceded that of plasma PRL but no sharp
increase in plasma VIP concentration occurred (Maletti, Besson,
Bataille, Laburthe and Rosselin, 1980). Gonadal steroids which are
known to stimulate the release of PRL (Neill, 1980; Section
1.4.3), did not alter the accumulation of cAMP in pituitary cells by
VIP (Rotsztejn, 1981) or affect the concentration of VIP in the adeno-
hypophysis (Rotsztejn, Besson, Beraud, Gagnant, Rosselin and
Kordon, 1980b). Oestradiol administered to ovariectomised rats
modulated the content of VIP in the hypothalamus and pituitary (Maletti
et al., 1982). This action of oestradiol was enhanced by high plasma
concentrations of PRL (Maletti et at., 1982). In addition, cortico¬
steroids have been reported to modulate the concentration of VIP in
the adenohypophysis (Rotsztejn et a!., 1980b), the responsiveness
of PRL cells to VIP (Rotsztejn et at., 1980a), inhibit the accumulation
of cAMP and release of PRL from pituitary cells in culture by VIP
(Rotsztejn et a I., 1981).
Purpose of the present studies:
The aim of the experiments described in this section was to
determine,
1. whether there was an increase in the concentration of VIP in
pituitary stalk blood which could be responsible for the spontaneous
surge of PRL on pro-oestrus (Gray et al. , 1970; Wuttke and Meites,
1970; Neill et al. , 1971) ;
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2. the effects of four different anaesthetics (Althesin, Ketalar,
Sagatal and urethane) on the concentration of VIP in pituitary
stalk plasma, in view of the ability of anaesthetics to alter
secretions of hypothalamic and pituitary peptides (Blake and
Sawyer, 1972; Smythe and Lazarus, 1973; Lawson and Gala,
1974; Sarkar et al., 1976).
7. 2. 2 Materials and Methods
(a) Animals:
All experiments were carried out on adult female rats of the
Wistar strain, weighing 200- 250 g, which were maintained under condi¬
tions described in Section 2.1. Only animals which had exhibited at
least two successive 4-day oestrous cycles (as assessed by the inspec¬
tion of daily vaginal smears, described in Section 2.1) were used for
experimentation. The injected dose of the selected anaesthetic is
given in Section 2.2.1.
Pituitary stalk blood was collected as described in Section 2.2.5
for two consecutive 30 min periods between 15.30 and 18.30 h each day.
Peripheral blood was obtained from the external jugular vein before
the pituitary stalk was cut. All samples were collected into tubes kept
on ice and containing EDTA (5.4 mM/1 blood) and Trasylol (5000 KIU/
ml). The plasma was stored frozen until assayed.
(b) Radioimmunoassay and calculations:
The concentration of VIP in the plasma samples was determined
by a specific radioimmunoassay (Section 2.3, Maletti et al., 1982).
The content (concentration x volume per 30 min) was calculated for
pituitary stalk blood. The significance of differences between means
was determined by the unpaired t-test. The differences between more
than two means was determined by analysis of variance followed by
the multiple range test (Duncan, 1957; Harter. 1960).
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7. 2. 3 Results
The VIP concentration of peripheral and pituitary stalk plasma
was determined using four anaesthetics: alphaxalone-alphadolone
acetate (Althesin), ketamine hydrochloride (Ketalar), sodium pento¬
barbitone (Sagatal) or ethyl carbamate (drethane) and are shown in
Table 7.2a and in histogram form in Figure 7.2a.
(a) VIP concentrations in peripheral plasma:
An analysis of variance of the VIP concentrations in peripheral
plasma over the four days of the oestrous cycle showed that there was
no statistically significant difference between the anaesthetics with
respect to the VIP profile. In addition, no statistically significant
differences were found on comparison of VIP levels on a particular
day of the cycle under different anaesthetics. However, in general,
the concentration of VIP in peripheral plasma was significantly (p <0.05)
less than in pituitary stalk plasma.
(b) VIP concentrations in pituitary stalk plasma:
Table 7.2a and Figure 7.2a show that the VIP concentration in
pituitary stalk plasma was significantly (p <0.05) greater than in
peripheral plasma on the same day, under each of the anaesthetics
except on dioestrus under Ketalar.
The VIP concentration and content in stalk plasma from animals
anaesthetised with Sagatal at metoestrus were significantly greater
(p <0.05) than those in metoestrus animals anaesthetised with any of
the other anaesthetics. Only under Ketalar was there a significantly
(p <0.05) higher concentration of VIP in stalk plasma on pro-oestrus
compared to on dioestrus. There were no significant changes in the
concentration and content of VIP in stalk plasma on any of the days
of the cycle under Althesin and urethane anaesthesia.
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7. 2. 4 Discussion and Conclusions
The VIP concentration in pituitary stalk plasma was overall
significantly (p <0.05) greater than in peripheral plasma. However,
there is no clear-cut evidence from the VIP concentrations in pituitary
stalk plasma that an increase in VIP release precedes the pro-oestrus
surge of PRL release. The day of the cycle when maximum VIP con¬
centrations were found in pituitary stalk plasma was dependent on the
anaesthetic used. Which of these data represents the physiological
VIP concentrations most closely is open to conjecture since pituitary
stalk blood samples cannot be obtained without inducing fairly deep
anaesthesia and considerable trauma, and the precise influence of the
anaesthetics and trauma on VIP and PRL release are not fully under¬
stood. Differences in VIP concentrations in pituitary stalk blood
collected under urethane and Pentobarbital were also found by Shimatsu
ef a!. (1981); the VIP concentration measured under Urethane
anaesthesia was 400 pg/ml less than that under Pentobarbital. The
prevention of ovulation and the LH surge by neural blocking agents
such as urethane, Ketalar and Pentobarbital, administered between
14.00 and 16.00 (the 'critical period') of proestrus (Everett, 1964;
Schwartz and Calderelli, 1965; Blake and Sawyer, 1972; Lincoln and
Kelly, 1972; Greig and Weisz, 1973) as well as a block of pulsatile LH
release in long-term ovariectomised rats (Arendesh and Gallo, 1978;
Sarkar and Fink, 1980; Watts and Fink, 1981) is well established.
These effects are due primarily to a block of the spontaneous LHRH
release (Carter and Dyer, 1979; Sherwood, Chiappa, Sarkar and
Fink, 1980) which prevents the subsequent release of gonadotrophins.
Althesin, a mixture of the steroids, alphadolone acetate and alphaxalone,
on the other hand, has been shown not to block ovulation or the LH
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surge, although the magnitude of the LH surge may be reduced (Sarkar
et al., 1976). Althesin does not appear to interfere with various fore-
brain-mediated functions as do anaesthetics such as Ketalar and Sagatal
(Timms, 1976), despite evidence obtained using cortical electroencephal¬
ography that Althesin is a more potent anaesthetic than either Sagatal
or urethane (Fink, Sarkar, Dow, Dick, Borthwick, Malwick and Twine,
1982). Moreover, both urethane (Findell, Larsen, Benson and Blask,
1981) and Sagatal (Carrodi, Fuxe and Hokfelt, 1966; Schanberg,
Schildkraut and Kopin, 1967) induce changes in brain monoamine content
and turnover. An investigation of the influence of several anaesthetics
on the oestrogen-induced afternoon PRL surge showed that ether and
Ketamine completely abolished the diurnal PRL surge (Clarke and Gala,
1981); urethane initially suppressed the PRL surge though plasma
PRL started rising about 8 h later. This initial inhibitory effect of
urethane was also observed with respect to the suckling-induced PRL
release (Burnet and Wakerley, 1976; Isherwood and Cross, 1980) and
was found to be over in approximately 4 h (Figure 7.2b; Brar, unpub¬
lished data) when suckling significantly (p <0.05) increased plasma
PRL concentrations. Suckling-induced release of PRL did not occur in
rats given Ketalar. These results are opposite to those reported
recently by Fink, Koch and Aroya ( 1983) who were only able to demon¬
strate an increase in plasma PRL after suckling in rats given Ketalar
but not urethane. The reason for this difference is not clear, partic¬
ularly since the same strain of rats was used in the studies by Fink
et at. (1983) and those in Figure 7.2b. Fink et al. ( 1983) did, however,
find that suckling induced an increase in TRH output into pituitary
stalk blood in animals anaesthetised with Ketalar but not in animals

















FIGURE 7.2b: Prolactin concentration (mean ± S.E.M.) of peripheral
plasma in groups of suckled ( Bfl ) and non-suckled
( CD ) lactating rats at 10 days post-partum (n=6).
Blood samples were collected 4-8 h after the onset of
Urethane anaesthesia (1 g/kg, i.p.).
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pituitary stalk blood correlated most closely with a decrease in pituitary
growth hormone release in animals anaesthetised with urethane as
opposed to Althesin or Sagatal (Chihara, Arimura and Schally, 1979).
The different effects of anaesthetics on the release of pituitary peptides
into systemic blood and hypothalamic peptides into pituitary stalk
blood does raise the possibility that the reason that there was no
dramatic increase in VIP release into pituitary stalk blood with the surge
in PRL release on pro-oestrus was, that all the four anaesthetics used
in the experiments described in this chapter masked any changes that
may occur in the conscious animal. Perhaps a better model would
have been animals made hyperprolactinaemic (e.g. by implantation of
pituitary transplants under the kidney capsule, Chapter IV), in which
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8.1 Summary
The aim of the experiments in Chapters III and IV was to determine
whether testicular steroids exert an inhibitory influence on the secretion
of LHRH into pituitary stalk blood. Long-term castration, for 30 days
(Chapter III) or 14 days (Chapter IV), did not alter the amount of
LHRH released into stalk blood, compared with that in intact control
rats. Long-term castration did, however, induce a marked increase in
the plasma concentrations of pituitary gonadotrophins (Chapters III
and IV), the pituitary content of LH and the number of LHRH receptors
in the anterior pituitary gland (Chapter III). Electrical stimulation of
the median eminence of castrated rats, using stimulus parameters known
to induce the optimum release of LH release in the intact animal, produced
significantly lower secretion of LHRH into stalk blood compared with
that in intact rats (Chapter IV).
The administration of three major testicular steroids, testosterone
(T), oestradiol (OE2) which is formed by aromatisation of T and 5a-
dihydrotestosterone (DHT) which is formed by 5a-reduction of T, by
subcutaneous injections for 8 days, all effectively suppressed the post-
castration increase in plasma LH concentration. The post-castration
increases in FSH concentration was suppressed only by OE2. Treatment
with OE2 lowered the numbers of pituitary LHRH receptors, although
these values were still higher than those in intact control rats. The
amount of LHRH in stalk blood was not significantly altered by administra¬
tion of either OE2, DHT or T (Chapter III).
In order to determine whether the suppression of gonadotrophin
secretion by elevated PRL secretion can be attributed to a suppression
of LHRH release or stimulation of DA release into stalk blood, male rats
were made hyperprolactinaemic by transplanting two anterior pituitary
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glands under the kidney capsule (Chapter IV). Neither the amount of
LHRH nor that of DA in stalk blood was altered by increasing plasma
PRL concentrations to values found in the lactating rat for a period of
42 days. Electrical stimulation of the median eminence was as effective
in hyperprolactinaemic rats as in control rats in increasing LHRH
release into stalk blood.
Removal of the testis of hyperprolactinaemic rats resulted in an
increase in gonadotrophin secretion which was lower compared with that
in control, castrated rats, but the amounts of LHRH in stalk blood were
similar in the control and hyperprolactinaemic castrated rats (Chapter IV).
Administration of T by subcutaneous implants (10 mm or 30 mm lengths)
demonstrated that plasma T concentrations equal to or greater than
4 n g/ml are required to suppress completely the post-castration increase
in the plasma gonadotrophin concentration, both in control rats and hyper¬
prolactinaemic rats. Neither 10 mm nor 30 mm T implants altered the
release of LHRH into stalk blood in the control or hyperprolactinaemic
castrated rats.
The hyperprolactinaemic rats were more sensitive than the control
rats to the anaesthetic effects of the steroid anaesthetic, Althesin.
The release of DA into stalk blood of intact hyperprolactinaemic
rats, intact control rats or castrated, control rats with and without T
implants, was not significantly different (Chapter IV). Thus, the
maintenance of low gonadotrophin release by the testes and elevated plasma
PRL concentrations does not appear to be due to a suppression of LHRH
secretion into stalk blood.
The enzymatic conversion in the brain and pituitary of oestrogens
by 2-hydroxylation, produces the metabolites, CAE1 and CAE2. These
catechol oestrogens were found to be potent stimulators of LH release
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in the immature male rat, at doses (50-100 pg/rat) at which their
parent oestrogens, OEx and OE2, were ineffective (Chapter V). CAEx
had no effect on PRL secretion although CAE2, OEl and OE2 stimulated
PRL secretion in the prepubertal male and female rat. CAE2 was more
potent than OE2 in stimulating LH release in the prepubertal female rat
and had no effect on weight of the ovaries or the uterus. However,
CAE2 suppressed the pre-ovulatory LH surge and uterotrophic effects
of PMSG in the immature female rat. OEx (2.5 pg/rat) was more potent
than OE2 in stimulating LH release in the immature female rat, although
the uterotrophic activity of OEx was equal to OE2. Therefore, the con¬
version of the oestrogens to catechol oestrogens, CAEX and CAE2,
produces metabolites that are capable of stimulating LH and PRL secretion
in prepubertal rats but lack the uterotrophic activity demonstrated by
their parent oestrogens.
The experiments in Chapters VI and VII were carried out to
determine whether there is any basis for considering that the 'gut-
peptides' CCK, gastrin and VIP, recently demonstrated to be localised
in the brain and pituitary, are physiological hypothalamic-pituitary
regulating factors. The release of CCK and VIP, but not gastrin, into
pituitary stalk blood was significantly greater than in peripheral blood.
Electrical stimulation of the amygdala, dorsal and ventral hippocampus,
preoptic area, paraventricular and suprachiasmatic nuclei and the median
eminence, using stimulus parameters known to produce the optimum
release of LH, did not alter the secretion of either CCK or VIP into
stalk blood. The release of gastrin into stalk blood could not be induced
by electrical stimulation of the median eminence, preoptic area or the
suprachiasmatic nuclei. Removal of the gastric antrum, in order to
remove the major peripheral source of gastrin, was found to reduce the
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concentrations of both gastrin and CCK in stalk blood. Electrical
stimulation of the median eminence of rats with the antrum removed
was ineffective in altering the release of CCK or gastrin in stalk blood.
The release of VIP into stalk blood, on the other hand, was not altered
by the removal of the entire gut which contains large amounts of VIP
(Polak et al., 1974; Larsson et al., 1976). An attempt to correlate
the release of VIP into stalk blood with the spontaneous surge of PRL
on pro-oestrus was complicated by the fact that the four anaesthetics
used (Althesin, Ketalar, Sagatal and urethane) may all affect PRL
secretion (Section 7.2.4: Burnet and Wakerley, 1976; Clarke and Gala,
1951; Fink et al., 1983). No clear-cut correlation between VIP release
into stalk blood on pro-oestrus and an increase in PRL release was found.
Therefore, the studies in Chapters VI and VII demonstrated that it is
unlikely that CCK and gastrin are physiological hypothalamic regulating
factors since the release of these peptides into stalk blood was not
greater than in peripheral blood after removal of the gastric antrum,
and could not be altered by stimulation of the hypothalamus or other
brain areas that contain these. The release of VIP into stalk blood was
significantly higher than in peripheral blood, suggesting a putative
role for VIP as a releasing factor. However, a physiological role for
VIP in stimulating PRL release on pro-oestrus was not conclusively
demonstrated, although a suppression of any changes that may have
occurred by the anaesthetics used, cannot be ruled out.
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8.2 Hypotheses
8. 2. 7 Modulation of LHRH secretion by testicular steroids and PRL
The demonstration that removal of testicular steroids did not alter
the release of LHRH or DA into stalk blood, despite an increase in
gonadotrophin secretion (Chapters III and IV; Gay and Midgley, 1969;
Yamamoto et al., 1970; Schally et at., 1973) suggests that the negative
feedback effects of the testes are exerted mainly at the level of the
pituitary gland. This hypothesis is supported by the fact that castra¬
tion increases pituitary LH content, the number of pituitary LHRH
receptors (Chapter III; Gay and Midgley, 1969; Kingsley and Bogdanove,
1973; Clayton et at., 1980; Frager et al., 1980) and the responsiveness
of the pituitary gland to exogenous LHRH (Debeljuk et al, 1974;
Nansel et al., 1979; O'Conner, Allen and Mahesh, 1980).
A pituitary site of action of the testicular steroids, T, DHT and
OE2, is also suggested by the demonstration that these steroids suppress
the post-castration rise in gonadotrophin release by a direct negative
feedback action on the pituitary gland (McEwen, Pfaff and Zigmond, 1970;
Kingsley and Bogdanove, 1971; Debeljuk, Arimura and Schally, 1972).
None of these steroids appeared to alter the secretion of LHRH into stalk
blood (Chapters III and IV) although they directly inhibit pituitary
responsiveness to exogenous LHRH in the castrated rat (Debeljuk
et al., 1974; Drouin et al. , 1976; Cheung and Davidson, 1977;
Henderson and Fink, 1977). However, in the long-term castrated rat,
any reduction in the responsiveness of the pituitary gland to LHRH in
stalk blood and LH secretion by T, DHT or OE2 is not accompanied by
a complete suppression of the post-castration rises in pituitary LH
content and pituitary LHRH receptor numbers (Chapter III; Conne
et a!., 1980). The post-castration increase in the number of pituitary
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LHRH receptors (Chapter III; Clayton and Catt, 1981; Frager et at.,
1981; Fraser et al., 1982) may not, therefore, be due to an increased
secretion of LHRH into stalk blood. The demonstration that rats
immunised against T had elevated numbers of pituitary LHRH receptors
(Fraser et at., 1982), indicates the important role of T in the moderating
of pituitary LHRH receptors. That androgens can act directly on rat
anterior pituitary cells in culture to decrease LHRH binding sites
(Giguere et at., 1981) lends further support to the hypothesis that the
negative feedback effects of testicular steroids are exerted at the level
of the pituitary gland. The requirement of normal LHRH secretion
from the hypothalamus to maintain normal numbers of pituitary LHRH
receptors, suggested by the facts that administration of an LHRH
antagonist, or lesions of the median eminence passive or active immuniza¬
tion of LHRH lowers the number of pituitary LHRH receptors (Clayton
eta!., 1982a,b; Fraser et at., 1982), is not disputed. The studies in
this thesis support the hypothesis that, in the presence of normal LHRH
secretion, testicular steroids modulate gonadotrophin secretion, at least
in part, by modulating pituitary LHRH receptors.
There are, however, studies suggesting an effect of testicular
steroids at the level of the hypothalamus. For example, a decrease in
the content of LHRH after castration has been proposed to be indicative
of increased LHRH secretion (Moguilevsky et al. , 1975; Root et at.,
1975; Shin and Howitt, 1976; Gross, 1980; Kalra and Kalra, 1980).
There was, however, no significant difference between control and
castrated rats in the basal release of LHRH into stalk blood while
electrical stimulation of the median eminence of castrated rats induced
significantly less release of LHRH into stalk blood than in control rats
(Chapters III and IV). Therefore, removal of the testes appears to
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decrease the amount of hypothalamic LHRH available for release.
Although OE2, DHT and T are all effective in restoring the hypothalamic
LHRH content of long-term castrated rats to values found in control
animals, after a period of 3-7 days (Campbell and Ramaley, 1978;
Gross, 1980; Kalra and Kalra, 1980), none of these testicular steroids
altered the basal release of LHRH or the LHRH release into stalk blood
induced by electrical stimulation of the median eminence (Chapters III
and IV). Studies in which T, DHT or OE2 implants have been placed
in the hypothalamus (Danguy, Ectors and Pasteels, 1976; Kalra and
Kalra, 1978, 1980) indicate that LHRH neurones in both the preoptic
area and the arcuate-median eminence complex are sensitive to the
feedback from T, DHT and OE2, in the male rat and OE2- and androgen-
binding sites have been demonstrated by autoradiographic studies to
occur in these hypothalamic regions (Pfaff, 1968; Sar and Stumpf, 1973).
In addition, T administration restores, while anti-androgen administration
prevents, the decrease in hypothalamic LHRH content induced by
castration (Kalra and Kalra, 1980). Yet, despite all this evidence
supporting an effect of T, DHT and OE2 at the level of the hypothalamus,
these steroids did not alter the secretion of LHRH into stalk blood of
long-term castrated rats which does raise the possibility that, in the
male rat, Althesin anaesthesia masks any changes that occur in LHRH
release into stalk blood.
The ability of elevated plasma PRL concentrations to reduce
gonadotrophin secretion and pituitary LHRH receptors in the intact rat
and prevent the post-castration increases in plasma gonadotrophin
concentration, pituitary LH content and pituitary LHRH receptors
(Bartke ef a/., 1977; McNeilly et al., 1978; Winters and Loriaux,
1978; McNeilly et al. , 1980; Fraser et a/., 1982; Marchetti and Labrie,
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1982), is postulated to be due to modulation of various parameters
by PRL at the level of the pituitary gland rather than by suppression
of LHRH release. Hyperprolactinaemia reduces the responsiveness of
the pituitary to LHRH (Winters and Loriaux, 1978; Greeley and Kizer,
1979; Tresguerres and Esquifino, 1981; Wuchenich and Cheung, 1981),
the number of pituitary LHRH receptors (Fraser et ah, 1982; Marchetti
and Labrie, 1982) and pituitary gonadotrophin concentrations (Bartke
et al., 1978; McNeilly et ah, 1978). A suppression of the responsive¬
ness of the pituitary to LHRH (Smith, 1980) and a reduction in pituitary
LHRH receptors (Clayton et ah, 1982) has also been associated with
elevated PRL concentrations in the lactating rat. Neither the high
(30 mm implant) nor the low (10 mm implant) dose of T altered the release
of LHRH into stalk plasma of castrated hyperprolactinaemic rats, but
the high dose did suppress the post-castration rise in plasma gonado-
trophins. Thus, a pituitary site of action of T in the hyperprolactin¬
aemic rat is also suggested.
The lack of any increase in DA release into stalk blood of hyper¬
prolactinaemic rats, despite elevated plasma PRL concentrations
(Chapter IV) and evidence suggesting that TIF DA turnover is in¬
creased by elevated plasma PRL concentrations (Hokfelt and Fuxe,
1972; Gudelsky et al., 1976; Moore, Demarest and Johnston, 1980;
Morgan and Herbert, 1980), may be due to several reasons. One of
these is suggested by Demarest and Moore (1981) who showed that
there was a sexual difference in the sensitivity of TIF DA neurones to
the stimulatory actions of PRL; the TIF neurones in the female are
more sensitive to circulating concentrations of PRL than those in the
male. The TIF neurones of the hyperprolactinaemic male rats may
therefore not respond to the elevated plasma PRL concentrations.
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Another reason why there was no change in the secretion of DA into
stalk blood of hyperprolactinaemic rats could be that much higher
concentrations of plasma PRL are required to stimulate DA release.
This proposal is supported on experiments by Cramer et al. (1979)
and Weber et al. (1983) in rats bearing PRL-secreting tumours (plasma
PRL concentrations >1000 ng/ml) compared with rats with pituitary
transplants (plasma PRL concentration >200 ng/ml). DA secretion into
stalk blood was only increased in rats with PRL-secreting tumours
(Cramer et al., 1979). The demonstration that lactating females (day
12 post-partum) which had continuously elevated plasma PRL concentra¬
tions (580 ng/ml) did not show increased TIF DA neuronal activity
(Demarest, McKay, Riegle and Moore, 1981a) supports the view that the
PRL feedback mechanism that activates TIF DA neurones does not always
operate in hyperprolactinaemic conditions. Perhaps such a situation
is also found in the hyperprolactinaemic male rat. The demonstration
that transplanted pituitary tumours that secrete large amounts of PRL
reduce the PRL content of the pituitary in situ (MacLeod, Smith and
De Witt, 1966; Chen, Minaguchi and Meites, 1967) and increase the PIF
activity of the hypothalamus (Chen et al., 1967) suggests that an auto-
regulatory role for PRL should also be considered. Certainly, plasma
concentrations of PRL that are induced by implanting 4 pituitary
glands (178 ng/ml) that do not alter the release of DA into stalk blood
(Cramer et al., 1979) do, however, reduce the PRL content of the
pituitary gland (McNeilly et al., 1978; Cramer et al., 1979).
A role for the adrenal steroids in modulating the release of
LHRH into stalk blood is likely in view of the fact that hyperprolactin-
aemia increases the size (McNeilly et at., 1978; Cramer et at., 1979)
and function (Schlein, Zarrow and Denenberg, 1974; Vasquez and
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Kitay, 1979) of the adrenal gland. In addition, in adrenalectomised
male rats bearing PRL and ACTH-secreting tumours, hyperprolactin-
aemia did not affect gonadotrophin secretion or the androgenic, action
of T (Weber et a!., 1982). Moreover, the suppression of LHRH release
but not the increase in DA release into stalk blood induced by PRL-
and ACTH-secreting tumours was absent in adrenalectomised tumour-
bearing rats (Weber et al., 1983).
8. 2. 2 Physiological role for catechol oestrogens
The stimulation of LH and PRL secretion in the pre-pubertal male
and female rat by acute administrations of CAE! or CAE2 raises the
possibility that the conversion of the oestrogens to CAEi and CAE2 is
a mechanism by which the effects of the parent oestrogens are prolonged.
This hypothesis seems plausible in view of the demonstration that OEi
and OE2 were ineffective in stimulating LH release at the low doses of
CAEx and CAE2 that stimulated LH release in the male rat. The physio¬
logical significance of a stimulation of LH secretion by the catechol
oestrogens in the male rat remains to be found, since oestrogens exert
a predominantly inhibitory influence of LH secretion in the adult male
rat (Chapters III and IV; Gayefo/., 1970; Yamamotoef o/., 1970).
The mechanism, by which the CAEs modulate hormone release from
the anterior pituitary gland has been subject to various speculations.
These have included the possibility that CAEs prevent the inhibitory
effects of DA on LH and PRL release. This attractive hypothesis has
been difficult to prove. No conclusive evidence has yet shown that the
CAEs provide a direct link between the oestrogenic and adrenergic
control of tonic and cyclic release of LH apart from demonstrations that
CAEs can inhibit DA synthesis (Lloy^and Weisz, 1978; Foreman and
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Porter, 1980) and compete with DA receptors in the rat anterior
pituitary gland (Schaeffer and Hseuh, 1979).
The mechanism by which a dose of CAE2 that stimulates LH
secretion and lacked uterotrophic activity, suppresses the release of
LH and uterotrophic effect induced by PMSG in the immature female rat
(Chapter V) remains unresolved. It is possible that in the PMSG-
treated rat, CAE2 has an anti-oestrogenic effect. This view is sup¬
ported by the facts that plasma OE2 concentrations reach a maximum
42-52 h after PMSG treatment (Wilson et at., 1974) and that CAE2 has
a high affinity for receptors in the uterus (Martucci and Fishman,
1976), and the hypothalamus and pituitary gland (Davies et a!., 1975).
The ability of CAE2 to block the OE2-induced accumulation of cAMP in
the brain (Paul and Skolnick, 1977) also suggests that an anti-oestrogenic
effect of CAE2 is plausible.
8. 2. 3 The roles of CCK, gastrin and VIP as releasing factors in the
hypothalamo - hypophysial system
The present results (Chapter VI) make it unlikely that gastrin
or CCK have a role as releasing factors in the hypothalamo-hypophysial
system, as defined by the neurohumoural hypothesis (Section 1.1.1).
Gastrin has been reported to be localised primarily in the pituitary
(Rehfeld, 1978; Rehfeld et aI. , 1980), was not secreted in higher
concentrations into stalk blood than peripheral blood (Section 6.2.2)
and was not released into stalk blood on electrical stimulation of the
median eminence. Despite the localization of CCK-immunoreactivity in
the external layer of the median eminence (Hokfelt et at., 1978; Loren
et al. , 1979; Vanderhaeghen et al. , 1980; Anhut ef o/., 1983),
electrical stimulation of the median eminence failed to increase the
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release of CCK into stalk blood. Although it is possible that the
optimal parameters required to induce the release of CCK from the
median eminence, were not used, most of the CCK (and gastrin) in the
stalk blood appeared to originate from the periphery (Section 6.3.3).
A physiological role for VIP as a releasing factor is proposed on
the basis that the release of VIP into stalk blood was significantly
greater than in peripheral plasma. The fact that electrical stimulation
of the median eminence did not stimulate VIP release into stalk blood can
be explained to be due to the fact that very few VIP fibres have been
found in the external layer of the median eminence (Larsson et al.,
1976; Rostene et at., 1982). In addition, there is no published evidence
to suggest that VIP fibres from areas such as the amygdala and supra-
chiasmatic nucleus project to the hypophysial portal vessels, or that the
optimal parameters required to induce VIP release were not used. The
source of VIP in stalk blood has not yet been resolved.
Although a suppression of any release of VIP into stalk blood on
pro-oestrus may have been masked by the anaesthetics used, it is
possible that the reason that there was no marked changes in VIP
release into stalk blood during the oestrous cycle is that the PRL-
releasing action of VIP may involve a suppression of the inhibitory
effect of DA on PRL release, possibly by an inhibition of DA release
(Kato et al. , 1978). The proof of this hypothesis and other questions,
such as whether the PRL-releasing effects of VIP are enhanced by a
brief removal of DA, as found for the action of TRH (Grosvenor and
Mena, 1980; Fagin and Neill, 1981), must await further research.
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APPENDICES
APPENDIX Al: Radioimmunoassay for luteinising hormone (LH) and
follicle-stimulating hormone (FSH): based on the
methods of Greenwood et al. (1963); Niswender et al.
(1968); Daane and Parlow (1971).
Al. 1 Stock Solutions
0. 01M Phosphate buffered saline (PBS):
8.17 g NaCl
0.10 g Na methiolate
0.25 g NaH2PCV2H20
1.193 g Na2HP04 anhydrous
per litre distilled H20
pH = 7.6
Antiserum buffer:
400 ml 0.01M PBS
9.306 g EDTA
dissolved by warming; pH adjusted to
7 with 5N Na OH before adding 1.65 ml
normal rabbit serum containing 0.1%
Na Azide per 0.5 litre 0.01M PBS.
Assay buffer (0.01M PBS/0. 7% BSA):
10.0 g bovine serum albumin (BSA)
per litre 0.01M PBS; filtered before
use; stored at 4°C.
0.01M PBS/5% egg white:
5 g egg albumin
per 100 ml 0.01M PBS; centrifuged at
2000 x g for 5 min before use.
A 1.2 Iodination
[a] Materials
Columns 12 x 1 cm Biogel P60; coated with 1.5 ml
0.01M PBS/5% egg white.
Hormones ovine-LH (LER-1056-C2; NIADDK) - 500 ng/ml
0.01M PBS; 10 (il aliquots stored at -40°C.
rat-FSH (FSH-I-1; NIADDK) - 100 Mg/ml; 20 Ml
aliquots stored at -40°C.
Na 125I 1 mCi/10 nl for LH





5.0 mg/ml 0.01M PBS;
2.5 mg/ml 0.01M PBS;
10 Ml used for LH
25 m! used for FSH
made up fresh before use.
5.0 mg/ml 0.01M PBS;
2.5 mg/ml 0.01M PBS;
25 Ml used for LH
25 Ml used for FSH
made up fresh before use.
(b) Protocol
(i) Defrost hormone aliquot.
(ii) Add Na125I and mix gently.
(iii) Add Chloramine T solution and mix gently.
(iv) Reaction time: 2 min for LH iodination
45 sec for FSH iodination.
<v) Add Na2S2Os and mix gently.
(vi) Apply to column; elute with 0.01M PBS at room
temperature.
(vii) Collect 1 or 0.5 ml fractions into tubes contain¬
ing 0.5 ml 0.01 PBS/5% egg white.
(viii) Estimate radioactivity in fractions; retain
fractions with peaks of radioactivity.
N.B. LH and FSH iodination: two peaks of radioactivity found to
elute; the labelled hormone eluted in the first peak and the free
125I in the second peak. The 125I-ovine LH and 125I-rat FSH
could be used for up to 10 days after purification after which it
could still be used for a further 2 weeks following re-chromato-
graphy on a Biogel P60 column.
A 1.3 Standards
Ovine LH (NIH-LH-S18; NIADDK) - 0.25, 0.5, 0.75, 1.2, 2.0,
4.0, 8.0 and 16.0 ng/ml 0.01M PBS/1% BSA; 200 Ml aliquots
stored at -40°C.
Rat FSH (FSH-RP-1; NIADDK) - 62.5, 125, 250, 500, 1000,
1500, 2000 and 4000 ng/ml 0.01M PBS/1% BSA; 200 nl aliquots
stored at -40°C.
Al.4 Assay protocol
All incubation at 40°C
Day LH
7 200 |ul standards/samples
200 pi assay buffer












cpm) diluted in assay
buffer
200 Ml 125I-ovine LH (~10,000
cpm) diluted in assay
buffer
200 Ml anti-rabbit gamma
globulin (ARGG)
diluted in 0.01M PBS
200 Ml ARGG diluted in 0.01M
PBS
Centrifuge tubes for 30 min
at 2000 x g; aspirate super¬
natant and count pellet
7 Centrifuge tubes for 45 min
at 2000 x g; aspirate super¬
natant and count pellet
APPENDIX A2: Radioimmunoassay for luteinising hormone-releasing
hormone (LHRH) and prolactin (PRL): based on the
methods described by Greenwood et al. (1963); Nett
etal. (1973); Pickering ( 1978)
A2.1 Stock Solutions
0.01M PBS: see A 1.1
Antiserum buffer: see Al.l
Assay buffer (for LHRH - O.OIM PBS/0. 7% gelatine):
1 g gelatine
dissolve by heating in 0.0 lM PBS and
made up to 1 litre
(for PRL - O.OIM PBS/1% BSA):
see Al.l
0. 1M Borate buffer:
0.618 g boric acid
0.1 g Na methiolate
11.8 ml 0.1M Na OH (4 g/100 ml distilled H20)
made up to 1 litre with distilled H20;
pH = 8.6
0.05M Phosphate buffer (PB):
12.5 g NaH2POij. 2HzO
59.65 g NagHPO^ anhydrous
per litre distilled H20
see Al.l
NaHC03
per 100 ml distilled H20
KI
sucrose
per 10 ml distilled H20
0. OIM PBS/5% egg white:
O.OIM NaHCO3:
1.14 g








For LHRH - 20 x 0.75 cm Sephadex G25 coated
with 0.01M PBS/1% gelatine.
For PRL - 25 x 1 cm Sephadex G50 coated with
200 nl human albumen (4.5% in 0.01M PBS).
Synthetic LHRH (ICI Pharmaceuticals Ltd,
Macclesfield) - 1 mg/10 ml 0.01M PBS; diluted
to 2 gg/20 gl in distilled H20, stored at -40°C.
Rat PRL (rat-PRL-I-5; NIADDK) - 100 gg/400 gl
0.01M NaHCOa; 5 gg/20ul aliquots stored at -40°C.
1 mCi in 10 gl for LHRH and PRL.
Chloramine T For LHRH: 2 mg/ml 0.01M PBS; 20 gl used.
For PRL: 1 mg/ml 0.05M PB; 15 gl used.
Made up fresh before use.
Na2S2Q For LHRH: 2 mg/ml 0.01M PBS; 20 gl used.
For PRL: 2.4 mg/ml 0.05M PB; 50 gl used.











Add 1 mCi 125I and mix gently.
Add Chloramine T and mix gently.
Reaction times: 15 sec for LHRH iodination
20 sec for PRL iodination.
Add Na2S205 solution and mix gently.
Transfer to column; elute for LHRH with 0.01M
PBS/0.1% gelatine and for PRL with 0.1M borate
buffer at pH = 8.6; for PRL iodination, the
container holding the mixture of labelled and free
hormone, chloramine-T and Na2S2Os is rinsed
twice with Kl/sucrose and the rinses eluted on
the column.
Collect fractions for LHRH - collect first 10 ml
fraction as a pool then 1 ml fractions until total
volume eluted is 22 ml: collect fractions for PRL
in 0.5 ml PBS/1% BSA.
Estimate radioactivity in fractions; retain
fractions with peaks of radioactivity.
N.B. LHRH iodination: two peaks of radioactivity found to elute;
the free 125 I eluted in the first 11-14 ml and 125I-LHRH eluted
in the 15-19 ml fractions. The 125I-LHRH could be used
without further purification for up to 10 weeks.
PRL iodination: two peaks of radioactivity found to elute;
the labelled hormone appeared in the first peak and the free
125I in the second. The 125I PRL was only used in the radio¬
immunoassay if prepared within 48 h of use.
A 2.3 Standards
Synthetic LHRH (ICI Pharmaceuticals Ltd, Macclesfield) -
7.8, 15.5, 31.0, 62.0, 125.0, 250.0 and 500.0 pg/ml 0.01 PBS/
0.1% gelatine; 200 pi aliquots stored at -40°C.
Rat PRL (rat-PRL-RP-1; NIADDK) - 0.5, 1.2, 2.0, 4.0, 8.0
16.0, 32.0 and 64.0 ng/ml 0.01M PBS/1% BSA; 200 pi stored
at -40°C.
A2.4 Assay protocol
All incubations at 4°C.
Day LHRH
7 200 pi standards/samples
200 pi assay buffer
200 pi antiserum diluted in
antiserum buffer
200 pi 125 I-LHRH (~5000 cpm)
diluted in assay buffer
PRL
200 pi standards/samples
200 pi assay buffer
200 pi antiserum diluted in
antiserum buffer
200 pi ARGG diluted in 0.01M
PBS
200 pi 125I-rat PRL (-10,000
cpm) diluted in assay
buffer
1 ml 0.01M PBS then centri¬
fuge for 45 min at 2000 x g;
aspirate supernatant and
count pellet
200 pi ARGG diluted in 0.01M PBS
5 Centrifuge for 45 min at 2000 x g;
aspirate supernatant and count
pellet











per 1 litre distilled HzO
1.0 g CuSOi4, or
1.56 g CuSO,t.5H20
per 100 ml distilled H20
2.0 g NaK Tartrate.4H2O
per 100 ml distilled H20
1:1 v/v of Bj : B2
50:1 v/v of A : B
Folin Ciocolteu Reagent diluted
1 : 1.5 with distilled H20
A3.2 Standards
Stock solution of bovine serum albumin (2.5 mg/ml distilled
H20) serially diluted to give standards of 50, 100, 150, 200 and
250 |ig/ml. A volume of 0.3 ml of these standards was estimated.
A3.3 Protocol
(i) 0.3 ml standards/samples
(ii) Add 3.0 ml C and mix
(iii) Stand for 15 min
(iv) Add 0.3 ml D and mix immediately
(v) Stand for 30-90 min
(vi) Read optical density at 750 nm
(vii) Determine protein concentration by linear
regression from a standard curve of log
absorbance versus log protein concentration.
APPENDIX A4: Cresyl fast violet stain for frozen sections of
formaldehyde-fixed brains: based on the method




90.0 ml 0.1M phosphate buffer (pH =7.4)
consisting of
0.296 g NaH2POl4.2HzO /100 ml distilled H20
1.150 g Na2HP02.12H20/100 ml distilled H20
A4.2 Staining Procedure
1. Leave sections in xylene for about 5 mins.
2. Hydrate through graded alcohols to water.
3. Stain in 1% cresyl fast violet for about 15 mins.
4. Rinse in tap water then pass through 70% alcohol.
5. Leave in acid alochol (1% HC1 in 80% alcohol) until
the sections are a pale blue colour.
6. Wash in 80% alcohol then in absolute alochol. Arrest
the differentiation in xylene.
7. Mount in DPX on sliced which were pre-cleaned in
alcohol and coated with Alum Gelatine + .
Results: nuclei-purple/blue; neurones-purple/blue.
"•* Alum Gelatine: 1.0 g Gelatine dissolved in 100 ml distilled HzO by
heating and stirring continuously.
0.1 g Chromium potassium sulphate dissolved in
100 ml distilled H20.
APPENDIX A5: OFG-Br.AB. method for cells of the anterior pituitary
(Slidders, 1961). (Tissue fixed in formaldehyde,
wax-embedded sections - 8-10 pm thick were used.)
A 5.1 Solutions
Bromine water: 45.0 ml 10% hydrobromic acid (aqueous)
5.0 ml 2.5% potassium permanganate (aqueous)
Alcian blue 100.0 mgAlcian Blue
1.0 ml sulphuric acid (conc.)
9.0 ml glacial acetic acid
90.0 ml distilled water
Mixed the dye and sulphuric acid, stirred
with a glass rod. Slowly added the glacial
acetic acid. Stirred again. Made up to
100.0 ml with distilled water and filtered.
Acid alcohol: 99.0 ml 70% alcohol
1.0 ml hydrochloric acid (conc.)
Celestine blue-
haematoxylin :
2.5 g Celestine Blue B
25.0 g ferric ammonium sulphate
70.0 ml glycerin
500.0 ml distilled water
The ferric ammonium sulphate was dissolved
in the cold distilled H20, the celestine blue
was added and the mixture boiled for a few
minutes. After cooling the stain was filtered
and the glycerine added.
Orange G: 500.0 mg Orange G
2.0 g phosphotungstic acid
95.0 ml absolute alcohol
5.0 ml distilled H20
Acid fuchsin: 500.0 mg acid fuchsin
0.5 ml glacial acetic acid
99.5 ml distilled H20
A5. 2 Staining Procedure
Part A :
1. Wash sections in tap water.
2. Treat with bromine water for 5 min.
3. Wash in running tap water for 5 min.
4. Rinse in distilled water.
5. Stain in alcian blue solution for 1 h.
6. Wash well in tap water.
Part B:
1. Stain with celestine blue-haematoxylin.
2. Wash in tap water.
3. Differentiate in acid alcohol.
4. Rinse in 95% alcohol.
5. Stain in orange G for 2 min then rinse in distilled H20.
6. Stain in acid fuchsin solution for 2-5 min (until basophil
cells are strongly coloured), then rinse in tap water.
7. Treat with 1% phosphotungstic acid for 5 min then rinse
in tap water.
8. Stain in 1.5% light green in 1.5% acetic acid for 1 min
then rinse in tap water to remove excess stain.
9. Flood with absolute alcohol.
10. Clear in xylene.
11. Mount in DPX on slides coated with alum gelatine (see
A4.2).
Acidophils
Basophil cells (s)
Basophil cells (R)
Chromophobe cells
Nuclei
Red blood cells
- orange-yellow
- dark green-blue
- magenta-red
- pale grey-green
- grey blue
- yellow
